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Abstract 
 
Cancer is presently responsible for about 25 % of all deaths in developed countries. It 
has a substantial impact on a patient's quality of life and many cancer treatments (such 
as chemotherapy) may have severe side-effects. New therapies that display a 
minimum of the drastic side-effects of current drugs are constantly sought after. 
 
The first comprehensive studies of the anti-tumour potential of gold compounds, 
including gold drugs, were published in the mid-to-late 1980’s. Gold(I) bisphosphine 
compounds of bis(diphenylphosphino)ethane (dppe) and related ligands with a 
tetrahedral coordination geometry turned out to be a particularly potent class of 
compounds. Clinical trials were, however, not pursued owing to the acute toxicity 
associated with them. The high toxicity of [Au(dppe)2]+ is attributable to the high 
lipophilicity of the cations which results in non-selective uptake into mitochondria in 
all cells. The tumour selectivity of tetrahedral gold(I) complexes was found to hinge 
on a fine balance between its lipophilic and hydrophilic character. 
 
One way of introducing the more hydrophilic character to a ligand or complex, 
necessary for selectivity, is the addition of heteroatoms. To this end, one of the aims 
of this project was to synthesise a range of ligands where the lipophilic ethane bridge 
of dppe was replaced by a hydrazine bridge. It was hoped that the addition of the 
nitrogen heteroatoms would increase the hydrophilic character of the ligands, thus 
rendering more selective drug candidates. Further modifications identified included 
the initial phenyl substituents on the phosphorous centres could be enriched by 
replacing the phenyl with either O-methylanisol or N,N-dimethylaniline. In both cases 
four extra heteroatoms per ligand were added, oxygen in the case of anisol and 
nitrogen in the case of aniline. With dimethylhydrazine or diethylhydrazine as starting 
material six ligands were synthesised and characterised. Crystallisation efforts 
afforded a x-ray crystal structure of bis(diphenylphosphino)diethylhydrazine. In 
contrast to the stability of the diethylhydrazine ligands, the dimethylhydrazine ligands 
were found to be prone to decomposition, at times even under an inert atmosphere. 
 
 v 
The aim of AuTEK Biomed is the inclusion of metals, in this case gold(I) and 
silver(I), to the above mentioned ligands (L) to enhance activity. To this effect, six 
phosphine-bridged gold complexes (ClAu-L-AuCl), six bischelated gold complexes 
(AuL2Cl), six phosphine-bridged silver complexes (NO3Ag-L-AgNO3) and six 
bischelated silver complexes (AgL2NO3) were attempted.  
 
It was found that the ClAu-L-AuCl complexes are very stable and readily crystallise 
from THF. Five of the six complexes could be characterised by x-ray crystallography. 
The sixth complex, that of bis(di(N,N-dimethylanaline)phosphino)dimethylhydrazine, 
could not be isolated due to the breakdown of the ligand upon addition of the metal 
starting material. Succesful preparation of five of the six AuL2Cl complexes was 
accomplished. These complexes where found to be slightly hygroscopic and storage 
under an inert atmosphere was required. Efforts to crystallise these complexes led to 
the crystallisation of conglomerates of micro crystals, which could not be analysed 
crystallographicly due to the disordered nature of the micro crystals.  
 
The synthesis of the bischelated gold complex of bis(di(N,N-dimethylanaline)-
phosphino)diethylhydrazine led to an interesting phenomenon which was studied 
further. Upon complexation, the expected yellow complex spontaneously turned 
bright red even when the solvent was removed. Efforts to crystallise this complex was 
not successful until the counter ion (Cl-) was replaced with that of NO3-. The crystal 
structure revealed that gold(I) had spontaneously oxidised to gold(III) and this crystal 
structure represents the first known complex to our knowledge of gold(III) chelated to 
four phosphorous centres. 
 
NO3Ag-L-AgNO3 complexes were mostly unstable and regularly led to the formation 
of a silver mirror on the reaction vessel. Even with this inherent instability of these 
complexes, it was possible to characterise three of the complexes to some extent and 
to analyse the complex of bis(diphenylphosphino)diethylhydrazine by  
x-ray crystallography. The molecular structure showed intricate connectivity between 
the complexes leading to polymeric structures. The tetrahedral silver complexes were 
markedly more stable and five of the complexes could be isolated and characterised. 
The molecular structure of bis(bis(diphenylphosphino)diethylhydrazine)silver nitrate 
could be determined.  
 vi 
 
Thirteen of the complexes were found to be sufficiently stable to be investigated as 
potencial drug candidates and were subjected to in vitro anti-tumour screening. These 
thirteen complexes were firstly screened against three cell lines, namely the cancerous 
HeLa and Jurkat cell lines and Lymphocytes obtained from healthy human donors. 
These results were analysed and selectivity for toxicity towards cancerous cell-lines 
vs the healthy cell line was calculated.  
 
Five complexes were identified as suitable for investigation on a further range of cell 
lines based on the specificity they displayed. Two of the complexes were of the type 
ClAu-L-AuCl, while the other three were of the type AgL2NO3. The five compounds 
were screened against A2780, A2780cis, Colo, MCF-7 and MCF-12 cell lines from 
which new selectivity profiles were calculated.  
 
Due to the mechanism of activity of [Au(dppe)2]+ being described as apoptosis 
induced through the disruption of mitochondrial membrane potential, so leading to 
cell arrest, it was decided to test whether these analogues would work through the 
same mode of action. To this end, the best two complexes, namely ClAu(MeO-4-
Ph)2PN(Et)N(Et)P(Ph-4-OMe)2AuCl and [{(MeO-4-Ph)2PN(Me)N(Me)P(Ph-4-
OMe)2}2 Ag]+.NO3-, selected through the analysing of selectivity calculations were 
subjected to the mitochondrial membrane potential and apoptosis assays. From the 
mitochondrial membrane potential assay it could be proven that these complexes do 
indeed affect the mitochondrial membrane potential by lowering the potential 
necessary to the cell for producing ATP. Results from the apoptosis assays were 
inconclusive and remain as future work. 
 
The hypothesis of this theses is that it is possible to fine tune the 
lipophilic/hydrophilic balance of tetrahedral Group 11 complexes to improve 
selectivity towards cancerous cells above healthy cells. This has to a certain extent 
been proven through the increased selectivities of these complexes when compared to 
[Au(dppe)2]+. It has to be mentioned that even though increased selectivities are 
observed for these complexes, the selectivities are not profound enough to merit 
further investigation into the anti-tumour activity of these complexes. 
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Chapter 1 
 
Group 11 Transition Metal Chemistry and 
Applications in the Medicinal Field  
 
1.1 INTRODUCTION 
 
In the USA and other developed countries, cancer is presently responsible for about 
25% of all deaths.1 On a yearly basis, 0.5% of the population is diagnosed with 
cancer. In the USA the most common male cancer type is prostate cancer (33%) and 
the most common occuring female cancer is breast cancer (32%). The cancer with the 
highest mortality rate for both females and males is however lung cancer (27% and 
31%, respectively).2 Figures for South Africa are as abysmal, with men dying from 
mainly lung cancer (21.9% in 2000) and woman mainly from cervical cancer (17.2% 
in 2000).3 
 
Cancer has a substantial impact on a patient's quality of life and many cancer 
treatments (such as chemotherapy) may have severe negative side-effects. In the 
advanced stages of cancer, many patients need extensive care, affecting family 
members and friends. Once referred to as "the C-word", cancer has a reputation for 
being a deadly disease. While this certainly applies to certain particular cancer types, 
the truths behind the historical connotations of cancer are increasingly being 
overturned by advances in medical care. Some types of cancer have a prognosis that is 
substantially better than non-malignant diseases such as heart failures and strokes.2 
 
                                               
1
 A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer, 
M.J. Thun, CA Cancer J. Clin., 2005, 55, 1, 10. 
2
 en.wikipedia.org/wiki/Cancer 
3
 www.mrc.ac.za 
 2 
Cancer research is defined as the intense scientific effort to understand disease 
processes and discover possible therapies. While the understanding of cancer has 
greatly increased since the last decades of the 20th century, radical new therapies are 
only discovered and introduced gradually.2 New therapies to curb cancer, while 
displaying a minimum of the drastic side-effects current drugs have, need to be 
constantly sought after.  
 
1.2 COORDINATION COMPOUND CHEMISTRY 
 
Phosphines are well known to chemists. Phosphine ligands are widely used in organic 
synthesis (e.g. Wittig reaction4) and transition metal phosphine complexes have been 
studied extensively, primarily in the context of their application as hydrogenation 
catalysts (e.g. Wilkinson’s catalyst5).6 Table 1.1 outlines some of the uses of 
phosphines as pertaining to biological systems. 
 
Phosphine Application Comment 
PH3 Fumigant7 Generated in situ  
Et3PAu(TATG) Auranofin8 Approved for clinical use 
R3P-Au-X High toxicity9 Limited anti-tumour activity 
Ph2P-Y-PPh2 Anti-tumour activity10 Activity related to structure 
(highest: Y = CH2CH2) 
XAu(Ph2P(CH2)nPPh2)AuX Cytotoxic, anti-tumour 
activity6 
Activity related to structure 
(highest: n = 2) 
[M(Ph2P(B)PPh2)2]X Cytotoxic, anti-tumour 
activity6 
M = Au, Ag, Cu 
B = (CH2)2, (CH2)3 or CH=CH 
trans-[Tc(dmpe)2Cl2]+ Heart imaging agent11 Cationic lipophilic complex transports 99mTc 
into myocardial cells 
Table 1.1: Phosphines and metal phosphine complexes of current interest in biology 
and chemistry. 
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Over 150 different phosphines have been tested for anti-tumour activity by the 
National Cancer Institute.12 None of the tested phosphines showed more than 
marginal anti-tumour activity. It was hypothesised that most of these phosphines are 
rapidly oxidised in vivo and that the coordination to transition metals might inhibit 
this oxidation to some extent.6  
 
1.2.1 Phosphine Ligands 
 
The fundamental characteristic of all phosphine compounds is the presence of a lone 
pair of electrons on the phosphorous atom.7 This makes it possible for phosphorous to 
behave as both a nucleophile and a Lewis base. The greater size and lower 
electronegativity of phosphorous with respect to nitrogen leads to higher polarisability 
and hence, phosphorous compounds are better nucleophiles when compared to 
nitrogen compounds.6 
 
Tertiary phosphines (PR3) are among the most commonly found ligands in transition 
metal complexes. There are examples of phosphine complexes of virtually every 
transition metal.13,14 This illustrates the versatility of these ligands and their ability to 
bind transition metals in both high and low oxidation states.6 
 
Alteration of the substituents on PR3 can cause substantial changes in the chemical 
and physical properties of the corresponding transition metal complexes and thus, the 
strength of the metal-phosphorous bond. Before 1970, almost all chemical behaviour 
was rationalised in terms of electronic effects of the phosphine substituents, but since 
then it has been recognised that steric effects are often as important and in many cases 
more important.15,16 Tolman introduced the ligand cone angle (Θ) as a measure of 
steric bulk and subsequently many physical parameters have been correlated to it.15 
By studying and understanding the changes effected by varying the substituents it is 
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 K.K. Chow, W. Levason, C.A. McAuliffe, Transition Metal Complexes of P, As, Sb 
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16
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 4 
possible to tailor these complexes to attain specific goals in reactivity (rational 
design).6 
 
The discovery of new chelating bisphosphines continues to attract considerable 
attention because of their role in the development of catalytically useful transition 
metal complexes.17,18 One of the simplest and most noteworthy of these bisphosphines 
is found in the group of alkane-bridged bisphosphines (i.e. R2P(CH2)nPR2, where R = 
phenyl and n = 2). This simple ligand system is abbreviated to dppe 
[bis(diphenylphosphino)ethane] and is used as a simple chelating ligand for various 
transition metals (Figure 1.1).17,18,19 
 
Ph2P PPh2
 
 
Figure 1.1: bis(diphenylphosphino)ethane (dppe). 
 
Bis(di(alkyl or aryl)phosphino)ethanes have found numerous applications in the 
design of monometallic transition metal compounds and catalysts. The appropriate 
bite angle provided by the ethane backbone has been implicated as the main reason 
for the prevalence of stable five-membered mononuclear chelates that demonstrate 
catalytic properties.19,20 
 
1.2.1.1 Nitrogen-Bridged Bisphosphines 
 
The discovery of bis(dihalophosphino)amines (Figure 1.2) has led to extensive 
research in the main group and transition metal chemistry of this class of ligand 
systems.21,22,23 Already in 1994, more than 300 published papers describe the rich 
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 G.W. Parshall, Homogeneous Catalysis, Wiley, New York 1980. 
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 L.H. Pignolet (Ed.), Homogeneous Catalysis with Metal Phosphine Complexes, 
Plenum, New York, 1983. 
19
 V.S. Reddy, K.V. Katti, C.L. Barnes, Inorg. Chem., 1995, 34, 5483. 
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 K.G. Moloy, R.W. Wegman, J. Chem. Soc., Chem. Commun., 1988, 820. 
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 J.F. Nixon, J. Chem. Soc. A, 1968, 2689. 
22
 A.R. Davies, A.T. Dronsfield, R.N. Haszeldine, D.R. Taylor, J. Chem. Soc., Perkin 
Trans. 1, 1973, 379. 
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coordination chemistry of R2PN(R’)PR2-type ligands.24 Varied bonding modes with 
transition metals have been observed. These include: i) monodentate ligation through 
PIII centre interaction; ii) bidentate chelation or bridging coordination; and iii) metal 
nitrogen σ-bond formation by means of the reaction at the nitrogen centre.24 In sharp 
contrast, the corresponding studies of dinitrogen-bridged bisphosphines such as 
bis(dihalophosphino)dialkylhydrazine (Figure 1.2) have until recent work by Reddy 
and Katti,19,25,26  been limited to only a few reports.27,28,29 
 
R
N
PX2X2P
R
N N
X2P
R
PX2
 
bis(dihalophosphino)amines           bis(dihalophosphino)hydrazine 
 
Figure 1.2: Nitrogen-bridged bisphosphines. 
 
Metal complexes containing bisphosphine ligands with a P-C-P framework have been 
the subject of numerous investigations during the past decades,30,31 while interest in 
analogous bis(phosphino)amine (also called diphosphazane) ligands, RN(PX2)2, has 
started to develop only more recently.24 Bis(phosphino)amine ligands have proven 
very versatile since substituents on both the phosphorous and the nitrogen atoms can 
be varied independently, resulting in subsequent changes in the P-N-P bond angle and 
the conformation around the phosphorous centre.32 Fairly small differences in these 
                                                                                                                                       
23
 R. Jefferson, J.F. Nixon, T.M. Painter, R. Keat, L. Stubbs, J. Chem. Soc., Dalton 
Trans., 1973, 1414. 
24
 M.S. Balakrishna, V.S. Reddy, S.S. Krishnamurthy, J.C.T.R. Burckett St. Laurent, 
J.F. Nixon, Coord. Chem. Rev., 1994, 129, 1. 
25
 V.S. Reddy, K.V. Katti, Inorg. Chem., 1994, 33, 2695. 
26
 V.S. Reddy, K.V. Katti, C.L. Barnes, Chem. Ber., 1994, 127, 1355. 
27
 M.D. Havlicek, J.W. Gilje, Inorg. Chem., 1972, 11, 1624. 
28
 H. Nöth, R. Ullmann, Chem. Ber., 1976, 109, 1942. 
29
 A.M.Z. Slawin, M. Wainright, J.D. Woollins, J. Chem. Soc., Dalton Trans., 2002, 
513. 
30
 R.J. Puddaphatt, Chem. Soc. Rev., 1983, 99. 
31
 B. Chaudret, B. Delavaux, R. Poilblanc, Coord. Chem. Rev., 1988, 86, 191. 
32
 R. Keta, L.M.Muir, K.W. Muir, D.S. Rycroft, J. Chem. Soc., Dalton Trans., 1987, 
2192. 
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ligands can cause significant changes in their coordination behaviour and the 
structural features of the resulting complexes.24,33  
 
The synthesis of alkyl- or arylamino(bis(dichlorophosphines)) involves the reaction of 
alkyl or aryl substituted primary amines (Equation 1.1) or their hydrochlorides 
(Equation 1.2) with PCl3.21,22,23 Silylated amines, instead of primary amines, can be 
used in condensation reactions to form bis(dihalo- or diarylphosphino)amines 
(Equations 1.3 and 1.4).24,34 
 
2 PCl3  + RNH2  →  RN(PCl2)2 + 2 HCl    Equation 1.1 
 
2 PCl3 + RNH2.HCl  →  RN(PCl2)2 + 3 HCl    Equation 1.2 
 
2 PCl3 + MeN(SiMe3)2  →  MeN(PCl2)2 + 2 Me3SiCl  Equation 1.3 
 
2 PPh2Cl  + HN(SiMe3)2  →  HN(PPh2)2 + 2 Me3SiCl  Equation 1.4 
 
The versatility of bis(phosphino)amines as ligands is illustrated by the fluoro 
diphosphazane derivative, MeN(PF2)2. Nixon et al.35 and later King36 showed that 
MeN(PF2)2 can bind to transition metals in a monodentate or bidentate binding mode, 
giving rise to mononuclear as well as dinuclear complexes. Cotton et al.37 have found 
that the same ligand is capable of stabilising metal-metal triple bonds (Figure 1.3) and 
dubbed [MeN(PF2)2] the “Nixon” ligand in view of its versatility. Related ligands 
with P-O-P or P-C-P backbones fall short on account of lower flexibility in the case of 
P-O-P and lower thermal stability in the case of P-C-P.24 
                                               
33
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34
 I.G. Colquhoun, W. McFarlane, J. Chem. Soc., Dalton Trans., 1977, 1674. 
35
 T.R. Johnson, J.F. Nixon, J. Chem. Soc. A, 1969, 2518. 
36
 R.B. King, Acc. Chem. Res., 1980, 13, 243. 
37
 F.A. Cotton, W.H. Ilsley, W. Kaim, J. Am. Chem. Soc., 1980, 102, 1918. 
 7 
 
L
M
M
L
RN
PX2
PX2
PX2
NR
PX2
 
 
Figure 1.3: Stabilising effect of diphosphazane ligand on metal-metal triple bonds. 
 
The fact that so little is known about hydrazine linked bisphosphines may, in part, be 
due to the lack of a simple synthetic route for such ligands. Gilje et al.27 and Nöth et 
al.28 have pioneered the synthesis of hydrazidophosphines. Their synthetic strategies 
involved: i) the condensation of PCl3 with the highly unstable 1,2-dimethylhydrazine 
at -196 oC; and ii) the treatment of the heterocyclic cage compound 
P[N(Me)N(Me)]3P with PCl3.38 Aside from giving low yields of 
Cl2PN(Me)N(Me)PCl2 (15-20%), these methods suffer from the above mentioned 
practical disadvantages. Therefore, the development of a one-step, straightforward 
and high-yielding synthetic route to Cl2PN(Me)N(Me)PCl2 by Katti et al.,25,26 had 
significant advantages in the long-term use of this ligand and its derivatives in the 
coordination chemistry of transition metals.25  
 
1.2.1.2 Chelating Bisphosphine Ligands 
 
The development of new bisphosphines that possess similar spacing between the PIII 
centres as in R2P(CH2)2PR2 presents the potential to expand the scope of the transition 
metal chemistry of chelating bisphosphines.19,29 In connection with this, the ethylene-
bridged bisphosphine R2PCH=CHPR2 has provided an example of a ligand with a 
similar chain length than that of dppe. The development of bisphosphines with main 
group centres (e.g. nitrogen) connecting the PIII centres offers new opportunities in 
tuning the electronic and steric characteristics of the interacting phosphines.19,29  
 
The dinitrogen-bridged bisphosphine is a useful synthon since: i) it has a similar chain 
length to that of dppe, suggesting its utility in the formation of mononuclear five-
                                               
38
 H. Nöth, R. Ullmann, Chem. Ber., 1974, 107, 1019. 
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membered chelates;25 and ii) the reactive chlorides may be used in the development of 
a wide spectrum of R’2PN(R)N(R)PR’2-type derivatives affording systematic tuning 
of nucleophilicity and pi-acidity of the PIII centres.24,25 It may be noted that the 
development of fundamental coordination chemistry of hydrazine-bridged 
bisphosphines may aid in furthering the chemistry of the related 
bis(phosphino)amines.24 
 
The substitution of X2PN(R)N(R)PX2-type precursors to yield R’2PN(R)N(R)PR’2-
type derivatives gives rise to a myriad of interesting ligands with varied properties 
that may be exploited. The variety of ligands accessible is shown in an exemplary 
fashion by the two reactions below (Scheme 1.1 and 1.2). Phosphinohydrazine ligands 
are easily produced with the addition of Grignard reagents or BuLi substitution 
(Scheme 1.1),29 and phosphitohydrazine ligands can be synthesised by the 
condensation reaction of alcohols with the precursor X2PN(R)N(R)PX2, utilising a 
simple base like NEt3 (Scheme 1.2).19,26,29 
 
N N
R R
PX2X2P
N N
R R
PR'2R'2P
Grignard Reagent 
or BuLi, R'X
 
 
 R = Me or Et, R’ = Alkyl or Aryl 
Grignard Reagent: (Alkyl or Aryl)MgX  
Scheme 1.1: Synthesis of bisphosphine hydrazine ligands. 
 
N N
R R
PX2X2P
N N
R R
P(OR')2(R'O)2P
 R'OH, Et3N
 
 
R = Me or Et, R’ = Alkyl or Aryl 
Scheme 1.2: Synthesis of bisphosphite hydrazine ligands. 
 
Katti et al.19,26 and Slawin et al.29 illustrated the complexation ability of these ligands 
to form coordination complexes of palladium, platinum, tungsten and molybdenum by 
various alkyl-, aryl-, alkoxy- and aryloxy-substituted dimethyl- and diethylhydrazine 
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ligands. The precursor compound, Cl2PN(Me)N(Me)PCl2, was shown to be capable of 
forming complexes with platinum and palladium.25 
 
1.2.2 The Chemistry of Gold 
 
Gold has been known to all major cultures since before the beginning of recorded 
history. Gold mining and gold refining operations are portrayed in Egyptian carvings 
dating back to 2500 B.C. The word gold stems from the old Norse gull and the Gothic 
gulth and is thought to be derived ultimately from the Sanskrit verb jval, meaning “to 
shine”. The symbol Au, on the other hand, comes from the Roman name for the 
element, aurum, which is related to aurora which means, “shining dawn”. The name 
is thus derived from the distinctive shining appearance of the metal.39,40,41 
 
Copper, silver and gold in their atomic state are all characterised by a single s valence 
electron configuration outside a completed d shell, but despite the similarities in 
electron structure and ionisation potentials there are few resemblances between gold, 
silver and copper. Gold is a soft, yellow metal with the highest ductility and 
malleability of any element. It is chemically inert and is not attacked by oxygen or 
sulphur, but reacts readily with halogens or with solutions containing or generating 
chlorine such as aqua regia. It dissolves in cyanide solutions in the presence of air or 
hydrogen peroxide to form [Au(CN)2]-. Addition of reducing agents to gold salts 
under suitable conditions give rise to colourful solutions containing colloidal gold or 
“purple of Cassius” as it is known.39,41,42 
 
Gold chemistry is more diversified than that of silver in that gold is found in six 
oxidation states, from –I to III and V. Gold(-I) and gold(V) have no counterparts in 
silver chemistry. Gold(-I) can be formed and stabilised by solvated electrons in liquid 
ammonia. In the series of metal alloys of the alkaline metals with gold, CsAu is 
classified less as an alloy than an ionic compound better written as Cs+Au-. Gold(V) is 
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42
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known in AuF5 and [AuF6]-, in which it has a low-spin [Xe]4f145d6 
configuration.40,41,43 
 
The other oxidation states of gold are more common with the most stable states being 
gold(I) and gold(III). Gold(I) (d10) can be found in three common geometries namely, 
linear (most common), trigonal and tetrahedral (Figure 1.4). Gold(II) (d9) can be 
found in square planar coordination compounds, while gold(III) (d8) can be found in a 
square planar (most common), square pyramidal or octahedral coordination (Figure 
1.5).40,41 
 
L AuI X AuI
L
L
X AuI
L L
LL
+
.X-
 
                        Linear                       Trigonal                      Tetrahedral 
 
Figure 1.4: Possible geometries of gold(I) complexes. 
 
AuIII
L X
XX
L X
XX
AuIII
L
AuIII
L L
XL
X
X
 
               Square Planar                Square Pyramidal                 Octahedral 
 
Figure 1.5: Possible geometries of gold(III) complexes. 
 
Gold(III) is regarded as a “harder” acid than gold(I) and hence, is more likely to form 
stable compounds with donor atoms such as nitrogen and oxygen, whereas gold(I) 
exhibits a distinct preference for the “softer” sulphur and phosphorous donor atoms.44  
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Wiley Interscience Publications, 1999. 
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Gold has the curious tendency to bind to other gold atoms; this is called aurophilicity 
and has been known to lead to the formation of clusters.45 If ligands are large, these 
gold-gold interactions tend to form dimers and if the ligands are small the interaction 
leads to polymeric chains, rings or even layered polymers. The Au–Au distances are 
usually about 3.0 Å, which is significantly less than the van der Waals contact. The 
distances generally observed are as follows: i) Au2(g): 2.50 Å, ii) AuII–AuII: ~2.60 Å, 
iii) Aux: 2.884 Å, iv) AuI–AuI: 2.75–3.40 Å; and v) sum of the van der Waals radii: 
3.4 Å.41 
 
1.2.2.1 Complexes of Gold(I) 
 
The majority of gold(I) complexes are linear and tend to be of the LAuX type, where 
L is a neutral donor such as R3P or R2S and X is a halogen, pseudohalogen or RS. The 
phosphine complexes are particularly stable and easy to prepare. Those with thioether 
ligands, for example (R2S)AuCl, are useful preparative intermediates, since R2S is 
easily displaced by other ligands. With higher concentrations of R3P ligands, higher 
coordination numbers are achieved, as in (Ph3P)3AuCl and [Au(PMePh2)4][PF6], 
where tetrahedral coordination is found.40,41,43 
 
Gold(I) thiolates, [AuSR]n have been extensively investigated in the context of 
chemotherapeutic agents for arthritis. They exist as linear, cyclic oligomeric or 
polymeric species (Figure 1.6).40 
 
S
R
Au Au
S
R
S
R
L Au SR
L Au SR
Au
S
Au
S
R
R
LL
 
                     Linear                    Cyclic Oligomeric             Chain Polymeric 
 
Figure 1.6: Possible conformations of [AuSR]n species. 
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The overwhelming preference of gold(I) for linear two-coordination has made 
complexes of higher coordination more rare. A few three-coordinate complexes are 
known46,47 and the existence of four-coordination has become more 
widespread,48,49,50,51 including some monochelating ligand complexes with near 
tetrahedral symmetry, namely [Au(PMePh2)4]+ and [Au(SbPh3)4]+.52,53 Reports of 
chelated gold(I) complexes were initially confined to bidentate ligands with rigid 
backbones: [Au(pdma)2]+ [pdma = o-phenylene-bis(dimethylarsine)] and 
[Au(dppen)2]+ [dppen = bis(diphenylphosphino)ethylene].46 The latter ligand (L) 
readily formed the ring-opened complex [(ClAu-L-AuCI],54 a type of species also 
formed by bis(diphenylphosphino)methane.55 As a result of the discovery of 
[Au(dppe)2]+ the attention of researchers changed to the more flexible chelating 
ligands and has since led to many new tetrahedral complexes.51,56,57  
 
1.2.2.2 Complexes of Gold(II) 
 
The number of gold(II) complexes is very scarce if compared to the more common 
gold(I) and gold(III) derivatives.58 Atomic ionisation potentials show that it is more 
difficult to obtain gold(II) than either copper(II) or silver(II), but easier to obtain 
gold(III) than either of the other two +3 ions. The only extensive series of genuine 
gold(II) compounds is found in dinuclear species exhibiting Au-Au bonds. These are 
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obtained by oxidative-addition of halogens to dinuclear gold(I) phosphine ylide 
complexes (Figure 1.7).58,59 Related bridged dinuclear gold(I) complexes, like 
Au2(S2CNR2)2 and Au2Cl2(Ph2PCR2PPh2), can similarly be oxidised to give gold(II)–
gold(II) bonds.40,41,58 
AuII
R2P
CH2
CH2
AuII
X
X
CH2
PR2
CH2
 
Figure 1.7: Dinulear gold(II) phosphine ylide complex. 
 
1.2.2.3 Complexes of Gold(III) 
 
Gold(III) is iso-electronic to platinum(II) and similarly displays predominantly square 
planar coordination. Complexes of the type [AuX4]- were X is a halogen or 
pseudohalogen are well characterised. When gold is dissolved in aqua regia or Au2Cl6 
is dissolved in HCl and the solution of AuCl4- is evaporated, auric acid can be 
obtained as yellow crystals of [H3O]+[AuCl4]-.3H2O. Other water-soluble salts such as 
KAuCl4 and NaAuCl4 are readily obtained. Neutral complexes of AuCl3 in the form 
of (R3E)AuCl3, can be synthesised from simple adducts were E = P, As or Sb. 
Cationic complexes like [Au(NH3)4]3+ are well characterised.40,41,43 
 
1.2.2.4 Organogold Compounds 
 
Alkyl derivatives of gold were among the first organometallic compounds of 
transition metals to be prepared. Both gold(I) and gold(III) compounds with σ bonds 
to carbon, as well as olefin complexes, are known. Gold(I) complexes are mainly 
complexes of the type RAuL, where L is a stabilising ligand. These complexes are 
prepared from the corresponding gold halides by reaction with LiR or RMgX. 
Gold(III) compounds are mainly complexes of the type R3AuL, [R2AuL]+ or 
R2AuXL.40,41,43 
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 H. Schmidbaur, K.C. Dash, Adv. Inorg. Radiochem., 1982, 25, 239. 
 14 
Triphenylphosphine complexes of gold(I) and gold(III), such as MeAuPPh3 and 
Me3AuPPh3, when reacted with methyllithium in ether, give the methylate ions 
[AuMe2]- and [AuMe4]-, which can be isolated as lithium amine salts and are very 
stable organogold compounds.40,41,43 
 
1.2.3 The Chemistry of Silver 
 
Of the three noble metals of Group 11, silver was the last to be discovered, since it is 
not nearly as abundant in the native metallic state as copper or gold. Even so it was 
discovered very early and recognised as a metal of unusual merit. First recordings of 
the use of silver date back to 3500 B.C. in Egypt, where its value was established as 
two fifths the value of gold in the code of Menes.39 
 
The Latin name for silver, argentum (from which the symbol Ag is derived), is in 
recognition of the brilliance of the metal, since argentum comes from the Greek name 
argyros, coming from a root for “bright’ or “shining”. Thus, as with gold, both the 
name and the symbol are tributes to the distinctive appearance of the metal.39,41 
 
Silver is a white, lustrous, soft and malleable metal with the highest known electrical 
and thermal conductivities. It is chemically less reactive than copper, except towards 
sulphur and hydrogen sulphide, which rapidly blackens silver surfaces. The metal 
dissolves in oxidising acids and in cyanide solutions in the presence of oxygen or 
peroxide.39,41 
 
Silver can be found in four oxidation states from 0 to III, with silver(I) being the most 
common. The most common geometries for silver(I) (d10) are linear, trigonal and 
tetrahedral, while both silver(II) (d9) and silver(III) (d8) are known to form square 
planar compounds.41,42 
 
1.2.3.1 Complexes of Silver(I) 
 
Many nitrogen ligands readily form complexes with silver(I) in water, with NH3 being 
the most important. The linear coordination of NH3 as [H3N-Ag-NH3]+ has been 
observed crystallographically, while with poly-amine ligands like bipyridine a more 
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complex behaviour is observed and tetrahedral cationic compounds may result.39,41,42 
Silver(I) has a relatively low affinity for oxygen donors, although compounds and 
complexes containing carboxylate ions are known. On the other hand, numerous 
complexes with the donor atoms sulphur, selenium, phosphorous and arsenic are 
known. Silver(I) is found to bind to peptides and proteins with a preference for the 
thioether sulphur atoms and imidazole nitrogen atoms.42,43   
 
Monophosphines mainly form complexes of the type (R3P)nAgX, with n = 1 - 4. The 
1:1 complexes are tetrameric, with either cubic or chair structures depending on steric 
requirements of both X and R3P (Figure 1.8).42 
Ag
XX
Ag
Ag
X X
Ag
P
P
P
P
Ag
XX
Ag
Ag
X
Ag
X
P
P P
P
 
                                         Cubic                                Chair 
 
Figure 1.8: Cubic and chair structures of silver(I). 
 
(R3P)2AgX complexes are generally dimeric with bridging X ions, but in the case of 
very bulky phosphines, linear cations, [R3P-Ag-PR3]+, can occur. Complexes with 
bridging bidentate phosphines tend to be dimers or tetramers (Figure 1.9), but with the 
addition of two ligands per silver(I), tetrahedral cationic species may form.42,43 
 
O
ON
O
O
NO
O
Ag
Ph2P PPh2
Ph2P PPh2
Ag
 
 
Figure 1.9: A dimeric silver(I) complex with bridging bidentate phosphine ligands. 
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1.2.3.2 Complexes of Silver(II) 
 
Numerous complexes of silver(II) are known and they are normally prepared by 
peroxodisulphate oxidation of silver(I) solutions containing the complexing ligand. 
With neutral ligands, cationic silver(II) complexes form crystalline salts, whereas with 
a mono-anionic bidentate ligand, neutral silver(II) complexes are obtained (Figure 
1.10).39,42,43         
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Figure 1.10: Neutral bis(picolinato)silver(II) complex. 
 
1.2.3.3 Complexes of Silver(III) 
 
Few simple silver(III) complexes are known due to the instability of the silver(III) 
ion. A silver(III) complex of remarkable stability is the one with 
ethylenedi(biguanide), which is obtained as a red sulphate when Ag2SO4 is treated 
with aqueous potassium peroxodisulphate in the presence of ethylenedi(biguanidium) 
sulphate (Figure 1.11). Silver(III) also form stable complexes with porphyrins.42,41,43  
N
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Figure 1.11: Ethylenedi(biguanide)silver(III). 
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1.3 ANTI-TUMOUR RESEARCH 
 
Cancer is a class of diseases or disorders characterised by uncontrolled division of 
cells. These cells have the ability to invade other tissues, either by direct growth into 
adjacent tissue or by migration and implantation into other sites (metastasis). 
Metastasis is the process by which cancer cells are transported through the 
bloodstream or lymphatic system and are spread to other tissues. Cancer may affect 
people of all ages, but older people have an increased risk as a result of DNA damage 
becoming more regular in aging DNA. Cancer is one of the leading causes of death in 
developed countries.2,60,61 
 
There are numerous types of cancer. Severity of symptoms depends on the site and 
character of the malignancy and whether there is metastasis. Most cancers can be 
treated, and some cured, depending on the specific type, location and stage. Once 
diagnosed, cancer is usually treated with a combination of surgery, chemotherapy and 
radiotherapy. As research develops, treatments are becoming more specific for the 
type of cancer pathology. Drugs that target specific cancers already exist for several 
cancers.2,60,61 
 
The unregulated cell growth that characterises cancer is caused by damage to DNA, 
resulting in mutations to genes that encode for proteins controlling cell division. Many 
mutation events may be required to transform a normal cell into a malignant cell. 
These mutations can be caused by chemicals or physical agents called carcinogens, by 
exposure to radioactive materials or by certain viruses that can insert their DNA into 
the human genome. Mutations mostly occur spontaneously, but some gene mutations 
are passed down from generation to generation.2,60,61 
 
Hippocrates, the "Father of Medicine", described several kinds of cancers. He called 
benign tumours oncos, Greek for swelling, and malignant tumours carcinos, Greek for 
crab or crayfish. This strange choice of name probably comes from the appearance of 
the cut surface of a solid malignant tumour, with a roundish hard centre surrounded by 
pointy projections, vaguely resembling the silhouette of a crab. He later added the 
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suffix -oma, Greek for swelling, giving the name carcinoma. Since it was against 
Greek tradition to open the body, Hippocrates only described and made drawings of 
outwardly visible tumours on the skin, nose and breasts. In the 16th and 17th centuries 
it became more acceptable for doctors to dissect bodies to discover the cause of death. 
Through the centuries it was thus discovered that cancer occured everywhere in the 
body. Treatment of cancers was initially based on the humor theory of four bodily 
fluids (black bile, yellow bile, blood and phlegm).2,60,61 
 
With the widespread use of the microscope in the 18th century, it was discovered that 
cancer can spread from the primary tumour through the lymph nodes to other sites. 
The use of surgery to treat cancer was being employed, but had poor results due to 
problems with hygiene. When Pierre and Marie Curie discovered radiation at the end 
of the 19th century, they stumbled upon the first effective non-surgical cancer 
treatment. With radiation came the first signs of multi-disciplinary approaches to 
cancer treatment.2,60,61 
 
Malignant tumour cells have distinct properties: i) evading apoptosis; ii) unlimited 
growth potential (immortalitisation) due to overabundance of telomerase; iii) self-
sufficiency of growth factors; iv) insensitivity to anti-growth factors; v) increased cell 
division rate; vi) altered ability to differentiate; vii) no ability for contact inhibition; 
viii) ability to invade neighbouring tissues; ix) ability to build metastases at distant 
sites; and x) ability to promote blood vessel growth (angiogenesis).2,60,61 
 
1.4 COORDINATION COMPOUNDS IN MEDICINE 
 
Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. It 
interferes with cell division in various ways, e.g. interfering with the duplication of 
DNA or the separation of newly formed chromosomes. Most chemotherapeutic drugs 
work by impairing mitosis (cell division), effectively targeting fast-dividing cells. 
Most forms of chemotherapy target all rapidly dividing cells and are not specific for 
cancer cells. Hence, chemotherapy has the potential to harm healthy tissue, especially 
tissue with a high replacement rate (e.g. intestinal lining). These cells usually repair 
themselves after chemotherapy. As these drugs cause damage to cells, they are termed 
cytotoxic. Some drugs cause cells to undergo apoptosis (so-called "cell suicide").2,60,61 
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The beginnings of the modern era of cancer chemotherapy can be traced directly to 
the discovery of nitrogen mustard (Figure 1.12), a chemical warfare agent, as an 
effective treatment for cancer. Two pharmacists, Louis Goodman and Alfred 
Gilman,62 were recruited by the United States Department of Defense to investigate 
potential therapeutic applications of chemical warfare agents. Autopsies of people 
exposed to mustard gas had revealed profound lymphoid and myeloid suppression. 
Goodman and Gilman reasoned that this agent could be used to treat lymphoma, since 
lymphoma is a tumour of lymphoid cells. They first set up an animal model by 
establishing lymphomas in mice and demonstrated they could treat them with mustard 
agents. Next, in collaboration with a thoracic surgeon, Gustav Linskog, they injected a 
related agent, mustine (the prototype nitrogen mustard anticancer chemotherapeutic 
drug), into a patient with non-Hodgkin's lymphoma. They observed a dramatic 
reduction in the patient's tumour masses. Although this effect lasted only a few weeks, 
this was the first step to the realisation that cancer could be treated by 
pharmacological agents. Cancer drug development since then has exploded into a 
multi-billion dollar industry.2 
 
N
Cl Cl
S
Cl Cl  
                                  Mustard Gas                                Mustine 
 
Figure 1.12: Mustard gas derivatives. 
 
The majority of chemotherapeutic drugs can be divided into: i) alkylating agents; ii) 
anti-metabolites; iii) anthracyclines; iv) plant alkaloids; v) topoisomerase inhibitors; 
and vi) anti-tumour agents. All of these drugs affect cell division or DNA synthesis 
and function.2,60,61 
 
Chemotherapeutic drugs of interest to this study are the group called alkylating 
agents. Currently, the most widely used anti-tumour drugs; cisplatin, carboplatin and 
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oxaliplatin (Figure 1.13) are classified as alkylating agents due to a similar mode of 
action in their anti-tumour activity to alkylating agents (i.e. DNA crosslinking). Drugs 
containing transition metals, especially platinum-based drugs, have been shown to 
impede DNA replication and repair.2 
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Figure 1.13: Commercially available platinum-based anti-tumour drugs. 
 
Cisplatin was discovered by a Michigan State University researcher, Barnett 
Rosenberg,63 working under an NCI contract. Rosenberg had initially wanted to 
explore the possible effects of an electric field on the growth of bacteria. He observed 
that the bacteria unexpectedly ceased to divide when placed in an electric field. The 
inhibition of bacterial division was pinpointed to an electrolysis product of the 
platinum electrode rather than the electrical field. This accidental discovery, soon 
initiated a series of investigations and studies into the effects of platinum compounds 
on cell division, culminating in the synthesis of cisplatin. Subsequently, Eve Wiltshaw 
et al. at the Institute of Cancer Research in the United Kingdom extended the clinical 
usefulness of platinum compounds with their development of carboplatin, a cisplatin 
derivative that combines broad anti-tumour activity and comparatively low 
nephrotoxicity.2 
 
As can be seen from the three anti-tumour drugs above, the use of metal complexes 
compounds as anti-tumour drugs is well established. The transition metal group 11 
compromises the diamagnetic metals copper (Cu), silver (Ag) and gold (Au). These 
elements are called noble metals or coinage metals due to having high resistance to 
corrosion and due to being used as coins since antiquity. The use of gold complexes 
as Rheumatoid Arthritic (RA) drugs is well established. The interest in the use of 
                                               
63
 B. Rosenberg, L. van Camp, T. Krigas, Patent no: US4339437, 1982. 
 21 
Group 11 metals as anti-tumour drugs has recently increased and many new 
gold,64,65,66 silver67,68 and copper69,70 compounds have been and are being tested as 
potential anti-tumour drugs.6 
 
1.4.1 Gold Compounds in Medicine 
 
Gold is normally present in human and animal tissues in minute concentrations. It has 
no natural biological function, although some algae are able to absorb considerable 
quantities of gold from solutions and there is one plant species known to concentrate 
the metal.71 Many gold compounds are highly toxic to animals, especially chloro auric 
acid and its salts, largely due to their oxidising ability.71 
 
1.4.1.1 History  
 
The earliest application of gold as a therapeutic agent originated in China. Gold was, 
furthermore, widely used by ancient physicians and surgeons. Many ancient cultures, 
such as those in India and Egypt used gold-based medicinal preparations, but China 
was the earliest to cure sickness with it and this has been dated back as far as 2500 
B.C.72 Since the discovery of gold, people have thought of it as having an immortal 
nature (e.g. resistance to chemical corrosion) and associated it with longevity. 
Consequently, gold was used as a medicine to seek longevity. Pure gold was used to 
treat furuncles, smallpox and skin ulcers and to remove mercury from skin and flesh. 
Some ancient references noted that gold drugs can cure joint disease and disease in 
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lungs. There were prescriptions containing gold for curing measles and other diseases. 
Plant and animal medicines were used in ancient prescriptions and many of these 
contain gold as a trace element.73, 44 
 
People in ancient times accumulated experience through trial and error and gradually 
developed useful gold drugs. Some of them had a reputation for having a good 
therapeutic effect. Ancient China had remarkable achievements in this field and some 
of these gold drugs have a relationship to their modern successors. In order to use 
pure gold for drugs, techniques were developed in the second century A.D. for refining 
gold and for separating gold–silver alloys. In order to use gold powder for drugs, 
techniques for making gold foil and powder were devised by alchemists.73  
 
Arising from the fact that people had a thirst for gold treatments and that gold was 
linked to the mystery of life, alchemists devoted themselves to the manufacture of the 
elixir for immortal life and tried to produce man-made “gold”. Though their 
objectives were absurd, they were successful in making a variety of imitation gold 
materials and had a deep understanding of the Au-Ag system, along with various 
other transition metal systems, i.e. Au-Cu, Cu-Zn, Cu-As, Cu-Hg, Sn-S, Hg-S, etc.73 
 
Ancient alchemists in China found chemical species which help in the dissolution of 
gold (i.e. Fe3+ and Cl-) and used cyanide-containing plants to dissolve gold. Potable 
gold referred to as “drinkable gold” and the earliest literature dealing with potable 
gold in China was “On Salt and Iron” written in 81 B.C. Since gold flakes or powder 
and medicinal gold are “heavy articles”, which cannot stay long in the stomach, and 
were in some cases toxic, alchemists sought to solve the problem by making 
“drinkable gold” as an elixir. We now know that cyanide is present in over a thousand 
plants and some of the traditional Chinese herbs used for medicine are amongst these. 
Fresh raspberries contain cyanide and this is the key factor enabling dissolution of 
gold in the prescription “Baopuzi: The Internal Chapter” for potable gold. The above 
considerations indicate that potable gold was in fact likely to contain a very small 
amount of dissolved gold. Metallurgical and chemical achievements of these ancient 
alchemists in China were therefore considerable.73 
                                               
73
 Z. Huaizhi, N. Yuantao, Gold Bull., 2001, 34, 24. 
 23 
 
In 1890 Koch74 discovered that KAu(CN)2 was lethal to the micro-organism 
responsible for tuberculosis (mycobacterium tuberculosis) in a test tube study. This 
paved the way for a sounder basis for gold therapy. This compound was administered 
to tuberculosis (TB) sufferers, but although there were positive results there were 
serious toxic side effects. After intensive synthetic efforts in the 1920’s several gold(I) 
thiol compounds were introduced for the treatment of tuberculosis. These compounds 
were later introduced as drugs against rheumatoid arthritis (RA) (see 1.4.1.2.1), which 
lead to the mistaken postulation of a relationship between TB and RA. However, after 
1935 the use of gold drugs for TB treatment was stopped due to serious side effects 
and a lack of clinical success.40 
 
1.4.1.2 Recent Developments in the Medicinal Applications of Gold Compounds 
 
Apart from the obvious use of gold alloys in dental restorations there are a number of 
direct applications of gold in medical devices. The excellent biocompatibility of gold 
led to its use in dental applications. Further applications include wires for pacemakers 
and gold plated stints used in the treatment of heart disease. Gold possesses a high 
degree of resistance to bacterial colonisation and because of this it is the material of 
choice for implants that are at risk of infection, such as the inner ear. Gold has a long 
tradition of use in these applications and is considered a very valuable metal in 
surgery.75 
 
An interesting medical product now being marketed in Japan is a gold-titanium patch, 
based on the theory of ion adjustment in the human body. It is considered that fatigue 
and stiffness are generally caused by the increase of positive ions in the body, causing 
the interruption in the circulation of blood. The gold-titanium patch adjusts this 
imbalance of ions by inducing an electric stimulus (due to the galvanic effect between 
the gold and titanium metals). The induced warmth is said to alleviate the pain (Figure 
1.14).75 
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Figure 1.14: Thermal image of patient before and after application of metallic patch, 
showing an increase in surface body temperature. 
 
Recent interesting developments include the use of microscopic spheres of gold for 
the delivery of vaccines, pharmaceuticals or DNA portions into the human body. Gold 
has the required adsorptive characteristics and biocompatibility for such applications. 
It has been used in the detection of deadly poisons such as anthrax, the development 
of gold-coated lasers to aid in skin rejuvenation and the testing of vaccines. Nano-
scale gold particles are being investigated for use in biomedical diagnostic kits.75 
 
Gold is the perfect raw material for certain rapid tests. A rapid test is an inexpensive, 
disposable, membrane-based technique that provides visual evidence of the presence 
of an analyte in a liquid sample.75 Applications for rapid tests include clinical uses 
(fertility tests, tumour markers, toxicology, allergies, viral infection),76,77,78 
agricultural uses (food safety, plant and crop diseases)78 and environmental uses 
(biological and environmental contamination).78 
 
Early rapid tests used coloured latex to produce the visual signal. Gold labels were 
first introduced into membrane-based rapid tests in the late 1980’s because of their 
greater potential stability and an ever-increasing demand for ultra sensitivity. These 
labels are based on gold colloids, a suspension of nanometre sized gold particles 
individually surrounded by a negative charge layer.79,80 This charge layer provides the 
                                               
76
 http://www.atfirstdiagnostic.com. 
77
 J.L. Greenwald, G.R. Burstein, J. Pincus, B. Branson, Curr. Infec. Dis. Rep., 2006, 
8, 125. 
78
 J.A. Chandler, Patent no: ZA9600802, 1996. 
79
 J.L. Brennan, N.S. Hatzakis, T.R. Tshikhudo, N. Dirvianskyte, V. Razumas, S. 
Patkar, J. Vind, A. Svendsen, R.J. Nolte, A.E. Rowan, M. Brust, Bioconjug. Chem., 
2006, 17, 6, 1373. 
 25 
means for the gold particles to repel each other and remain in suspensed form 
indefinitely. Gold is essentially inert and forms almost perfect spherical particles 
when properly manufactured. Proteins bind to the surfaces of these gold particles with 
enormous strength when correctly coupled, thus providing a high degree of long-term 
stability, both in the solid and solvent-free state. If manufacturing processes ensure 
that gold particles of any accurately defined diameter can be manufactured 
reproducibly, there will be minimal batch-to-batch variation. What's more, different 
sizes of gold may be used for different applications, thus making it a very flexible raw 
material for both manufacture and development. Overall, the superior stability, 
sensitivity and reproducibility of manufacture, makes gold a first class raw material 
component for a wide range of rapid test applications.75,78,81  
 
One of the connections between the chemistry and the biology of gold is the use of 
gold for the solving of crystal structures of proteins. Gold, due to its high scattering 
factor for x-rays, is used as a label on crystalline proteins to solve the phasing 
problem experienced in these large structures. In these endeavours both gold(I) as 
[Au(CN)2]- and gold(III) as [AuCl4]- or [AuI4]- have been used. What was commonly 
observed in these structures was the binding of gold to mostly histidine (free nitrogen 
containing amino acid)82 or cysteine (free sulphur containing amino acid)83 moieties 
in protein molecules. It is now known that many proteins depend on a free cysteine 
for activity and the loss of this free site due to gold binding will lead to inactivity of 
the protein.40 
 
1.4.1.2.1 Gold(I) in Rheumatoid Arthritis Treatment 
 
Gold and gold-containing compounds have historically been used in drugs for the 
treatment of a wide range of ailments. The use of gold compounds in medicine is 
called chrysotherapy (from the Greek word for gold, chrysos). The Frenchman 
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Jacques Forestier reported in 1929 that the use of gold complexes was beneficial in 
the treatment of arthritis.84 Later work, after World War II, demonstrated conclusively 
that gold drugs are effective in treating RA patients.6,75,85  
 
RA is an inflammatory disease characterised by a progressive erosion of the joints 
resulting in deformities, immobility and a great deal of pain. It is an autoimmune 
disease in which the body's immune system mounts a response against itself. This 
results in a malign growth of the synovial cells (the cells lining the joint) called a 
pannus and permeation of the joint space by cells of the immune system, primarily 
macrophages, and associated production of immunoglobulin proteins called 
rheumatoid factors. Phagocytic cells release degradative enzymes such as collagenase 
and generate the reactive oxygen species, hydroxyl radical (.OH) and superoxide  
(O2-), all of which contribute to the resulting tissue damage. This progressive 
inflammatory response is promoted by raised levels of chemical mediators such as 
prostaglandins, leukotrienes and cytokines.85 
 
The class of RA drugs that include gold compounds are termed Disease-Modifying 
Anti-Rheumatic Drugs, the DMARDS. As the name suggests, DMARDS, act to 
impede or even stop the progression of RA. These are appropriately employed for 
newly diagnosed patients so as to manage the disease by halting progression. Gold-
based compounds fall within the DMARDS class, as there is experimental evidence to 
indicate that chrysotherapy is disease modifying. Unfortunately, as with all 
chemotherapies, chrysotherapy is associated with various negative side effects. This 
leaves scope for improvement of therapies.6,40,71,44,85 
 
There are two classes of gold compounds used in the treatment of RA. Membership of 
each class relates to the inherent chemistry of the compound and dictates their mode 
of administration and therefore bio-distribution. The first class of compounds is 
generally polymeric, charged and water-soluble. By contrast, the second class of 
compound is monomeric, neutral and lipophilic. Class I (Figure 1.15) comprises: i) 
sodium aurothiomalate (e.g. Miocrin, Myochrysine, Myocrisin, Shiosol and 
Tauredon); ii) sodium aurothiopropanol sulphonate (e.g. Allochrysine Limière); iii) 
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aurothioglucose (e.g. Aureotan, Auromyose and Solganol); and iv) sodium 
aurothiosulphate (e.g. Fosfocrisolo and Sanocrysin). The Class II drugs have but one 
member, which is: triethylphosphinegold(I) tetra-acetylated thioglucose, commonly 
known as auranofin (e.g. Aktil, Crisinor, Crisofin and Ridaura). All of these drugs are 
registered trademarks and commercially available.71,44,85 
 
S
CO2
CO2
Au
2-
n
             
Au S SO3
HO -
n
 
                   Sodium aurothiomalate          Sodium aurothiopropanol sulphonate 
 
O
S Au
OH
OH
HO
HO
n
                  
Au S SO3SO3S
3-
 
                     Aurothioglucose                                       Sodium aurothiosulphate 
 
O
S Au
OAc
OAc
AcO
AcO PEt3
 
Auranofin 
 
Figure 1.15: Commercially available gold-based Rheumatoid Arthritis drugs. 
 
RA is not a well understood disease. RA can be treated by a variety of drugs, 
including gold-based drugs, but not cured. Similarly, the mechanism of action of gold-
drugs is also not well understood. The mode of administration of the Class I drugs via 
intramuscular injections of suspensions indicates that the drugs are delivered to the 
vascular system. This is rich in the blood protein albumin and it is thought that the 
gold drug undergoes a substitution reaction so that an albumin molecule replaces one 
of the thiomalate ligands. Subsequent metabolism may involve the substitution of the 
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second thiolate ligand of the drug by another albumin molecule resulting in the 
original gold atom existing within a ball of protein that is presumably carried to the 
site of inflammation. Once at the target site, the gold may be extracted by cyanide (a 
metabolite of thiocyanate generated at sites of inflammation) to form a small anionic 
species, [Au(CN)2]-, that is known to have a very high stability constant. It was thus 
postulated that this may be the active species. A similar mechanism of action is 
envisaged for auranofin. The conclusion of what is known about the metabolic 
pathways of both Class I and II drugs is that the administered drugs rapidly undergo 
substitution reactions of one sort or another and therefore can be regarded as 
prodrugs.40,44,71,85 
 
There is evidence to suggest that auranofin inhibits the production of reactive oxygen 
species such as .OH and O2- produced during the oxidative burst of activated 
polymorphonuclear cells (a phagocytic cell of the immune system). In this case the 
active metabolite may be aurocyanide. One suggestion is that gold complexes may 
react with the cyanide released during phagocytosis forming aurocyanide. This can 
readily enter cells and has been shown to inhibit the oxidative burst.85 
 
Recently de Wall et al.86 have put forward another theory, which postulates that 
gold(I) is oxidised to gold(III) in vitro and in vivo. They have shown that platinum(II) 
and their iso-electronic gold(III) complexes led to the inhibition of the immune 
response by the blocking of the Class II major histocompatibility complex (MHC) 
proteins. MHC proteins are responsible for many of the autoimmune responses 
associated with RA and their inhibition would prevent the symptoms seen in typical 
RA patients. 
 
1.4.1.2.2 Gold in HIV and Asthma Treatment  
 
In the desperate quest to seek a cure for AIDS, some gold drugs have been evaluated 
for activity against human immunodeficiency virus (HIV).87,88 Early results suggest 
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that there might be some inhibition of HIV exhibited by gold compounds such as 
sodium aurothiomalate and aurothioglucose. Some gold compounds used in the 
treatment of RA have demonstrated effectiveness against severe bronchial asthma 
owing to their immuno-suppressant properties.89,90 Recent reviews describing new 
agents for treating asthmatics suggest that gold-therapy might be limited to severe 
cases such as chronic corticosteroid-dependent asthma, i.e. as second-line agent as for 
the treatment of RA by DMARDS. Phosphine gold(I) thiolates have been evaluated 
for their activity against parasitic diseases such as malaria91 and Chagas disease. 
However, in terms of drug development, to date most attention has been devoted to 
the investigation of the anti-tumour potential of gold compounds (see 1.4.1.2.4).6,44,92 
 
1.4.1.2.3 Gold in Anti-Microbial Treatment 
 
The implication of microbial infection as a causative agent in arthritis was the 
stimulus for the investigation of the anti-microbial properties of gold complexes. The 
early work by Robert Koch74 demonstrated that gold compounds were active against 
the Tubercle bacillus. Subsequent extensive work in the 1930's and 1940's 
demonstrated that a variety of gold compounds were active against a broad spectrum 
of micro-organisms.93 Activity in in vitro test systems was demonstrated against both 
gram negative and gram positive bacteria, a number of strains of mycoplasma and the 
protozoan Leishmania. Gold complexes were able to modify the course of a number 
of in vivo infections in a variety of animal hosts. Many of these early studies were 
flawed and the lack of evidence for the role of an infectious agent in RA resulted in 
this work not being pursued.85  
 
Today there is a growing need for new clinical anti-microbial agents. The therapeutic 
efficacy of drugs currently available for the treatment of a class of bacteria known as 
“problem Gram positive cocci” is limited by the emergence of multiple-resistant 
strains such as methicillin-resistant Staphylococus aureus (MRSA) and enterococci 
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e.g. Enterococcus faecalis.94 Vancomycin (Figure 1.16) is the drug of choice for these 
organisms but it too has limitations as it must be administered by intravenous infusion 
and there are problems with resistance.85  
 
 
 
Figure 1.16: Structure of Vancomycin. 
 
In recent studies a number of different metal complexes have been tested for anti-
microbial activity.95 The compounds were tested against a number of bacterial strains 
including clinical isolates of MRSA, methicillin-sensitive S. aureus, enterococci, 
coagulase-negative staphylococci and streptococci. A gold(I) thiocyanate complex, 
Au(SCN)(PMe3) demonstrated activity against Gram positive bacteria including 
MRSA. Comparative toxicity against mammalian cells was evaluated in vitro against 
the CHO (Chinese Hamster Ovary) cell line. The gold complex demonstrated good 
selectivity for bacteria over mammalian cells with an IC50 of 0.33 against 
Staphylococcus aureus and 0.77 against Enterococcus faecalis, and with lethal doses 
of at least 10x higher necessary to kill CHO cells.85 
 
Further investigation of gold complexes led to the identification of a series of gold(I) 
phosphonium dithiocarboxylate complexes which have activity against Gram positive 
bacteria including “problem Gram positive cocci”. The anti-microbial activity of the 
gold(III) compounds AuCl2(damp) and Au(OAc)2(damp) (Figure 1.17) have been 
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investigated. Both exhibit broad spectrum activity against a range of organisms with a 
small degree of specificity against the Gram positive organisms S. aureus and E. 
faecalis with the more water soluble diacetate derivative being the most potent. Both 
complexes show similar toxicity against mammalian CHO cells indicating that the 
diacetate complex is the more selective of the two complexes for bacteria over 
mammalian cells.85 
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Figure 1.17: Anti-microbial gold(III) compounds. 
 
1.4.1.2.4 Gold(I) in Anti-Tumour Treatment 
 
The first comprehensive studies of the anti-tumour potential of gold compounds, 
including gold drugs, were published in the mid-to-late 1980’s and these studies still 
have relevance today.96 A key outcome of this early work was the conclusion that 
gold was essential for elevated potency. These studies showed that the most promising 
class of gold(I) compounds were the phosphine gold(I) thiolates, i.e. related to the 
structure of auranofin (Figure 1.15). Active compounds featuring P-Au-S as structural 
element displayed the first structure activity relationship. This principle proved 
fruitful in screening for anti-tumour activity where thiols such as 6-mercaptopurine 
and 6-thioguanine were utilised.97,98 The potency of phosphine gold(I) thiolates was 
found to be higher in a range of human cancer cell lines when compared with the free 
thiols.44  
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A large number of phosphine complexes (R3PAuX) have been evaluated and all 
exhibit in vitro potent cytotoxicity against tumour cells.96 Variations of the phosphine 
substituents (R3P) modulate the anti-tumour activity in vivo as do changes in the 
counter ion X. Anti-tumour activity is lowest for the complexes that contain a good 
leaving group (e.g. Cl-, NO3-), although cytotoxic potency is unaffected. These 
complexes are very reactive towards thiols and it may be predicted that the ligand is 
rapidly exchanged by –SH groups in vivo. Potent in vitro cytotoxic activity and in vivo 
anti-tumour activity have been observed only for gold(I) complexes with coordinated 
phosphine ligands, while complexes with ligands R2S, pyridine, or cyclo-octadiene 
show low cytotoxicity and marginal anti-tumour activity. Activity of phosphines is 
mostly attributed to the lipophilic nature of these compounds. The lipophilic 
phosphines are believed to aid in the uptake of the complex into the cell, while 
polymeric gold(I) thiolates do not readily enter cells.6  
 
Another avenue of investigation has been to synthesise gold complexes containing 
ligands with known anti-tumour activity.99 Examples of this are a series of Ph3PAu(I)-
nucleotide complexes containing ligands such as 5-fluorouracil and 6-mercaptopurine, 
phosphinogold(I) ferrocene complexes such as [µ-1,1-bis(bis(diphenylphosphino))-
ferrocene] di(gold choride), more recently a series of novel nitrogen containing 
phosphino gold(I) ferrocenes,100 and a gold(III) complex of streptonigrin, a substituted 
7-amino-quinoline-5,8,-dione.85,99 
 
Gold(I) bisphosphine compounds of dppe and related ligands with a tetrahedral 
coordination geometry turned out to be a particularly potent class of compounds but 
clinical trials were not pursued owing to the acute toxicity associated with them.6 
However, subsequent studies have focused on chemically modifying the aromatic 
substituents, such as to form n-pyridyl analogues, so as to moderate the lipophilicity 
of the compounds and to emphasise their apparent anti-mitochondrial activity.44,85 The 
physiological action of tetrahedral complexes will be discussed further in Chapter 3. 
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1.4.1.2.5 Gold(III) in Anti-Tumour Treatment 
 
Factors, that suggest a study of the anti-tumour potential of gold compounds might be 
worthwhile, relate to the fact that gold in the +3 oxidation state has the same 
electronic configuration and structural characteristics as platinum(II), a component of 
the world’s most widely-used anticancer drug, cisplatin [(NH3)2PtCl2]. The major 
drawback of cisplatin is the exhibition of serious side effects.44,71,85,101,102 
 
The gold(III) compounds investigated for potential anti-tumour activity are inevitably 
four-coordinate and feature square planar geometries, as found for cisplatin. A similar 
mechanism of action, i.e. interaction with DNA and disruption of normal cellular 
processes, was initially assumed for these compounds. In connection with this, 
evidence has been provided that some species bind to DNA.44,71,101 
 
One of the key problems that hampered the development of gold(III) complexes is 
their low stability under physiological conditions. Gold(III) compounds are strong 
oxidation agents and are able to oxidise a series of biomolecules such as methionine 
and glycine. In recent years, owing to the contributions of a few research groups, new 
gold(III) compounds have been synthesised and characterised that show sufficient 
stability under physiologically relevant conditions. The stability of gold(III) 
compounds can be enhanced by introducing chelating ligands. Gold(III) complexes 
should ideally be coordinated by at least two chelating nitrogen donors which lowers 
the redox potential of the metal centre and thereby stabilises the complexes.71,101,102 
 
There are basically three classes of gold(III) compounds receiving serious attention at 
present. The three classes are: i) those incorporating biologically active species such 
as streptonigrin;64,103 ii) compounds with imine (pyridine-type nitrogen) donor 
atoms;64,104 and iii) organogold compounds, i.e. containing Au-C bonds.64,,105 
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Whereas, the overwhelming majority of gold(III) compounds investigated thus far, 
contain ligands containing some combination of chloride, nitrogen, oxygen and 
carbon as donor atoms, perhaps it is significant that arguably the compound showing 
the most promise contains a sulphur donor atom and is a complex of 2-
mercaptobenzoate.44,106 
 
The chelating binding mode of the thiosalicylate ligand in this gold(III) complex, {p-
MeOC6H3CH2NMe2} Au(SC6H4CO2-2) (Figure 1.18), is very different to the 
previously characterised gold(I) thiolate complexes. These complexes might display 
different biological activities, which could be of interest given the medical importance 
of gold-thiolate complexes.85,106 Further analogues of (damp)AuC12 have been 
evaluated in this way. Biochemical studies indicate that these compounds have a 
mechanism of action significantly different to that of cisplatin suggesting that this is a 
potentially important novel class of metal-containing anti-tumour agents.85 
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Figure 1.18: The chemical structure of the 2-mercaptobenzoate gold(III) compound, 
{p-MeOC6H3CH2NMe2} Au(SC6H4CO2-2). 
 
Other gold(III) compounds receiving attention are those patented by Leung et al.107 
and compounds being studied by Guo et al.,102 Messori et. al.101 and Yang et al.108 An 
Associate Professor at the National University of Singapore, Pak Hing Leung and his 
team have discovered that phosphine supported gold complexes have excellent anti-
tumour activity and clinical trials are likely to begin in the near future.75  
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The Research group of Zijan Guo102 at Ninjang University, China, has studied a series 
of gold(III) compounds that show potential anti-tumour activity. The three gold(III) 
complexes  studied are: i) [Au(Quinpy)Cl]Cl; ii) [Au(Quingly)Cl]Cl; and iii) 
[Au(Quinala)Cl]Cl (Figure 1.19). The ligands coordinate to gold(III) in a tridentate 
mode forming two five-membered chelate rings. The gold(III) in these complexes 
shows a slightly distorted square planar coordination formed by three nitrogen atoms 
of the ligand and one chloride atom. All the complexes have shown considerable 
cytotoxic activity against several tumour cell lines. The complexes are able to replace 
the DNA stain, ethidium bromide (EB), from the DNA-EB system, suggesting that 
they may intercalate into DNA. It is not clear whether such an interaction is 
responsible for the observed cytotoxicity.102 
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Figure 1.19: Gold(III) coordination compounds showing  
potential anti-tumour activity. 
 
Chang-Tong Yang108,109,110 and his group at the University of Singapore have studied 
2-phenylpyridine gold(III) complexes (Figure 1.20) with, among others, a dithiolate 
ligand. These thiolate gold(III) complexes were found to be more stable than the 
similar dicarboxylate complexes. Their research included gold(III) complexes with 
chelated mono-anionic N–N- ligands (Figure 1.20). These compounds have shown 
some cytotoxicity.108,109,110 
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Figure 1.20: Compounds investigated by the group of Chang-Tong Yang. 
 
In an attempt to find the physiological mode of action of gold(III) complexes, 
Messori101 and his group at the University of Florence have taken representative 
gold(III) complexes and subjected them to numerous experiments to find the elusive 
mechanism of cytotoxicity. What they found was that the interactions of gold(III) 
complexes with the DNA double helix were generally weak, reversible and 
predominantly electrostatic in nature, suggesting that DNA is not the primary target 
for the cytotoxic effects of these complexes. Later experiments with bovine serum 
albumin as a general model for plasma proteins revealed different patterns of 
reactivity for the various compounds in relation to the specific chemical properties of 
the gold(III) complexes. In some cases close adducts were formed in which the bound 
gold(III) centres are probably coordinated to histidine residues at the surface of the 
protein. It was hypothesised that the ability of selected gold(III) complexes to tag 
either cysteine or histidine residues may result in specific damaging of crucial 
intracellular proteins, thus accounting for the relevant cytotoxic effects of these 
compounds.101,111 
 
1.4.2 Silver Compounds in Medicine 
 
Silver is neither toxic nor essential for human beings either as an element or in its 
complexed form and the human body normally contains no silver. However, for 
micro-organisms it is highly toxic, since silver(I) ions block the activity of thio-
enzymes. Even traces of colloidal silver kill any germs present in water. Chronic 
ingestion of soluble silver compounds over long periods of time produces black 
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coloration of the skin, liver, kidneys, etc. as insoluble silver sulphide precipitates. The 
condition is known as argyria. When silver nitrate solution is dropped on the skin, it 
causes the skin to turn black.41 
 
1.4.2.1 History 
 
For thousands of years silver has been highly regarded as a versatile healing tool. In 
ancient Greece, Rome, Phoenicia and Macedonia silver was used extensively to 
control infections and spoilage. Hippocrates taught that silver healed wounds and 
controlled disease. Around 400 B.C. he listed as a singular treatment for ulcers "the 
flowers of silver alone, in the finest powder". Herodotus, a Dorian Greek historian, 
describes how the King of Persia carried with him boiled water in silver flagons to 
prevent sickness. In 69 B.C. silver nitrate was described in the contemporary Roman 
pharmacopoeia. Pliny the Elder, an ancient Roman nobleman, in his survey of the 
world's knowledge, states in Natural History (78 A.D.), Book XXXIII, Section XXXV, 
that the slag of silver "... has healing properties as an ingredient in plasters, being 
extremely effective in causing wounds to close up...".112,113 
 
The popularity of medicinal silver developed from 702 A.D. to 980 A.D. throughout the 
Middle East where it was widely used and esteemed for blood purification, heart 
conditions and controlling halitosis. Paracelsus, an alchemist, physician, astrologer 
and general occultist (circa 1520), extensively incorporated silver in medical 
applications. Angelus Sala used silver nitrate to successfully treat chorea, Tabes 
dorsalis (syphilis), and "doubtably epilepsy". These silver salts were reported by Sala 
to occasionally cause the bluish hue of skin discoloration due to overuse (Argyria). It 
is widely thought that during the Middle Ages silver utensils and goblets contributed a 
bluish hue to the skin tone of the upper class, resulting in the term “royal blue 
bloods”. Plausibly the term “born with a silver spoon in his mouth” was coined during 
that time for the same reason as an attribute for describing the good fortune of health 
more than having wealth. These blue bloods were noted to have obtained a measure of 
protection from the rampant plagues common to Europe in those centuries. The use of 
silver to provide bacteria-free tableware, pacifiers and storage vessels has been 
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practiced throughout history. Today it is known that metallic silver will dissolve in 
water to the level of 5-10 mg/L and this water will therefore be toxic to Escherichia 
coli and Bacillus typhosus.112,113 
 
Pioneers of the American West would often put a silver dollar into a jar or container 
of milk to help keep it fresh without refrigeration. They would drop silver and copper 
coins in their barrels of drinking water to combat bacteria and algae. During the wars 
with Napoleon the armies of Tsar Alexander used water casks lined with silver to 
clean drinking water from rivers and streams. This practice by the Imperial Russian 
army was common through World War I and continued to be incorporated by some 
units in the Soviet Army during World War II. Raulin recorded the first clinical 
description of the water-cleansing effect by silver in 1869. He observed that 
Aspergillus niger could not grow in silver vessels.112 
 
The Swiss botanist von Nageli recorded one of the remarkable discoveries of the 19th 
Century in 1869. Von Nageli coined the term "oligodynamic" to describe the 
microbiocidal properties of a metal hydrosol (e.g. copper, silver and tin) at minute 
concentrations. Recent studies confirm that silver ions are active against bacteria at 
concentrations as low as one part per billion in pure water. Silver ions react rapidly 
with the walls of prokaryotic cells typical of micro-organisms, whereas the 
membranes of eukaryotic cells of mammals strongly resist any effect by 
silver.112,113,114 
 
In 1884 the German obstetrician C.S.F. Crede115 observed that there was a 79% 
relationship between blind children and maternal venereal disease. He subsequently 
introduced a prophylactic 1% silver nitrate eye solution for newborns for the 
prevention of ophthalmia neonatorum. Following its introduction the incidence of eye 
disease in newborns dropped to about 0.2%. His treatment was a milestone in clinical 
prophylaxis and became a government regulation throughout most of the world. By 
1897 silver nitrate began to be used in America to prevent blindness in newborns and 
is still used today. By 1910 Henry Crookes had documented that certain metals, when 
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in a colloidal state, had strong germicidal action, but were harmless to human beings. 
The oligodynamic concept motivated the development of many anti-microbial 
processes and products.112, 113 
 
1.4.2.2 Recent Developments in the Medicinal Applications of Silver Compounds 
 
1.4.2.2.1 Silver in Anti-Microbial Treatment  
 
During World War II Charles L. Fox,116 a surgeon, observed that many soldiers died 
of uncontrolled bacterial infection in open wounds. He had long used silver nitrate as 
part of his medical practice, but it was far too aggressive with protein structures - 
limiting its clinical uses. His research at the Department of Surgery and Microbiology, 
College of Physicians and Surgeons, Columbia University, New York, led to the 
discovery of silver sulphadiazine (Figure 1.21).117 This combination provided 
controlled release of silver ions in a wound along with an active antibiotic drug. Silver 
sulphadiazine provided a steady, long-term delivery of silver ions onto or into a 
wound. It is a dual antagonist: silver has the primary activity against pathogens but 
should an organism be sensitive to sulphonamids the sulphadiazine component will 
also be active. This dual function has been studied extensively and its effectiveness 
against a wide range of bacteria, fungi, extracellular viruses and protozoa has been 
proven.112 
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Figure 1.21: Sulphadiazine. 
 
In the early 1970’s, Drs. Becker, Marino and Spadaro118 of the Veterans 
Administration Hospital in Syracuse, New York, pioneered the study of silver-coated 
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fabrics for the treatment of complex bone infections. Having studied with Dr. Becker, 
Dr. A.B. Flick began developing broader clinical applications for silver nylon fabrics 
in partnership with Dr. Becker during his Orthopaedic Surgery residency training at 
the University of Vermont.119,120 Dr. Flick subsequently entered private practice and 
continued his research independently.113 
 
During roughly the same time three other university centred research teams 
investigated the wound healing properties of silver plated fabrics after the application 
of an electrical potential. Dr. Alvarez,121 at the Department of Dermatology, 
University of Miami, in 1985, studied the effect of electrically activated silver-coated 
fabrics on an animal model of skin wounds in pigs. Dr. Marino and Dr. Albright,122 at 
the Department of Orthopedic Surgery, Louisiana State University, 1983 - 1986, 
studied the effect of electrically activated silver plated fabrics on chronic bone 
infections in humans. Dr. Chu and Dr. McManus,123 at the Army Surgical Research 
Centre, Fort Sam, Houston, 1989 - 1996, studied the effect of electrically activated 
and non-electrically activated silver-coated fabrics on several animal burn wound 
models.112,113 
 
Research initiated in the 1990's by the Chinese government through the Department of 
Materials Science and Engineering, Tsinghua University, Beijing, studied the reaction 
between bacteria and silver ions. Their goal was to develop an effective antiseptic that 
would sanitise almost any surface. They developed a silver/zircon phosphate complex 
that proved to be an excellent disinfectant with stable, long-term sterilisation effects. 
This silver complex maintained perfect safety with no toxicity to humans. The 
Science and Technology Ministry of China certified the new anti-microbial as a 
"National Key New Product". It is marketed as Concal PAg-40TM.112 
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In the U.S., silver is being used as a broad-spectrum antiseptic in several commercial 
areas. For example, silver dihydrogen citrate (Axenohl) is an electrolytically 
generated compound that works well in combination with other compounds used as 
hard surface disinfectant for food contact surfaces, clinical work surfaces, medical 
disinfectant wipes and water treatment systems. The black polyvalent silver oxide, 
Ag404, is a compound with two single-charged and two triple-charged silver atoms. It 
is a microbacidal compound effective against bacteria, yeast and mold. It is a safe, 
EPA (Environmental Protection Agency) approved, antiseptic compound. Tetrasil is 
an example of this oxide used in a bactericidal topical ointment. It is the best choice of 
silver compound currently available for sanitising acrylic hot tubs.106,112 
 
1.4.2.2.2 Silver in Anti-Tumour Treatment  
 
The use of silver compounds in pharmaceuticals has been hampered by their 
unfavourable chemical properties. Many silver(I) complexes are light sensitive and 
the insolubility of AgCl always presents a problem when silver compounds come into 
contact with physiological fluids. Over 100 silver compounds have been evaluated for 
anti-tumour activity by the National Cancer Institute (NCI) and only five have shown 
marginal activity.6 
 
By slowing down the rapid-ligand exchange reactions common in silver(I) chemistry 
it seems likely that a silver complex could be designed that would not be precipitated 
by Cl-. This might lead to in vivo anti-microbial and anti-tumour activity. Tetrahedral 
bisphosphine silver(I) complexes might be a good candidate to withstand 
physiological conditions.6 This will be discussed further in Chapter 2 and 3. 
 
1.5 CONCLUSION 
 
As can be seen from the literature, silver and gold both have long histories as metals 
of worth, either as decoration or as bartering tool. Due to the interest in the properties 
of these metals, the rich chemistry of Group 11 transition metals and indirectly also 
the chemistry of related metals has been explored extensively.  
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The use of ligands to manipulate the properties of metal compounds and more 
specifically those of the transition metals is well known and documented. These 
ligands contain more often than not phosphorous and bidentate phosphine ligands 
have become common in metal complexation. The versatility of dppe, for example, to 
bind metal ions is enormous. Due to recent synthetic advances the incorporation of a 
hydrazine bridge instead of an ethane bridge has become possible. This small 
alteration gives new opportunities to manipulate the steric and electronic properties of 
these phosphines. 
 
Gold and silver have long histories as medicinal tools, both in metaphysical and 
genuine medical applications. The research into the physical and biological properties 
of these two metals has yielded important medicinal drugs. The application of gold-
based auranofin in the treatment of RA is well documented and recently gold-based 
anti-tumour drugs are becoming as effective as platinum-based anti-tumour drugs at 
treating cancer.44 Silver is still seen to be superior in its use as anti-microbial agent. 
Silver complexes, however, are said to be physiologically too unstable to be used as 
anti-tumour drugs, but tetrahedral silver might hold the break-through required to 
stabilise the complexes sufficiently to enable them to reach the target site. 
 
The anti-tumour properties of these two metals have recently come into the spotlight 
with the exploration of [Au(dppe)2]+ and [Ag(dppe)2]+ as potential anti-tumour agents. 
The cytotoxicity of these tetrahedral gold(I) and silver(I) compounds was found to 
directly relate to their lipophilic cationic nature. The lipophilic/hydrophilic balance 
was found to modulate cytotoxicity, bioavailability and cell uptake of the drugs. In 
this thesis the chemistry and anti-tumour properties of gold(I) and silver(I) complexes 
were investigated. To this effect the incorporation of hydrazine-bridged bisphosphines 
to further fine-tune the hydrophilic/lipophilic balance of tetrahedral gold(I) and 
silver(I) complexes was employed. 
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Chapter 2 
 
Synthesis of Hydrazine-Bridged Ligands and Related 
Group 11 Transition Metal Complexes  
 
2.1 INTRODUCTION 
 
In this chapter the synthesis of bidentate phosphine ligands with a flexible backbone 
and the subsequent gold and silver complexes of these ligands will be discussed. The 
flexible backbone was provided by dimethyl or diethyl hydrazine. The addition of 
varied phosphine moieties served to introduce small variations in the electronic and 
steric properties of the ligand. The complexation of gold(I) and silver(I) to these 
ligands was aimed at providing a range of complexes with varied, yet related 
properties. The complexes were earmarked for anti-tumour activity tests and the 
results were expected to give insight into the structure/toxicity and 
structure/selectivity relationship of these complexes. 
 
2.2 LIGAND SYNTHESIS 
 
2.2.1. Ligand Precursor Synthesis 
 
The synthetic route pioneered by Katti et al.25 to produce bis(dichlorophosphino)-
dimethylhydrazine (2) involved the treatment of 1,2-dimethylhydrazine dihydro-
chloride with phosphorous trichloride (PCl3) (Scheme 2.1). PCl3 was used as both 
solvent and reactant and the mixture was refluxed for 36 hours to give 
Cl2PN(Me)N(Me)PCl2 (2) in 92% yield.25 
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Scheme 2.1: Synthesis of bis(dichlorophosphino)dimethylhydrazine. 
 
The 3lP NMR spectrum of the product (2) was in agreement with literature and 
consisted of a single peak at 160.2 ppm. The 1H NMR spectrum of 2 consisted of a 
deceptively simple triplet centred at 3.15 ppm (J = 3.7 Hz), presumably due to virtual 
coupling of the methyl groups to the two phosphorous atoms. Katti et al.25 had found 
that the high yield and the purity of 2 remained unchanged even when the reaction 
was carried out at a scale of up to 50 – 100 g, suggesting the feasibility of this reaction 
in large scale. The presence of two trivalent phosphorous centres in 2 presents the 
possibility of using this ligand as a electron donor toward transition metals. To prove 
this theory, Katti et al.25 reacted 2 with (PhCN)2PdCl2 and (COD)PtCl2to produce the 
new metallocyclic compounds [(Cl2PN(Me)N(Me)PCl2)MCl2] containing M = Pd(II) 
(3) or Pt(II) (4) centres. The determination of the molar mass of 3 and 4 in solution 
indicated them to be monomeric in solution. The 31P NMR spectra of 3 and 4 in 
CDCl3 revealed sharp singlets at 151.9 and 121.4 ppm, respectively. The downfield 
3lP chemical shift of the free ligand 2 (160.2 ppm) as compared to the Pd(II), 3, (151.9 
ppm) and Pt(II), 4, (121.4 ppm), complex has been noted earlier for a number of 
Pd(II)/Pt(II) complexes of R2PN(R')PR2.24,25,36 
 
Employing a similar technique to that of Katti et al.,25 Slawin et al.29 were able to 
synthesise the analogous diphosphine, Cl2PN(Et)N(Et)PCl2 (Scheme 2.2), from the 
reaction of 1,2-diethylhydrazine dihydrochloride and phosphorous trichloride. 
 
N N
Et Et
HH
.2HCl   +   excess PCl3 N N
Et Et
PCl2Cl2P
+   4HCl
 
               5                                                                                 6 
Scheme 2.2: Synthesis of bis(dichlorophosphino)diethylhydrazine. 
 
 45 
This method employed the dropwise addition of PCl3 to a finely ground sample of 
1,2-diethylhydrazine dihydrochloride resulted in the formation of a viscous orange 
suspension. The reaction mixture was heated under reflux for 96 hours and excess 
PCl3 was removed in vacuo to leave a viscous orange oil. Kugelrohr distillation of the 
crude product yielded 6 as a colourless oil in good yield (72%). The 31P NMR 
spectrum of 6 showed a singlet at 156 ppm, an upfield shift of approximately 4 ppm 
compared to the value reported for Cl2PN(Me)N(Me)PCl2 by Katti et al.25 Having 
successfully synthesised Cl2PN(Et)N(Et)PCl2, Slawin et al.29 were able to use this 
compound as a precursor in nucleophilic substitution reactions and reactions with 
Grignard reagents to produce a range of aryloxy- and aryl-substituted 
phosphorous(III)hydrazides.29 
 
Synthesis of ligand precursors (2 and 6) in our group was done in a similar manner to 
the synthetic routes pioneered by Katti et al.25 and Slawin et al.29 1,2-dimethyl 
hydrazine dihydrochloride (1) or 1,2-diethylhydrazine dihydrochloride (5) were 
suspended in an excess of PCl3. The reaction mixture was heated to reflux under 
argon and monitored by visual inspection until most of the starting material had been 
consumed, while formation of yellow oxidic side products was still minimal (between 
8 and 48 hours). The excess PCl3 was removed in vacuo and recycled. The resulting 
suspension of chlorophosphine and phosphorous oxides was treated with oxygen-free, 
dry ether. This led to the precipitation of all unreacted starting material and oxides. 
The ether was decanted from the solids and concentrated in vacuo to yield the 
products (2 and 6) in >95% yield as colourless to slightly yellow oils. 
 
Katti et al.25 also reported the synthesis of various metal complexes in which 
diphosphine derivatives of Cl2PN(Me)N(Me)PCl2 act as P, P’ chelates.19,25 Slawin et 
al.29 later described the synthesis of metal complexes containing derivatives of 
Cl2PN(Et)N(Et)PCl2 acting as P, P’ chelates as well as further examples involving 
derivatives of Cl2PN(Me)N(Me)PCl2. 
 
2.2.2. Synthesis of Aryl-Substituted Bisphosphine Ligands 
 
To demonstrate the versatility of Cl2PN(Et)N(Et)PCl2 (6) as a ligand precursor Slawin 
et al.29 reacted 6 with four equivalents of RMgBr (R = Ph or CH2Ph) in diethylether to 
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synthesise the diphosphines Ph2PN(Et)N(Et)PPh2 (7) and (PhCH2)2PN(Et)N(Et)-
P(CH2Ph)2 (8) as colourless to pale yellow solids in good yields (70% and 74%, 
respectively) (Scheme 2.3).29 This method had first been used by Katti et al.25 to 
convert Cl2PN(Me)N(Me)PCl2 (2) to Ph2PN(Me)N(Me)PPh2 (9). 
 
N N
Et Et
PCl2Cl2P
+   4 RMgBr N N
Et Et
PR2R2P
+  4 ClMgBr
 
R = Ph (7), R = CH2Ph (8) 
Scheme 2.3: Synthesis of bis(phosphino)hydrazine ligands. 
 
The 31P NMR spectra of compounds 7 and 8 showed singlets at 64.2 ppm and 64.8 
ppm, respectively.29 This was in agreement with what Katti et al.19 had found for the 
related compound 9 (31P NMR 62.5 ppm). 
 
Slawin et al.29 also successfully synthesised a series of ligands containing phenyl 
groups with substituents in the ortho position (Scheme 2.4). Reaction of 
Cl2PN(Me)N(Me)PCl2 (2) with the Grignard reagent o-tolylmagnesium chloride, (2-
Me)PhMgCl, or o-anisylmagnesium bromide, (2-MeO)PhMgBr, yielded ((2-
Me)Ph)2PN(Me)N(Me)P(Ph(2-Me))2 (10), and ((2-MeO)Ph)2PN(Me)N(Me)P(Ph(2-
OMe))2 (11), respectively, while the reaction of Cl2PN(Et)N(Et)PCl2 (6) with o-
anisylmagnesium bromide generated ((2-MeO)Ph)2PN(Et)N(Et)P(Ph(2-OMe))2 (12). 
 
N N
R
PCl2Cl2P
R
+  4 N N
R R
PP
R' R'
+  4 ClMgBr
MgBr
R'
2 2  
R = Me, R’ = CH3 (10); 
R = Me, R’ = OCH3 (11); 
R = Et, R’ = OCH3 (12); 
Scheme 2.4: Synthesis of ortho substituted bis(phenylphosphino)hydrazines. 
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The 31P NMR spectra of 10, 11 and 12 showed singlets at 47.2, 42.6 ppm and 40.5 
ppm, respectively. The R2PN(R’)N(R’)PR2 ligands described were all air-stable solids 
although the starting materials, 2 and 6, hydrolysed rapidly in air.29 
 
Six ligands were synthesised for our purposes. Three derivatives of each of the 
chloro-precursors Cl2PN(Me)N(Me)PCl2 (2) and Cl2PN(Et)N(Et)PCl2 (6) were 
synthesised. The addition of phenyl-, p-methoxyphenyl- or N,N-dimethyl-p-
aminophenyl-groups to the phosphorous centres was hoped to yield a range of ligands 
characterised by small variations in their steric properties. The resulting ligands: i) 
bis(diphenylphosphino)dimethylhydrazine (13); ii) bis(diphenylphosphino)diethyl-
hydrazine (14); iii) bis(di(p-methoxyphenyl)phosphino)dimethylhydrazine (15); iv) 
bis(di(p-methoxyphenyl)phosphino)diethylhydrazine (16); v) bis(di(N,N-dimetyl-p-
aminophenyl)phosphino)dimethylhydrazine (17) and vi) bis(di(N,N-dimetyl-p-
aminophenyl)phosphino)dimethylhydrazine (18) (Scheme 2.5) were conveniently 
synthesised using the corresponding bis(chlorophosphino)hydrazine and the 
appropriate Grignard reagent.  
 
N N
R R
P PR' R'
N N
R R
Cl2P PCl2
MgBr   4  R'
ether / THF
+
2 2
0oC
 
R = Me, R’ = H (13); R = Et, R’ = H (14); 
R = Me, R’ = OMe (15); R = Et, R’ = OMe (16); 
R = Me, R’ = NMe2 (17); R = Et, R’ = NMe2 (18); 
 
Scheme 2.5: Syntheses of bisphosphine hydrazine ligands. 
 
The reaction of the ligand precursors with the Grignard reagents in either diethylether, 
in the case of the phenyl Grignard reagent, or in THF, in the case of the remaining two 
Grignard reagents proceeded without any problems. The reactions were carried out by 
adding Grignard reagent drop-wise at 0 oC and stirring at 0 oC for a period of 4 hours, 
after which the reaction was left to reach room temperature overnight. The 
consecutive rapid addition of brine to the reaction mixture under argon led to two 
layers. The organic layer was subsequently removed by means of a separating funnel, 
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dried over anhydrous magnesium sulphate and removed in vacuo to yield the products 
13 - 18 as sticky yellow semi-liquids in yields of 70 – 90%. 
 
The ligands were found to be almost pure after work-up (>95% based on the 31P NMR 
spectrum) and were shown to be sufficiently pure for further reactions. It was possible 
to further purify 14 through crystallisation from ether at –20 oC, while attempts to 
purify and crystallise the other 5 ligands were unsuccessful.  
 
A comparison of the compounds in Table 2.1 shows that electron donor substituents 
in ortho position result in significant upfield shift (compounds 11 and 12; 31P NMR 
signals 42.6 ppm and 40.5 ppm, respectively) of the adjacent phosphorous atom, 
while substituents in the para position (compounds 15 and 16; 31P NMR signals 61.4 
ppm and 61.0 ppm, respectively) hardly influence the 31P-NMR spectroscopic shifts if 
compared to the unsubstituted derivatives 13 and 14 (31P NMR signals 63.3 ppm and 
63.4 ppm, respectively). This overall upfield shift of ortho substituted aryls at a 
phosphorous centre compared to other substituents has been described by Grim et 
al.124 and is said to be attributable to a γ effect, described as an upfield contribution to 
the chemical shift caused by a substituents in the position γ to the nucleus in question. 
                                               
124
 S.O. Grim, A.W. Yankowsky, Phos. Sulf., 1977, 3, 191. 
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No. 
Methylhydrazine 
Compound 
31P 
NMR 
No. 
Ethylhydrazine 
Compound 
31P 
NMR 
2 N N
Me Me
PCl2Cl2P
 
160.9 
160.219 
6 N N
Et Et
PCl2Cl2P
 
156.3 
156.329 
13 N N
Me
PPh2Ph2P
Me
 
63.3 
62.519 
14 N N
Et
PPh2Ph2P
Et
 
63.4 
64.829 
10 N N
P(Ph-2-Me)2(Me-2-Ph)2P
Me Me
 
47.129 8 N N
Et
P(CH2Ph)2(PhCH2)2P
Et
 
64.829 
11 N N
Me
P(Ph-2-OMe)2(MeO-2-Ph)2P
Me
 
42.629 12 N N
Et
P(Ph-2-OMe)2(MeO-2-Ph)2P
Et
 
40.529 
15 N N
Me
P(Ph-4-OMe)2(MeO-4-Ph)2P
Me
 
61.4 16 N N
Et
P(Ph-4-OMe)2(MeO-4-Ph)2P
Et
 
61.0 
17 N N
Me
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
Me
 
61.5 18 N N
Et
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
Et
 
60.4 
 
Table 2.1: 31P NMR spectroscopic shifts of bisphosphine hydrazine ligands. 
 
The functionality of the hydrazine bridge proved to have a profound impact on the 
stability of the ligand. The methylated hydrazine-bridged was markedly less stable 
when compared to the ethylated hydrazine bridge. While all three of the ethylated 
ligands were stable when kept under argon, two of the methylated ligands showed 
slow degradation even when kept under argon. Ligand 13 has been previously 
described as hygroscopic and was found to easily decompose unless the utmost care 
was taken.19 Ligand 15 was more stable, but still showed degradation after prolonged 
periods of storage. Ligand 17 proved to be stable when stored under argon, but 
showed signs of decomposition in the presence of metal salts during complexation 
reactions. In sharp contrast to this behaviour ligand 14 in crystalline form showed 
prolonged stability even when kept in moist air. 
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2.2.3. Synthesis of Pyridyl-Substituted Bisphosphinohydrazine Ligands 
 
The chemistry of water-soluble coordination compounds has received significant 
interest in the past few years, particularly in the area of biphasic catalysis.125,126,127 
Even though there is currently a large interest in this field, the lack of suitable water-
soluble ligands is a serious bottleneck. The ligands synthesised for catalytic purposes 
may, however, be exploited for the use in the biochemical field where water solubility 
is a huge advantage in delivering biologically active metal centres to the desired site 
of activity. Bisphosphines containing a hydrazine bridge have also been reported to 
add solubility to these ligands as compared to their carbon analogues. When a 
hydrazine backbone is coupled with tertiary bisphosphines containing 2-, 3- and 4-
pyridyl substituents the water solubility can be greatly enhanced. A small amount of 
pyridyl substituted phosphines are known and methods for their preparation, have 
more often than not, failed in the past.125,128 Recent methods described by Berners-
Price et al.125 have been successful in synthesising a range of these ligands and 
thereby opening up the study of these kinds of ligands for applications not only in 
industry, but also in the biomedical field. 
 
The synthesis of pyridyl-substitututed bisphosphines as developed by Berners-Price et 
al.125 calls for the slow addition of 2-, 3- or 4-bromopyridine to a solution of butyl 
lithium and TMEDA (N,N,N’,N’-tetramethylethylenediamine) in diethylether at  
–115 oC, followed by quenching with Cl2P(CH2)2PCl2. We applied the same method 
for the attempted synthesis of the analogous hydrazine-bridged pyridyl phosphine 
ligands with the only difference being that the quenching was carried out with 
Cl2PN(Et)N(Et)PCl2 instead of Cl2P(CH2)2PCl2. The reaction mixture was then stirred 
for 2 hours, allowed to warm to –80 oC over an 11 hour period, followed by warming 
to ambient temperature over a 3-4 hour period. Berners-Price et al.125 found that the 
addition of TMEDA increased the reactivity of pyridyllithium towards the 
chlorophosphine precursor and low temperatures suppressed competitive addition or 
coupling reactions.125 
                                               
125
 R.J. Bowen, A.C. Garner, S.J. Berners-Price, I.D. Jenkins, R.E. Sue, J. Organomet. 
Chem., 1998, 554, 181. 
126
 W.A. Hermann, C.W. Kohlpainter, Angew. Chem. Int. Ed., 1993, 32, 1524. 
127
 B.E. Hanson, Coord. Chem. Rev., 1999, 185, 795. 
128
 G.R. Newkome, Chem. Rev., 1993, 93, 2067. 
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The synthesis of 2-, 3- and 4-pyridyl substituted diethylhydrazine-bridged 
bisphosphine ligands proved to be straightforward (Scheme 2.6). The 31P NMR 
spectra of the crude reaction mixtures showed only one distinct phosphorous signal 
for bis(di(3-pyridyl-phosphino))-1,2-diethylhydrazine (20) and bis(di(4-
pyridylphosphino))-1,2-diethyl hydrazine (21) ligands, respectively (Table 2.2). 
Bis(di(2-pyridylphosphino))-1,2-diethylhydrazine (19) seemed to produce moderate 
amounts of two other phosphorous containing side products. This could be 
circumvented by cooling the reaction mixture below –115 oC with liquid N2 and 
thereby minimising the production of these side products.  
 
4 BuLi (hexane)
                           +    4 RBr
4 TMEDA (ether)
-115oC
N
N
LiR + Cl2P PCl2
NN
Et Et
R2P PR2
NN
Et Et
4
 
R = 2-pyridine (19), R = 3-pyridine (20), R = 4-pyridine (21) 
 
Scheme 2.6: Synthesis of 2-, 3- and 4-pyridylphosphines. 
 
Ligand  Nr. 31P NMR 
Bis(di(2-pyridylphosphino))-1,2-diethylhydrazine 19 60.1 
Bis(di(3-pyridylphosphino))-1,2-diethylhydrazine 20 54.2 
Bis(di(4-pyridylphosphino))-1,2-diethylhydrazine 21 53.6 
Table 2.2: 31P NMR spectroscopic shifts of pyridyl substituted diethylhydrazine 
bisphosphines. 
 
The purification of the three ligands, however, proved to be problematic. 1H-NMR 
spectroscopic investigation of the products after an aqueous work-up with brine (to 
remove Li-salts and polar side products) showed numerous signals in the 1H-NMR 
spectrum indicative of a large number of impurities. Purification of the resulting 
organic phase by precipitation or crystallisation failed due to the similar solubilities of 
the product and the impurities. Various solvent extraction methods also lead to the 
decomposition of the ligands. Due to the instability of the ethylhydrazine 
bisphosphine ligands the methylhydrazine bisphosphine ligands were not attempted.
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Unpurified ethylhydrazine bisphosphine ligands were therefore used in complexation 
reactions in the hope that the resulting complexes might be easier to purify. Broad 31P 
NMR signals were observed for the complexes, accompanied by signals arising from 
the ligand and from various other phosphorous containing products. In most cases the 
complexation led to the formation of colloidal gold or silver. Efforts to try to 
precipitate the complexes led to the breakdown of the complexes into characteristic 
ligand fragments. 
 
2.3 Gold Complexes 
 
In the vast majority of its complexes gold(I) exhibits linear two coordination. As a 
consequence ligand exchange reactions occur rapidly via an associative mechanism 
and a three-coordinate transition state (Scheme 2.7). Facile ligand exchange reactions 
with thiols have been reported to play an important role in the anti-arthritic activity of 
many gold(I) compounds, but they may also bring about reduction in the cytotoxic 
potency of gold(I) phosphine complexes. It seems likely that tetrahedral gold(I) 
complexes containing chelated bisphosphine ligands are more stable with respect to 
ligand-exchange as this would require a dissociative mechanism (five-coordinated 
gold(I) species are unknown) (Scheme 2.8).6 
 
L Au L   +   Y
Associative
Au
Y
LL
L Au Y   +   L
 
Scheme 2.7: Associative ligand exchange of linear gold(I). 
 
Au
P
P
P
P
Dissociative
Associative
X
Au
PP
P
P
+  Y Products
 
Scheme 2.8: Dissociative ligand exchange of tetrahedral gold(I). 
 
The study of four-coordination and chelation have until recently been neglected in 
gold(I) chemistry. Early investigations describe examples of bisphosphine ligands as 
chelating ligands for gold(I), but even as recent as 1988, studies involving more 
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flexible bidentate phosphines did not report four-coordinate gold(I) complexes. In 
general the characteristic products were reported to have bridged digold or annular 
structures in which gold(I) was coordinated in a linear fashion. Complexes of the type 
XAuPh2P(CH2)nPPh2AuX have been characterised for n = 1 to 12.6  
 
In the early 1980’s the existence of tetrakis(monophosphine)gold(I) complexes was 
established. 31P NMR solution studies of monophosphine gold(I) complexes in the 
presence of free PR3 demonstrated that complexes with different Au:P ratios 
underwent rapid ligand exchange. 31P NMR studies of the bisphosphine-bridged 
digold complex ClAuPh2P(CH2)2PPh2AuCl in the presence of free dppe demonstrated 
that the bischelated complex [Au(dppe)2]+ was present in solution at Au:P ratios as 
low as 1:1.5. Furthermore, the four-coordinated complex exhibited remarkably high 
kinetic stability.6  
 
The complexation of gold(I) to the above bisphosphinohydrazine ligands to give 
bridged or tetrahedral complexes was straightforward. The use of either 
dimethylsulphidegold(I) chloride ((Me2S)AuCl) or tetrahydrothiophenegold(I) 
chloride ((THT)AuCl) made no difference to the formation of the complexes as both 
sulphur containing ligands were easily displaced by the incoming phosphorous centres 
and both sulphur ligands could be removed in vacuo.  
 
The synthesis of ClAuPh2PN(Me)N(Me)PPh2AuCl (Figure 2.9, 22) was achieved by 
suspending the gold(I) precursor in THF and adding the ligand (13) dissolved in 
dichloromethane (DCM). Preparing a solution of 13 in THF before adding it to the 
gold(I) precursor led, however, to the breakdown of the ligand. As soon as the two 
reagents were mixed a micro-crystalline precipitate formed, which could be separated 
by filtration. This micro-crystalline powder proved insoluble in a range of organic 
solvents including highly polar solvents like DMSO and DMF. The stability of the 
new gold(I) complex is in stark contrast to the lability of the ligand, that was 
discussed above. To slow down the formation of crystals, the reaction was carried out 
in DCM. This made it possible to analyse the complex by NMR spectroscopy before 
insoluble crystals could form. To grow crystals suitable for single crystal X-Ray 
analysis one or two drops of THF were added to the DCM solution, which over a 
period of five hours led to the formation of crystals. 
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R2P PR2
NN
R' R'
R2P PR2
NN
R' R'
Au Au
Cl Cl
+   2 (R")AuCl
 
R = Ph; R’ = Me; R” = THT or SMe2 (22) 
R = Ph; R’ = Et; R” = THT or SMe2 (23) 
R = 4-PhOMe; R’ = Me; R” = THT or SMe2 (24) 
R = 4-PhOMe; R’ = Et; R” = THT or SMe2 (25) 
R = 4-PhNMe2; R’ = Me; R” = THT or SMe2 (26) 
R = 4-PhNMe2; R’ = Et; R” = THT or SMe2 (27) 
 
Scheme 2.9: Phosphine-bridged digold complexes. 
 
Compound ClAuPh2PN(Et)N(Et)PPh2AuCl (Figure 2.9, 23) was synthesised from the 
gold(I) precursor and ligand in THF. As soon as the reaction turned clear, stirring was 
halted and crystals big enough for single crystal X-Ray analysis formed overnight. 
Unlike crystals of complex 22, crystals of complex 23 are soluble in both CDCl3 and 
d-DMSO. 
 
Complexes ClAu((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2AuCl (Figure 2.9, 24) 
and ClAu((4-MeO)Ph)2PN(Et)N(Et)P(Ph(4-OMe)2AuCl (Figure 2.9, 25) were both 
synthesised by dissolving the gold(I) precursor in DCM and adding the corresponding 
ligand. The addition of a few drops of THF led to the growth of crystals suitable for 
use in single crystal X-Ray analysis. The presence of THF during the initial 
complexation led to undesirable side products as a result of breakdown of the ligand.  
 
The synthesis of complex ClAu((4-Me2N)Ph)2PN(Me)N(Me)P(Ph(4-NMe2))2AuCl 
(Figure 2.9, 26) was not successful due to breakdown of the ligand during 
complexation. Various combinations of solvents were tried in an attempt to facilitate 
the formation of the complex. The addition of the ligand to the gold(I) starting 
material consistently led to a change in colour from colourless to dark blue-purple. 
The dark blue-purple mixture was analysed by NMR for the presence of 26, but due to 
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the complexity of the mixture, no positive identification could be made. It is 
interesting to note that the ligand itself is stable under argon, but the addition of any 
gold or silver compound led to the immediate breakdown of the ligand. 
 
Complex ClAu(Me2N-4-Ph)2PN(Et)N(Et)P(Ph-4-NMe2)2AuCl (Figure 2.9, 27), in 
contrast to its analogous methylhydrazine derivative, was formed in DCM as solvent 
with minimal breakdown of ligand. The reaction was done in the absence of THF, as 
this led to significant breakdown of ligand.  
 
The four complexes i) [(Ph2PN(Me)N(Me)PPh2)2 Au]+.Cl- (Scheme 2.10, 28); ii) 
[(Ph2PN(Et)N(Et)PPh2)2 Au]+.Cl- (Figure 2.10, 29); iii) [((MeO-4-
Ph)2PN(Me)N(Me)P(Ph-4-OMe)2)2 Au]+.Cl- (Figure 2.10, 30) and iv) [((MeO-4-
Ph)2PN(Et)N(Et)P(Ph-4-OMe)2)2 Au]+.Cl- (Figure 2.10, 31) were synthesised in a 
similar manner. Two equivalents of ligand were dissolved in DCM and one equivalent 
of solid gold(I) precursor was then added. The rapid formation (within seconds) of the 
complex was accompanied by a slight darkening of the light yellow solution. All 
efforts to grow single crystals of these complexes failed. It was possible to obtain 
crystalline deposits of some of the complexes, but these turned out to be disordered 
lumps of crystalline material, which could not be analysed by single crystal X-Ray 
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R2P PR2
NN
R' R'
+   (R")AuCl2
R2P PR2
NN
R' R'
R2P PR2
NN
R' R'
Au
+
.Cl-
 
R = Ph; R’ = Me; R” = THT or SMe2 (28) 
R = Ph; R’ = Et; R” = THT or SMe2 (29) 
R = 4-PhOMe; R’ = Me; R” = THT or SMe2 (30) 
R = 4-PhOMe; R’ = Et; R” = THT or SMe2 (31) 
R = 4-PhNMe2; R’ = Me; R” = THT or SMe2 (32) 
R = 4-PhNMe2; R’ = Et; R” = THT or SMe2 (33) 
 
Scheme 2.10: Bisphosphine gold complexes. 
 
The synthesis of the complexes [(((4-Me2N)Ph)2PN(Me)N(Me)P(Ph(4-NMe2)2)2 
Au]+.Cl- (Scheme 2.10, 32) and [((Me2N-4-Ph)2PN(Et)N(Et)P(Ph-4-NMe2)2)2 
Au]+.Cl- (Scheme 2.10, 33) was accompanied by an unexpected phenomenon. Initially 
the reaction mixture of the complexes in THF after the addition of gold(I) precursor 
showed the characteristic yellow colour associated with complexes of this type, but 
upon stirring for prolonged periods the solution darkened and turned red. The same 
colour change was observed when the solvent was removed in vacuo. The yellow 
solid changed from yellow to red in the absence of any solvent while standing under 
an argon atmosphere. When doing the same reaction in DCM as solvent the colour 
change was observed to be markedly faster. Due to the breakdown of the 
methylhydrazine ligand upon complexation this effect could, however, not be studied. 
The ethylhydrazine ligand showed, as discussed above, greater stability and 31P NMR 
studies showed that the colour change was accompanied by a shift in the phosphorous 
signal from 85.9 ppm to 96.5 ppm. These two signals seemed to reach an equilibrium 
when the signal intensities had reached a ratio of 1:2. This equilibrium ratio was 
reached after about 15 min in DCM or 40 min in THF and then remained constant for 
several days. 
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Efforts to crystallise complex (33) led to the crystallisation of a small amount of the 
corresponding bridged complex (27) as long colourless needles together with a 
crystalline precipitate showing a powder diffraction pattern. To facilitate the 
crystallisation of the bischelated complex, 33 was redissolved in DCM and the anion 
was exchanged from chloride to nitrate via a metathesis reaction with silver nitrate. 
This resulted in a dark brown solution from which red crystals suitable for X-ray 
crystallographic analysis could be grown. 
 
The determination of the crystal structure revealed that the gold(I) centre in 33 had 
been oxidised to gold(III) (34) (Scheme 2.11). It is not clear whether the oxidation 
took place during the normal course of the reaction or during the metathesis reaction. 
However, the slow change of colour from yellow to red during the reaction and the 
subsequent downfield shift in the 31P NMR spectrum from 84.9 ppm to 96.5 ppm, 
indicating further deshielding of phosphorous centres due to higher oxidation of gold 
ion, led us to believe that the slow oxidation of the gold centre from gold(I) to 
gold(III) took place during complex formation and not during methatesis. A small 
downfield shift has also been observed for Ph3PAuIIIMe3 and (Ph3P)2AuIIIMe relative 
to Ph3PAuIMe, with 31P NMR shifts of 1.11, 1.18 and 0.53, repectively.43 This slow 
oxidation would thus also correspond to the colour change from yellow to red.  
 
+
.Cl-
R2P PR2
NN
R' R'
R2P PR2
NN
R' R'
Au
3+
.3Cl-
R2P PR2
NN
R' R'
R2P PR2
NN
R' R'
Au
spontanious
 
                                   33                                                  34 
R = Ph-4-NMe2; R’ = Et 
 
Scheme 2.11: Oxidation of gold(I) to gold(III). 
 
The unexpected behaviour is not yet fully understood but may have to do with the fact 
that the bulky amino groups favour pi-stacking in the square planar arrangement 
(Figure 2.1). The molecular structure of the trinitrate complex (35) was unfortunately 
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obtained at a late stage of the project, disallowing further investigations into the 
formation and the properties of the complex. 
 
 
Figure 2.1: Crystal structure of 35 showing the distinct square planar configuration 
and pi-stacking of phenyl rings. 
 
Analysis of the 31P NMR spectra of the gold complexes (Table 2.3) inidicates a 
general downfield shift of about 25 ppm for the metal complexes in comparison to the 
free ligands (Table 2.1). This can be rationalised if one takes into account the 
deshielding experienced by the phosphorous atoms due to the electron withdrawing 
nature of the metal cation. Generally the bridged gold(I) complexes show a marginal 
downfield shift compared to the bischelated derivatives. A similar effect is also 
observed (although more pronounced) in the analogous dppe gold complexes 
ClAu(dppe)AuCl (36, 27.1 ppm) and [Au(dppe)2]+ (37, 20.7 ppm).129 
                                               
129
 S.J. Berners-Price, P.S. Jarrett, P.J. Sadler, Inorg. Chem., 1987, 26, 3074. 
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No. Complex 
31P 
NMR 
No. Complex 
31P 
NMR 
22 
N N
Me Me
Ph2P PPh2
Au 
Cl
Au
Cl
 
87.1 28 
NN
MeMe
PPh2Ph2P
N N
Me Me
Ph2P PPh2
Au
+
Cl-
 
83.9 
23 
N N
Et Et
Ph2P PPh2
Au 
Cl
Au
Cl
 
87.6 29 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Au
+
Cl-
 
86.5 
24 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
85.1 30 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
81.9 
25 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
84.7 31 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
83.9 
26 
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
Unstable 32 
NN
MeMe
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au
+
Cl-
 
Unstable 
27 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
83.5 33 
NN
EtEt
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au
+
Cl-
 
84.9 
 
Table 2.3: 31P NMR spectroscopic shifts of gold(I) complexes. 
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An exemplary titration of (THT)AuCl with ligand 14 indicated the stability of the 
bischelated gold(I) complexes (Figure 2.2) as previously shown for related gold(I) 
complexes. From bottom to top 0.5 equivalents of ligand 14 were added to 
(THT)AuCl. At a ratio of 0.5:1 the bridged complex 23 is formed as indicated by the 
broad singlet at 87.7 ppm together with a small amount of bischelated complex 29 as 
indicated by a singlet at 86.5 ppm. The broadening of the bridged gold complex signal 
is indicative of phosphorous ligand exchange on the NMR time scale, while 29 shows 
a sharp signal (no exchange at NMR time scale), implying that the bischelated 
complex is kinetically more stable. An unknown complex not found under normal 
reaction conditions is observed (triplet at 88.8 ppm, J = 68 Hz). This unknown 
complex is possibly attributable to the reverse addition of the gold precursor to the 
ligand in the NMR tube, making the [(P-P)Au(µ-(P-P)2)Au(P-P)] complex formation 
possible (Figure 2.2). Already at a ligand:Au ratio of 1:1 bis-chelated complex 
becomes the predominat species. The unknown species once formed does not seem to 
dissappear, while at a ratio of 1.5:1 excess ligand is indicated by a peak at 63.3 ppm. 
The premature appearance of the residual ligand and bischelated species signals might 
be due to the removal of gold(I) centres by the unknown species formed in the first 
addition of ligand. 
 
Ph2 Ph2
AuAu
N N
EtEt
PPh2Ph2P
N N
EtEt
PPh2Ph2P
N
N Et
Et
P
P
Ph2
N
NEt
Et
P
Ph2
P
 
Figure 2.2: [(P-P)Au(µ-(P-P)2)Au(P-P)] complex 
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62646668707274767880828486889092
62646668707274767880828486889092
62646668707274767880828486889092
62646668707274767880828486889092
 
 
Figure 2.3: Titration of (THT)AuCl with ligand 14 (from top to bottom: 2:1; 1.5:1; 1:1; 0.5:1; ratios of ligand 14:(THT)AuCl. 
L:M = 2:1 
L:M = 1.5:1 
L:M = 1:1 
L:M = 0.5:1 
 62 
2.4 Silver Complexes 
 
In contrast to the chemistry of gold(I), four-coordination is common for silver(I) 
phosphine complexes. This is often achieved by Ag-X-Ag bridges such as in 
Et3PAgX which has a tetrameric cubane structure.130 Linear coordination is generally 
only found with very bulky ligands and non-coordinating anions. Tetrakis 
monophosphine complexes can usually only be isolated with large non-coordinating 
anions. Halides generally bind to the metal with the exclusion of the fourth phosphine 
ligand. 31P NMR studies have demonstrated the high kinetic lability of phosphines in 
[Ag(PR3)4]+ complexes.6  
 
Investigations of silver(I) complexes with bidentate phosphine ligands have been far 
less extensive. 31P NMR studies have shown that the bridged dinuclear complex 
(AcO)AgPh2P(CH2)2PPh2Ag(OAc) exists in CDCl3 solution at a Ag(OAc):dppe ratio 
of 2:1, and the silver-phosphorous spin coupling is resolved only at low temperatures 
(<221 K). In contrast to this, at a ratio of 1:2 for Ag(OAc):dppe, two overlapping 
doublets (attributable to the unequal 31P-107Ag and 31P-109Ag coupling constants) are 
resolved at 300 K. The addition of excess dppe caused only slight broadening of the 
multiplet resonance and the appearance of a slightly broadened peak for free dppe, 
indicating a relatively slow exchange between free and bound ligand on the NMR 
time scale.6 
 
It was found that many bischelated silver(I) phosphines showed enhanced kinetic and 
thermodynamic stability compared to monodentate phosphine complexes. 
[Ag(dppe)2]NO3 was reported to be stable in the presence of Cl- and showed no light-
mediated decomposition. Ligand exchange reactions with thiols appeared to be more 
thermodynamically favourable for [Ag(dppe)2]NO3 compared to the gold(I) 
analogue.6  
 
The complexation of silver(I) to the hydrazine bisphosphine ligands proved to be 
more difficult than in the case of gold(I). Formation of the phosphine-bridged silver 
complex (NO3)AgPh2PN(Me)N(Me)PPh2Ag(NO3) (38) could not be achieved due to 
                                               
130
 M.R. Churchill, J. Donahue, F. Rotella, Inorg Chem., 1976, 15, 2752. 
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the breakdown of the ligand and the deposition of a silver mirror on the side of the 
reaction vessel. Various solvent systems were tried, yet all led to decomposition. The 
phosphorous signal of the complex could be identified in the 31P NMR spectrum at 
66.6 (dd, J=246.4 Hz, J=284.2 Hz) ppm but the product could not be isolated.  
 
The complexes (NO3)AgPh2PN(Et)N(Et)PPh2Ag(NO3) (39), (NO3)Ag((4-MeOPh)2P-
N(Me)N(Me)P(Ph(4-OMe))2Ag(NO3) (40) and (NO3)Ag((4-MeO)Ph)2PN(Et)N(Et)-
P(Ph(4-OMe))2Ag(NO3) (41) were synthesised by dissolving AgNO3 in a few drops 
of acetonitrile and addition of a solution of the corresponding ligand in DCM. Care 
was taken to stop the reaction and remove solvent before the solution started turning 
brown and complex decomposition took place. We were fortunate to be able to 
crystallise complex 39 from a mixture of acetonitrile, EtOAc and hexane.  
 
It was not possible to synthesise complex (NO3)Ag((4-Me2N)Ph)2PN(Me)N(Me)-
P(Ph(4-NMe2))2Ag(NO3) (42) due to the breakdown of ligand during complexation 
reminiscent of similar observations for the analogous gold complex. The 
complexation of (NO3)Ag((4-Me2N)Ph)2PN(Et)N(Et)P(Ph(4-NMe2))2Ag(NO3) (43) 
was once again possible and was done according to the method described for 39 – 41. 
The formation of the complex was accompanied by a colour change from colourless 
to dark blue.  
 
The four complexes: i) [(Ph2PN(Me)N(Me)PPh2)2 Ag]+.NO3- (44); ii) [(Ph2PN(Et)-
N(Et)PPh2)2 Ag]+.NO3- (45); iii) [(((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2)2 
Ag]+.NO3- (46) and iv) [(((4-MeO)Ph)2PN(Et)N(Et)P(Ph(4-OMe))2)2 Ag]+.NO3- (47) 
were synthesised in a similar manner. One equivalent of silver(I) nitrate was dissolved 
in a drop of acetonitrile, to which was added two equivalents of the corresponding 
ligand dissolved in DCM. The addition of the ligand in DCM led to the precipitation 
of finely divided AgNO3. The complexation was complete within 30 minutes, i.e. 
after all solid silver nitrate was dissolved. All of the reaction mixtures turned 
colourless with progression of the reaction. While complex 44 proved to be unstable 
over time, it was stable enough to do some characterisation of the complex. It was 
possible to obtain crystals of complex 44 by performing the reaction in THF, reducing 
the volume and leaving the solution standing overnight.  
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It was not possible to fully characterise the complex [(((4-
Me2N)Ph)2PN(Me)N(Me)P(Ph(4-NMe2)2)2 Ag]+.NO3- (48), due to the breakdown of 
ligand and deposition of a silver mirror during complexation. In contrast, the 
complexation of the related [(((4-Me2N)Ph)2PN(Et)N(Et)P(Ph(4-NMe2)2)2 Ag]+.NO3- 
(49) went smoothly and was done according to the method described for 44 - 47. The 
formation of the complex was accompanied by a colour change from colourless to 
light brown. 
 
Complexes of silver(I) showed similar trends than the gold(I) complexes with respect 
to their 31P NMR data (Table 2.4). The upfield shifts of the silver complexes as 
compared to the ligand precursor is not as pronounced as that of gold, with a shift of 
only about 10 ppm for the bridged silver complex vs almost 25 ppm for the bridged 
gold analogues (c.f. Tables 2.3 and 2.4). A more noticeable difference can be seen 
between the bridged and bischelates, when compared to the similar effect observed 
for gold. A characteristic feature of these complexes was the interaction of the spin 
active isotopes 107Ag and 109Ag with 31P resulting in a doublet for the bridged 
complex and a doublet of doublets for the bischelates (Figure 2.4). Studies by 
Berners-Price et al.131,132 have shown a similar trend as evident by 31P-NMR-signals 
for (AcO)Ag(dppe)Ag(OAc) (50) at 3.3 ppm and [Ag(dppe)2]+ (51) at 4.4 ppm vs the 
free ligand signal at -12.3 ppm. Berners-Price et al.131 have found that the broad 
signals in 50 resolved into a complex multiplet upon cooling to 221 K, indicating the 
three combinations of 107Ag and 109Ag in the bridged species. Coupling constants of 
1J(109Ag-31P) = 757 Hz, 1J(109Ag-31P) = 657 Hz and various smaller couplings were 
found for 50. The bischelated silver(I) complex (51) showed well-resolved couplings 
with coupling constants of 1J(109Ag-31P) = 266 Hz and 1J(109Ag-31P) = 231 Hz. With 
the addition of excess ligand, a slight broadening was observed which is indicative of 
relatively slow exchange on the NMR time scale (>400s-1) of free and bound dppe 
ligand. 
                                               
131
 S.J. Berners-Price, C. Brevard, A. Pagelot, P.J. Sadler, Inorg. Chem., 1985, 24, 
4278. 
132
 S.J. Berners-Price, R.K. Johnson, A.J. Giovenella, L.F. Faucette, C.K. Mirabelli, 
P.J. Sadler, J. Inorg. Biochem., 1988, 33, 285. 
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No Complex 31P NMR No Complex 31P NMR 
38 
N N
Me Me
Ph2P PPh2
Ag 
NO3
Ag
NO3
 
75.3 
d 
J=764.2 
44 
NN
MeMe
PPh2Ph2P
N N
Me Me
Ph2P PPh2
Ag
+
NO3-
 
68.4 
dd 
J=245.7 
J=283.5 
39 
N N
Et Et
Ph2P PPh2
Ag 
NO3
Ag
NO3
 
77.1 
d 
J=782.9 
45 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Ag
+
NO3-
 
69.1 
dd 
J=248.1 
J=285.3 
40 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag 
NO3
Ag
NO3
 
Unstable 46 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
66.2 
dd 
J=246.9 
J=284.9 
41 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag 
NO3
Ag
NO3
 
74.2 
d 
J=834.2 
47 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
67.5 
dd 
J=249.9 
J=285.3 
42 
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag 
NO3
Ag
NO3
 
Unstable 48 
NN
MeMe
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag
+
NO3-
 
66.6 
dd 
J=246.4 
J=284.2 
43 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag 
NO3
Ag
NO3
 
74.5 
d 
J=819.6 
49 
NN
EtEt
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag
+
NO3-
 
67.6 
dd 
J=248.3 
J=286.1 
 
Table 2.4: 31P NMR spectroscopic shifts of silver(I) complexes 
7080
             
67686970
 
a                                                      b 
Figure 2.4: 31P NMR showing typical 107/109Ag–31P interactions of bridged complex 
39 (a) and bischelated complex 45 (b). 
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2.5 MOLECULAR STRUCTURES 
 
2.5.1 Bis(diphenylphosphino)diethylhydrazine (14) 
 
N N
Ph2P PPh2
Et Et
 
 
The molecular structure of bis(diphenylphosphino)diethylhydrazine (14) with the 
atom numbering scheme is shown below in Figure 2.7 and selected bond distances are 
in Table 2.5. Full data tables can be found in Appendix A. 
 
14 was obtained as light yellow single crystalline flakes from the worked-up 
diethylether layer. The diethylether layer was concentrated and kept at –20 oC for 1-3 
days. The supernatant was removed from the crystalline flakes and placed back in the 
freezer for further crystallisation. 
 
The crystals of 14 (Figure 2.7) are found to be monoclinic, crystallising in the space 
group P21/c. Crystals of the dppe analogue show similar characteristics with it being 
monoclinic and crystallising in the space group P21/n.133 Dppe has, however, an extra 
plane of symmetry in the centre of the compound and has two molecules per unit cell 
vs 14 having four per unit cell.  
 
Dppe is seen to adopt a staggered conformation while 14, in contrast, shows a gauche 
conformation. This gauche conformation adopted by hydrazine has been well 
documented and studied both experimentally and by ab anitio molecular modelling.134 
It was found that the ground-state geometry of hydrazine is gauce with a dihedral 
angle close to 90o. Ab initio theoretical estimates of the gauche-anti and gauche-syn 
barrier heights fall in the ranges 1.6-6.2 and 9.7-13.7 kcal/mol, respectively. In 
hydrazine, the relative stability of the conformations are gauche > anti > syn.134 The 
                                               
133
 C. Perizzi, G Perizzi, Acta Cryst., 1979, B35, 1785. 
134
 A.H. Cowley, D.J. Mitchell, M.H Whangbo, S. Wolfe, J. Am. Chem. Soc., 1979, 
101, 18, 5224. 
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planar conformation of dppe also allows it to form stacks of molecules (Figure 2.5), 
that is not possible in 14 (Figure 2.6). 
 
 
Figure 2.5: Mercury representation of dppe135 showing parallel molecule packing. 
 
 
Figure 2.6: Mercury representation of 14 showing the perpendicular N-N bridges and 
head to tail packing (arrow). 
 
Bond lengths and angles (Table 2.5) are in the typical range expected for P-N and P-C 
bonds.26 A normal hydrazine N-N bond length of 1.427 Å is observed.  
                                               
135
 DPPETH.cif file obtained from Cambridge Crystallographic Database.  
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Bond lengths [Å] Angles [°] 
N(1)-N(2) 1.427(3) N(2)-N(1)-P(1) 116.4(2) 
N(1)-P(1) 1.710(2) N(1)-N(2)-P(2) 118.4(2) 
N(2)-P(2) 1.692(2) Torsion angle [°] 
  P(1)-N(1)-N(2)-P(2) -79.7(2) 
Table 2.5: Selected bond lengths, angles and torsion angles for 14. 
 
 
Figure 2.7: ORTEP diagram of 14 drawn at the 50 % probability level. Hydrogen 
atoms have been omitted for clarity. 
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2.5.2 Bis(phenylphosphino)cyclo-tetramethyldihydrazine (52) 
 
PhP
N N
PPh
NN
Me Me
Me Me
 
 
The molecular structure of bis(phenylphosphino)cyclo-tetramethyldihydrazine (52) 
with the atom numbering scheme is shown below in Figure 2.8 and selected bond 
distances are in Table 2.6. Full data tables can be found in Appendix A. 
 
In an attempt to crystallise ligand 13, bis(diphenylphosphino)dimethylhydrazine, the 
worked-up diethylether reaction mixture was concentrated and kept at –20 oC for two 
days. Two small crystals were formed and on analysis of one of the crystals, 52 was 
identified as the formed product. Analysis of the 31P NMR of ligand 13 showed 
product 52 being present in less than 5 % in the sample. Further analysis of 52 was 
not attempted due to the small amount of this side product. 
 
The compound crystallises in the orthorhombic crystal system, space group Pbca. The 
molecule has a centre of symmetry and the six-membered ring adopts a chair 
conformation with the phenyl groups on the phosphorous atoms being trans to each 
other (Figure 2.8). Katti et al.26 have observed in related compounds (e.g. 
[HNP(Et)N(Me)]2 and [HNP(Ph)N(Me)]2), that the chair conformation was favoured 
over the boat conformation and was seen to readily crystallise. [HNP(Ph)N(Me)]2 is 
found to also crystallise in space group Pbca, while [HNP(Et)N(Me)]2, with the 
ethane substituent on the phosphorous, crystallises in a monoclinic crystal system, 
space group P21/c. Bond lengths and angles of 52 are, with values for N-N of 1.432 
Å, P-N of 1.695 Å and P-Carom of 1.841 Å (Table 2.6), in the range observed in related 
structures. 
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Bond lengths [Å] Angles [°] 
N(1)-N(2)#1 1.432(2) N(2)#1-N(1)-P(1) 120.94(9) 
N(1)-P(1) 1.695(1) N(1)#1-N(2)-P(1) 120.04(9) 
Torsion angle [°]  N(1)-P(1)-N(2) 106.49(6) 
P(1)-N(1)-N(2)#1-P(1)#1 -43.20 #1 = -x, -y, -z 
Table 2.6: Selected bond lengths, angles and torsion angles for 52. 
 
 
Figure 2.8: ORTEP diagram of 52 drawn at the 50 % probability level as viewed 
approx. perpendicular to N1-N2-N2#1-N1#1. Hydrogen atoms have been omitted for 
clarity. 
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Figure 2.9: Mercury representation of 52 showing chair conformation. 
 
2.5.3 Bisphosphine-Bridged Gold Complexes 
 
N N
Me Me
Ph2P PPh2
Au 
Cl
Au
Cl
 
N N
Et Et
Ph2P PPh2
Au 
Cl
Au
Cl
 
Bis(diphenylphosphino)dimethylhydrazine 
di(gold chloride) (25) 
Bis(diphenylphosphino)diethylhydrazine 
di(gold chloride) (26) 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
Bis(di(4-methoxyphenyl)phosphino)-
dimethylhydrazine di(gold chloride) (27) 
Bis(di(4-methoxyphenyl)phosphino)-
diethylhydrazine di(gold chloride) (28) 
 
Crystal structure was not obtained N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
Bis(di(N,N-dimetyl-4-aminophenyl)-
phosphino)dimethylhydrazine di(gold 
chloride) (29) 
Bis(di(N,N-dimetyl-4-aminophenyl)-
phosphino)diethylhydrazine di(gold 
chloride) (30) 
Table 2.7: Crystal structures of bisphosphine-bridged gold complexes. 
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The molecular structures of bis(diphenylphosphino)dimethylhydrazine di(gold 
chloride) (22), bis(diphenylphosphino)diethylhydrazine di(gold chloride) (23), 
bis(di(4-methoxyphenyl)phosphino)dimethylhydrazine di(gold chloride) (24), 
bis(di(4-methoxyphenyl)phosphino)diethylhydrazine di(gold chloride) (25) and 
bis(di(N,N-dimetyl-4-aminophenyl)phosphino)diethylhydrazine di(gold chloride) (27) 
with the atom numbering schemes are shown below in Figures 2.10 – 2.14 and 
selected bond distances are compared in Table 2.8. Full data tables can be found in 
Appendix A. 
 
Micro-crystals of 22 were obtaines when 0.5 equivalents of 13 dissolved in DCM was 
added to 1 equivalent of the gold(I) precursor suspended in THF. To slow down 
crystal formation and grow crystals of suitable size the reaction was done in DCM 
and, to initiate crystallisation, a drop of THF was added and the solution left 
overnight. On the other hand, crystals suitable for analysis of 23 spontaneously grew 
upon mixing 1 equivalent of gold(I) precursor and 0.5 equivalents of 14 in THF. 
 
Complexes 24 and 25 were obtained in a similar manner to complex 22. 0.5 
equivalents of the corresponding ligand, 15 or 16, dissolved in DCM were added to 1 
equivalent of gold(I) precursor dissolved in DCM. Crystal formation was initiated by 
the addition of a drop of THF after which the solution was left for 2 days at room 
temperature. 
 
Needle-like colourless crystals of 27 were isolated from the attempted crystallisation 
of the red coloured 33 (see below). Attempts at crystallising complex 27 by any other 
means were not successful due to the breakdown of the complex and ligand. 
 
Even though the five complexes crystallise in different space groups, all the 
complexes, with the exception of complex 27, exhibit a two-fold rotation axis. 
Complex 22 crystallises in the tetragonal crystal system, space group P41212, complex 
23 in the orthorhombic space group Pccn. Complexes 24 and 25 both crystallise in the 
monoclinic crystal system, space group C2/c, and 27 crystallises in the monoclinic 
system with space group P21/c. The crystal structures of complexes 23, 24 and 25 all 
include a THF molecule. This inclusion might be the key to the ease of crystallisation 
of these crystals as these complexes spontaneously crystallise in THF. While complex 
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22 also spontaneously crystallises from THF it does not include THF in the crystal. 
Complex 27 includes one disordered molecule of DCM into the structure. 
 
The term ‘aurophilicity’ was introduced in 1989 to describe phenomena in the 
structural chemistry of gold which could not be readily rationalised by conventional 
concepts of chemical bonding. Gold shows a clear preference not only for short and 
strong bonds, suggesting a small atomic/ionic radius and a high electronegativity, but 
also for small coordination numbers.46,136,137 
 
The most striking phenomenon in the structural chemistry of gold is the tendency of 
the low-coordinate compounds of gold(I) to associate into dimers, oligomers or even 
uni- and multi-dimensional polymers via direct gold-gold contacts.46,138 The metal 
atoms approach each other to an equilibrium distance of between 2.7 and 3.4 Å. This 
range includes the distance between gold atoms in gold metal.59,136 
 
The Au-Au distances of complexes 23, 24, 25 and 27 (Figures 2.11, 2.12, 2.13 and 
2.14) are 3.131 Å, 3.122 Å, 3.141 Å and 3.186 Å, respectively and are clearly in the 
range of aurophilic interactions while the Au-Au distance of 3.482 Å in complex 22 
(Figure 2.10) is slightly too long for a true aurophilic interaction (normally 2.7 – 3.4 
Å).41  
 
A direct comparison of these complexes and the analogous dppe complex; 
ClAu(dppe)AuCl (36) shows that the preference for the gauche conformation of the 
hydrazine backbone (as discussed for 14) may explain the observed intramolecular 
Au-Au interactions as compared to the intermolecular Au-Au interactions observed in 
the two polymorphs of 36. The formation of intermolecular Au-Au interactions 
between dimers of 36 may be attributed to the different conformation of the ethyl 
backbone as illustrated by the torsion angles of the two polymorphs (-18.6 o and  
                                               
136
 H. Schmidbaur (ed.), Gold: Progress in Chemistry, Biochemistry and Technology, 
J. Wiley & Sons, Chichester, 1999. 
137
 H. Schmidbaur, Gold Bull., 2000, 33, 3. 
138
 (a) H. Schmidbaur, Gold Bull., 1990, 23, 11; (b) H. Schmidbaur, Chem. Soc. Rev., 
1995, 24, 391. 
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50.7 o).139 Intermolecular Au-Au contacts are also observed for the analogous 
ClAu(dppen)AuCl complex (dppen = bis(diphenylphosphino)ethene), where the 
ethene bridge is constrained to a cis conformation by the double bond. This 
observation supports the argument that the geometry of the ligands may at least 
partially determine the geometry of the complex. 
 
In all complexes gold(I) forms almost linear complexes with P-Au-Cl angles of 
between 175.68 o and 179.22 o (Table 2.9). N-N bond lengths between 1.405 Å and 
1.43 Å, similar to compounds 14 and 52, are observed as well as P-N bond lengths 
between 1.67 - 1.710 Å and P-Carom lengths of 1.76 Å - 1.84 Å. The Au-P and Au-Cl 
bonds are similar to those reported for other phosphinogold(I) chloride complexes 
with slightly shorter Au-P bond lengths (2.224 Å - 2.239 Å) than Au-Cl bond lengths 
(2.291 Å - 2.313 Å).139,140 
                                               
139
 D.S. Eggleston, D.F. Chodosh, G.R. Girard, D.T. Hill, Inorg. Chim. Acta, 1985, 
108, 221. 
140
 P.A. Bates, J.M. Waters, Inorg. Chim. Acta, 1985, 98, 125. 
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Compound 14 22 23 24 25 27 
Bond lengths [Å] 
Au-Au  3.487 3.131(5) 3.122(7) 3.141(7) 3.19(1) 
Au-P  2.232(2) 2.233(1) 2.224(1) 2.227(1) 
2.238(5) 
2.239(6) 
Au-Cl  2.298(2) 2.302(1) 2.291(1) 2.294(1) 
2.313(5) 
2.313(7) 
P-N 
1.710(2) 
1.692(2) 
1.702(5) 1.679(3) 1.678(2) 1.685(3) 
1.68(2) 
1.67(2) 
N-N 1.427(3) 1.43(1) 1.416(6) 1.417(4) 1.405(6) 1.43(2) 
Angles [°] 
P-Au-Cl  176.34(6) 179.22(4) 175.68(3) 175.99(4) 
176.6(2) 
175.9(3) 
N-N-P 
116.4(2) 
118.4(2) 
113.3(5) 118.4(3) 115.7(2) 117.5(2) 
119(1) 
118(1) 
Torsion angle [°] 
P-N-N-P -79.7(2) -114.13 98.61 105.97 -101.14 -96.4 
Symmetry 
operator 
 
-x + 1, 
-y + 1, 
-z + 1/2 
-x + 3/2, 
-y + 1/2, 
z 
-x + 1, 
y, 
-z + 1/2 
-x + 1, 
y, 
-z + 3/2 
 
Table 2.8: Selected bond lengths, angles and torsion angles for free ligand 14 and 
complexes 22, 23, 24, 25 and 27. 
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Figure 2.10: ORTEP diagram of 22 drawn at the 50 % probability level as viewed 
down the c-axis. Hydrogen atoms have been omitted for clarity. 
 
 
Figure 2.11: ORTEP diagram of 23 drawn at the 50 % probability level as viewed 
down the b-axis. Hydrogen atoms have been omitted for clarity. 
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Figure 2.12: ORTEP diagram of 24 drawn at the 50 % probability level. Hydrogen 
atoms have been omitted for clarity. 
 
 
Figure 2.13: ORTEP diagram of 25 drawn at the 50 % probability level. Hydrogen 
atoms and a molecule of THF have been omitted for clarity. 
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Figure 2.14: ORTEP diagram of 27 drawn at the 50 % probability level. Hydrogen 
atoms and a disordered molecule of DCM have been omitted for clarity. 
 
The insolubility of complex 22 in both non polar and highly polar solvents once 
crystallised may be a result of the tightly packed parallel helixes, that are formed in 
the solid state (Figure 2.15). While the complex readily crystallises from THF it does 
not include THF in the structure as complexes 23, 24 and 25 do. This structure 
exhibits a left-handed α-helical packing down the c-axis. This unique packing results 
in parallel helixes that have no voids large enough to include solvent (Figure 2.16) 
and leads to a stabilising short contact distance of 2.899 Å between Cl and H(15).  
 
Complex 23 exhibits columns of head-to-tail complexes forming channels filled with 
THF. Intermolecular short contacts of 2.822 Å and 2.835 Å are displayed between Cl 
and H(1a) and Cl and H(14), respectively. The Cl-H(1a) interaction can be seen on the 
head-to-tail arranged complexes in a column between chlorides and adjacent 
hydrogen atoms situated on the ethyl substituted hydrazine bridge (Figure 2.17). The 
Cl-H(14) interaction occurs between chlorides and hydrogens situated on a phenyl 
ring in close proximity. Hydrogen bonding distances between the THF O(1) atom and 
H(1b) and H(22) are observed to be 2.553 Å and 2.698 Å, respectively.  
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Figure 2.15: Mercury representation of 22 packing viewed along the b-axis showing 
left handed α-helical packing (arrows). 
 
 
Figure 2.16: Mercury representation of 22 viewed along the c-axis showing tightly 
packed α-helices. 
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Figure 2.17: Mercury representation of 23 showing head-to-tail arrangement (arrow), 
H-Cl and H-O interactions (dotted line). 
 
Complexes 24 and 25, like 23, show intermolecular short contacts of 2.892 Å between 
Cl and H(1c) for 24 and 2.817 Å between Cl and H(1b) for 25. This interaction can be 
seen in the head to tail arranged compounds in a column down the b-axis between 
chlorides and adjacent hydrogen atoms situated on the methyl and α-carbon of ethyl 
substituted hydrazine bridge, respectively (Figure 2.18). Hydrogen bonding distances 
between THF (O(3)) and 24 (H(15) and H(17b)) are observed to be 2.608 Å and 2.557 
Å, respectively and 2.667 Å and 2.555 Å for O(3) to H(15) and H(17b) in 25. Other 
intermolecular hydrogen bond lengths of 2.629 Å and 2.637 Å are observed between 
O(1) and H(13) in 24 and O(1) and H(13) in 25, respectively. 
 
While ligand 14 and complex 23 showed alternating N-N bridges in a head-to-tail 
arrangement, complexes 24 and 25 show parallel N-N bridges. The complexes also 
showed corrugated sheets of complexes with inter-dispersed THF molecules (Figure 
2.19).  
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Figure 2.18: Mercury representation of 24 (above) and 25 (below) showing head-to-
tail arrangement (arrows), H-Cl and H-O interactions (dotted lines). 
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Figure 2.19: Mercury representation of corrugated sheets present in complexes 24 
and 25. 
 
Complex 27 is seen to have intermolecular short contacts of 2.888 Å and 2.844 Å 
between Cl(2) and H(48c) and Cl(2) and H(38a), respectively (Figure 2.20). An 
interesting observation to note is that only one of the chloride atoms (Cl(2)) shows 
any H-Cl interaction. 
 
 
Figure 2.20: Mercury representation of 27 showing H-Cl interactions (dotted lines). 
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2.5.8 Bis(bis(di(N,N-dimetyl-4-aminophenyl)phosphino)diethylhydrazine)gold 
trinitrate (35) 
 
N N
Et Et
P(Ph-4-NMe2)2(MeN-4-Ph)2P
N N
Et Et
P(Ph-4-NMe2)2(MeN-4-Ph)2P
Au
3+
3NO3-
 
The molecular structure of bis(bis(di(N,N-dimetyl-4-aminophenyl)phosphino)-
diethylhydrazine)gold trinitrate (35) with the atom numbering scheme is shown below 
in Figure 2.23 and selected bond distances are found in Table 2.9. Full data tables can 
be found in Appendix A. 
 
Efforts to crystallise the complex bis(bis(di(N,N-dimetyl-4-aminophenyl)phosphino)-
diethylhydrazine) gold(I) chloride (33) failed. When the anion of the complex was 
changed from chloride to nitrate via a metathesis reaction with silver nitrate it was 
possible to crystallise 35 from DCM and hexane as bright red crystal flakes. 
 
Complex 35 crystallises in the orthorhombic space group Pban. The molecule shows 
two-fold rotation and an inversion centre coinsiding with the Au centre. The Au 
centre shows a slightly distorted square planar geometry with two phosphorous atoms 
7.45o above and below the plane (gray line) formed by the remaning two phosphorous 
atoms and the gold atom (Figure 2.21). 
 
Figure 2.21: Mercury representation of distorted square planar geometry around the 
Au centre in complex 35. 
 
The molecules are packed in such a way as to accommodate three nitrate ions, two 
being ordered and one being disordered. Cavities also showed the inclusion of a 
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disordered hexane. Due to the Au-P bond lengths and square planar conformation of 
this complex and most importantly the presence of 3 NO3- counterions per complex a 
formal charge of 3+ was assigned to the Au centre. The observed Au-P bond length of 
2.387 Å is only slightly shorter than that in the tetrahedral gold(I) dppe analogue 
which has Au-P bond lengths of 2.389 Å and 2.416 Å.56 Two distinct P-Au-P angles 
are formed, an endocyclic angle of 83.50o forms between the gold and the 
phosphorous centres on the same ligands and a larger exocyclic angle of 96.99 o 
between gold and phosphorous centres on opposite chelating ligands (Figure 2.22). 
This is to be expected as this is the indication of the bite angle of the ligand in 
question.  
 
Figure 2.22: Mercury representation of endocylic and exocyclic angles displayed by 
complex 35. 
 
A pi-pi interaction or aromatic interaction is a noncovalent interaction between organic 
compounds containing aromatic moieties. pi-pi interactions are caused by 
intermolecular overlapping of p-orbitals in pi-conjugated systems, so they become 
stronger as the number of pi-electrons increases.141 
 
The intermolecular interaction of aromatic systems has been studied extensively, 
especially in the last two decades.142,143 The importance of the attraction between pi 
systems has been stressed repeatedly in many fields of chemistry from molecular 
biology to material design. The pi-pi interaction influences the three-dimensional 
structures of biological systems such as protein and DNA144 and is important for the 
crystal packing of organic molecules containing aromatic rings such as nonlinear 
                                               
141
 http://en.wikipedia.org/wiki/Pi-pi_interaction. 
142
 V. Spirko, O. Engkvist, P. Soldan, H.L. Selzle, E.W. Schlag, P. Hobza, J. Chem. 
Phys., 1999, 111, 572. 
143
 K.S. Kim, P. Tarakeshwar, J.Y. Lee, Chem. Rev., 2000, 100, 4145. 
144
 K.M. Guckian, T.R. Krugh, E.T. Kool, J. Am. Chem. Soc., 2000, 122, 6841. 
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optical materials.145 This is also important for molecular recognition processes in 
biological and artificial systems.146147 
 
A stabilising effect observed in this complex is the occurrence of pi-pi interactions 
between the various phenyl rings (Figure 2.24). A phenyl centroid to centroid distance 
of 3.819 Å is observed between the respective four pairs of phenyl rings. 
 
A search through the literature and the Cambridge Crystallographic Database revealed 
this complex to be the first example of a discrete cationic gold(III) atom coordinated 
to four chelating phosphorous centres in a square planar fashion. Traditionally gold(I) 
is seen as a “soft” metal centre mostly forming complexes with “soft” ligands like 
phosphorous and sulphur while gold(III) is seen as a “hard” metal centre mostly 
coordinating to “hard” ligands like nitrogen and oxygen. The occurance of P-N 
(“soft”-“hard”) mixed ligand complexed to gold(III) is not uncommon. The striking 
feature of this complex is its unusual combination of a “hard” metal centre and four 
“soft” chelating phosphous centres.  
 
Bond lengths [Å] Angles [°] 
P(1)-Au(1)  2.387(8) N(1)#1-N(1)-P(1) 111.0(2) 
N(1)-P(1)  1.683(3) P(1)#2-Au(1)-P(1)#1 172.54(4) 
N(1)-N(1)#1  1.429(6) P(1)#2-Au(1)-P(1)#3 83.50(4) 
Torsion angle [°]  P(1)#1-Au(1)-P(1)#3 96.99(4) 
P(1)-N(1)-N(1)#3-P(1)#3 -68.81 #1 -x + 1/2, y, -z + 1 
#2 -x + 1/2, -y + 3/2, z #3 x, -y + 3/2, -z + 1 
Table 2.9: Selected bond lengths, angles and torsion angles for 35. 
 
                                               
145
 R. Vallee, P. Damman, M. Dosiere, E. Toussaere, J. Zyss, J. Am. Chem. Soc., 
2000, 122, 6701. 
146
 F.M. Raymo, K.N. Houk, J.F. Stoddart, J. Org. Chem., 1998, 63, 6523. 
147
 S. Tsuzuki, K. Honda, T. Uchimaru, M. Mikami, K. Tanabe, J. Am. Chem. Soc., 
2002, 124, 1, 104. 
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Figure 2.23: ORTEP diagram of 35 drawn at the 50 % probability level as viewed 
down the a-axis. Hydrogen atoms and two disordered molecules of NO3- and hexane 
were left out for clarity. Superscripts 2 – 4 indicate symmetry operator created atoms: 
No. 2 = -x + 1/2, y, -z + 1; No. 3 = -x + 1/2, -y + 3/2, z and No. 4 = x, -y + 3/2, -z + 1. 
 
Figure 2.24: ORTEP diagram of 35 drawn at the 50 % probability level as viewed 
down the b-axis. Hydrogen atoms and molecules of NO3- and hexane were left out for 
clarity. 
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2.5.9 Bis(diphenylphosphino)diethylhydrazine di(silver nitrate) (39) 
 
N N
Et Et
Ph2P PPh2
Ag 
NO3
Ag
NO3
 
The molecular structure of bis(diphenylphosphino)diethylhydrazine di(silver nitrate) 
(39) with the atom numbering scheme is shown in Figures 2.26 and selected bond 
distances are in Table 2.10. Full data tables can be found in Appendix A. 
 
Complex 39 crystal-lised from a mixture of acetonitrile, EtOAc and hexane after 
being left at –20 oC for two weeks. 
 
39 crystallises in the orthorhombic space group Pna21. The centre of a polymeric α-
helix produced by complex 39 is filled by nitrate counter ions. Three oxygen atoms 
from three different nitrate ions occupy the equatorial positions of a trigonal 
bipyramid and two silver atoms are situated at the axial positions (Figure 2.25). This 
complex arrangement connects each silver atom of one complex to a silver atom in a 
neighbouring complex. The resulting α-helices (Figure 2.27) are packed parallel to 
each other and run down the c-axis of the crystal (Figure 2.28).  
 
O
O O
Ag
Ag
P
PP
N N
P
NN
O
O O
Ag
Ag
P P
NN
 
Figure 2.25: Representation of helix formed by complex 39. 
 
Polymerisation in silver nitrate complexes analogous to 39 is common as seen for 
example in the case of (NO3)Ag(dppe)Ag(NO3) (50), that forms long chains with P-
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Ag-P units as the connecting entity.148 These long chains are also periodically 
connected by short chains of Ag-O-Ag bonds, giving rise to sheets of connected 
complexes.  
 
The Ag-P bond distances of 2.334 Å and 2.349 Å in 39 are considerably shorter than 
those of 50 (2.414 Å and 2.436 Å). The trigonal bipyramidal structure of 39 consists 
of four long Ag-O bonds in the range of 2.5 Å and two short Ag-O bonds in the range 
of 2.3 Å. Two longer bonds are to the same NO3-, while two sets of a short and long 
bond are connected to the other two nitrates, respectively. This compares to  
Ag-O bond lengths between 2.68 Å and 2.17 Å in 50. Complex 39 exhibits Ag-O-Ag 
angles in the range of 93 o and 99 o and O-Ag-O angles in the range of 66 o to 75 o.
                                               
148
 S-Z Hu, Jiegou Huaxue (Chin.) (Chinese J. Struct. Chem.), 2000, 19, 153 (cif file 
obtained from the Cambridge Crystallographic Database). 
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Bond lengths [Å] Angles [°] 
P(1)-Ag(1)  2.334(2) N(1)-N(2)-P(2) 116.9(4) 
P(2)-Ag(2)  2.349(2) N(2)-N(1)-P(1) 117.7(4) 
O(1)-Ag(1)  2.302(5) Ag(1)-O(1)-Ag(2)#1 97.9(2) 
O(2)-Ag(1)#1  2.553(5) Ag(2)#2-O(2)-Ag(1)#1 98.7(2) 
O(4)-Ag(1)#3  2.506(5) Ag(1)#3-O(4)-Ag(2) 94.0(2) 
O(1)-Ag(2)#1  2.592(5) O(1)-Ag(1)-P(1) 164.7(1) 
O(2)-Ag(2)#2  2.314(5) O(2)#4-Ag(2)-P(2) 154.2(1) 
O(4)-Ag(2)  2.548(5) P(1)-Ag(1)-O(4)#1 116.3(1) 
N(1)-P(1)  1.699(6) P(1)-Ag(1)-O(2)#3 126.8(1) 
N(2)-P(2)  1.705(6) P(2)-Ag(2)-O(4) 118.8(1) 
N(1)-N(2)  1.406(8) P(2)-Ag(2)-O(1)#3 137.7(1) 
Torsion angle [°]  O(1)-Ag(1)-O(4)#1 71.7(2) 
P(1)-N(1)-N(2)-P(2) 99.5(5) O(1)-Ag(1)-O(2)#3 67.3(2) 
  O(4)#1-Ag(1)-O(2)#3 72.7(2) 
  O(2)#4-Ag(2)-O(4) 75.9(2) 
  O(2)#4-Ag(2)-O(1)#3 66.4(2) 
  O(4)-Ag(2)-O(1)#3 66.6(2) 
  N(3)-O(1)-Ag(1) 114.6(4) 
  N(3)-O(1)-Ag(2)#1 132.6(4) 
#1 -x, -y, z + 1/2 N(3)-O(2)-Ag(2)#2 116.2(4) 
#2 x, y, z + 1 N(3)-O(2)-Ag(1)#1 143.5(4) 
#3 -x, -y, z - 1/2 N(4)-O(4)-Ag(1)#3 116.8(5) 
#4 x, y, z - 1 N(4)-O(4)-Ag(2) 101.5(4) 
Table 2.10: Selected bond lengths, angles and torsion angles for 39. 
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Figure 2.26: ORTEP diagram of 39 drawn at 50 % probability level. Hydrogen atoms 
have been omitted for clarity. 
 
 
Figure 2.27: Mercury representation of 39 showing the polymeric helix. Hydrogen 
atoms have been omitted for clarity. 
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Figure 2.28: Mercury representation of 39 packing viewed along the c-axis. 
Hydrogen atoms have been omitted for clarity. 
 
2.5.10 Bis(bis(diphenylphosphino)diethylhydrazine)silver nitrate (45) 
 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Ag
+
NO3-
 
The molecular structure of bis(bis(diphenylphosphino)diethylhydrazine)silver nitrate 
(45) with the atom numbering scheme is shown below in Figure 2.29 and selected 
bond distances are in Table 2.11. Full data tables can be found in Appendix A. 
 
Compex 45 was synthesised by adding 2 equivalents of 14 dissolved in THF to 1 
equivalent of silver(I) nitrate suspended in THF. The solvent was reduced in vacuo 
and the reaction mixture left overnight to form colourless crystal plates. Various 
crystals tested were found to be twinned and subsequently could not be analysed. A 
crystal suitable for X-ray analysis was finally found and analysed.  
 
45 crystallises in the triclinic space group Pī. Complex 45 shows an arrangement 
where nitrate counter ions and THF molecules occupy cavities between the metal 
cations. The silver(I) atom shows a tetrahedral coordination with Ag-P bond lengths 
between 2.513 Å and 2.531 Å and endocyclic P-Ag-P angles of 79.2 o and 79.3 o. The 
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related [Ag(dppe)2]+.NO3- (51) complex shows similar Ag-P bond lengths of about 
2.52 Å and endocyclic P-Ag-P angles of about 84 o.149 The difference in P-Ag-P 
angles of 79 o and 84 o shows the difference in chelating bite angle between these two 
ligands, with 51 having a larger bite angle than ligand 14. This difference in bite angle 
may be attributed to the difference in the bisphosphine bridge and more specifically 
the shorter distance between N-N vs C-C, bringing the two phosphorous atoms closer 
to each other in the case of N-N and hereby presumably causing a smaller bite angle. 
Other bond lengths and angles where within the expected range. 
 
Bond lengths [Å] Angles [°] 
N(1)-P(1)  1.73(2) N(2)-N(1)-P(1) 107(1) 
N(2)-P(2)  1.68(1) N(1)-N(2)-P(2) 120.1(9) 
N(3)-P(3)  1.70(1) N(4)-N(3)-P(3) 120(1) 
N(4)-P(4)  1.74(2) N(3)-N(4)-P(4) 108(1) 
P(1)-Ag(1)  2.531(5) P(3)-Ag(1)-P(2) 129.0(2) 
P(2)-Ag(1)  2.526(4) P(3)-Ag(1)-P(4) 79.3(1) 
P(3)-Ag(1)  2.513(4) P(2)-Ag(1)-P(4) 128.8(2) 
P(4)-Ag(1)  2.528(4) P(3)-Ag(1)-P(1) 125.9(2) 
N(1)-N(2)  1.47(2) P(2)-Ag(1)-P(1) 79.2(1) 
N(3)-N(4)  1.42(2) P(4)-Ag(1)-P(1) 121.3(2) 
Torsion angle [°]   
P(1)-N(1)-N(2)-P(2) -60(1)   
P(3)-N(3)-N(4)-P(4) -60(1)   
Table 2.11: Selected bond lengths, angles and torsion angles for 45. 
 
                                               
149
 C.S.W. Harker, E.R.T. Tiekink, J. Coord. Chem., 1990, 21, 287. 
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Figure 2.29: ORTEP diagram of 45 drawn at 50 % probability. Hydrogen atoms and 
a molecule of THF have been omitted for clarity. 
 
2.6 Conclusion 
 
A series of hydrazine-bridged phosphine ligands including the previously reported 
compounds Ph2PN(Me)N(Me)PPh2 and Ph2PN(Et)N(Et)PPh2 as well as the new 
derivatives ((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2, ((4-MeO)Ph)2PN(Et)N(Et)-
P(Ph(4-OMe))2, ((4-Me2N)Ph)2PN(Me)N(Me)P(Ph(4-NMe2))2, ((4-Me2N)Ph)2PN(Et)-
N(Et)P(Ph(4-NMe2))2 was successfully synthesised by adopting and modifying 
existing methods. A total of six ligands were prepared in this manner. Three of these 
ligands have methyl substituted hydrazine bridges and three have ethyl substituted 
hydrazine bridges. Other differences include the use of phenyl, methoxyphenyl and 
dimethylaminophenyl substitutents on the free phosphorous sites. Attempts to extend 
these efforts to the synthesis of the analogous 2-, 3- and 4-pyridal ligands were not 
successful due to problems in separating the products from various side products.  
 
The synthesis of gold(I) and silver(I) complexes of the aforementioned ligands was 
attempted. The synthesis of bisphosphine-bridged digold species was mostly 
successful and crystal structures of five of these complexes could be obtained: 
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ClAuPh2PN(Me)N(Me)PPh2AuCl; ClAuPh2PN(Et)N(Et)PPh2AuCl; ClAu((4-
MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2AuCl; ClAu((4-MeO)Ph)2PN(Et)N(Et)-
P(Ph(4-OMe))2AuCl and ClAu((4-Me2N)Ph)2PN(Et)N(Et)P(Ph(4-NMe2))2AuCl. 
These crystal structures show large similarities in the paddle like arrangement of the 
P-Au-Cl moieties and other structural features. The complexes were found to be 
stable in crystalline form in moist air. The synthesis of the tetrahedral gold(I) species 
was in most cases also successful. These compounds were found to range in colour 
from light yellow to bright orange and in the case of complex 34 and 35, red. The 
complexes were also found to be hygroscopic. Attempts to crystallise these complexes 
led to disordered crystals giving powder diffraction patterns when analysed. The 
crystallisation of complex 35 revealed the spontaneous oxidisation of gold(I) to 
gold(III) with a change from tetrahedral to square planar coordination. 
 
The synthesis of bisphosphine-bridged disilver species was more problematic when 
compared to the analogous gold species. Attempts regularly led to the formation of a 
silver mirror on the reaction vessels. We were able to crystallise one of the complexes 
of this type, namely NO3AgPh2PN(Et)N(Et)PPh2AgNO3. This structure showed long 
helical columns of interconnected silver complexes. The synthesis of the bischelated 
silver(I) species was easier than that of the disilver species and the crystal structure of 
[(Ph2PN(Et)N(Et)PPh2)2Ag]+.NO3- showing distinct tetrahedral coordination was 
successfully determined. 
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Chapter 3 
 
Biological Activity of Complexes 
 
3.1 INTRODUCTION 
 
The anti-tumour potential of gold(I) phosphine complexes was first identified at the 
time when auranofin was shown to kill tumour cells in culture. This sparked the 
interest of Berners-Price et al.6,150 and led to the development of the bischelated 
gold(I) phosphine anti-tumour compound [Au(dppe)2]Cl (37), whose active entity 
was found to be the cationic ion [Au(dppe)2]+. Whereas auranofin exhibited only 
modest anti-tumour activity in one animal tumour model, [Au(dppe)2]+ exhibited 
significant in vivo anti-tumour activity in a range of tumour models in mice. It was 
selected for pre-clinical trials, but was unfortunately abandoned after the 
identification of severe hepatoxicity in dogs.6,150  
 
The high toxicity of [Au(dppe)2]+ is attributable to the high lipophilicity of the cation 
which results in non-selective uptake into mitochondria in all cells. Delocalised 
lipophilic cations (e.g. Rhodamine 123) have a long history as potential anti-tumour 
drugs and have been shown to preferentially concentrate within tumour cell 
mitochondria in response to elevated mitochondrial membrane potentials, which are 
characteristic features of carcinoma cells.151 Clinical development of compounds of 
this type has been hindered by severe toxicity, but several classes of delocalised 
lipophilic cations have demonstrated a relationship between anti-tumour selectivity 
and lipophilic-hydrophilic balance.6,150  
 
                                               
150
 S.J. Berners-Price, Chem. Aust., 2004, 71, 10. 
151
 J.S. Modica-Napolitano, J.R. Aprille, Advan. Drug Deliv. Rev., 2001, 49, 63. 
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Inhibition of tumour colony formation by [Au(dppe)2]Cl has been associated with 
preferred inhibition of protein synthesis, DNA protein cross-links and DNA strand 
breaks. The in vitro activity of [Au(dppe)2]Cl was seen to be less inhibited than that 
of auranofin by the presence of serum proteins in the tissue culture medium due to 
better stablity in the presence of serum proteins, thiols and disulphides. These 
findings provided evidence for a mechanism of anti-tumour activity for 
[Au(dppe)2]Cl that differed from that of auranofin.152 
 
Berners-Price et al.152 set out to determine whether [Au(dppe)2]Cl induced 
cytotoxicity was related to changes in mitochondria. Studies were carried out on 
intact isolated rat hepatocytes. They found that within 30 minutes of exposure, 
[Au(dppe)2]Cl had been taken up by isolated hepatocytes and distributed to 
mitochondria, nucleus, cytoplasm and cellular membranes. The isolated rat 
hepatocytes were found to lose cellular viability as indicated by the release of lactate 
dehydrogenase. [Au(dppe)2]Cl also induced a rapid dissipation of the inner 
mitochondrial membrane potential, efflux of calcium, increased mitochondrial 
respiration, mitochondrial swelling and increased permeability of the inner 
membrane to cations and protons in isolated mitochondria.153 Cytotoxic effects to 
isolated hepatocytes appeared to be a result of the inhibition or uncoupling of 
oxidative phosphorylation by gold(I) phosphine complexes. These results suggested 
that mitochondria were a possible target organelle for [Au(dppe)2]Cl cytotoxicity in 
intact isolated rat hepatocytes.152 
 
Further studies done by Berners-Price et. al.154 found that the anti-tumour activity of 
[Au(dppe)2]Cl and tetrahedral bis(dipyridylphosphino)gold(I) complexes in vivo 
showed a dependence on lipophilicity in subcutaneous colon 38 tumours. The most 
lipophilic and hydrophilic compounds showed no significant tumour growth delay. 
However, a compound of intermediate lipophilicity showed significant anti-tumour 
                                               
152
 M.J. McKeage, L. Maharaj, S.J. Berners-Price, Coord. Chem. Rev., 2002, 232, 
127. 
153
 P.F. Smith, G.D. Hoke, D.W. Alberts, P.J. Bugelski, S. Lupo, C.K. Mirabelli, G.F. 
Rush, J. Pharmacol. Exp. Therap., 1989, 249, 944. 
154
 M.J. McKeage, S.J. Berners-Price, P. Galettis, R.J. Bowen, W. Brouwer, L. Ding, 
L. Zhuang, B.C. Baguley, Cancer Chemother. Pharmacol., 2000, 46, 343. 
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activity, less dose-limiting toxicity and higher gold concentration in plasma and 
tumours compared with the more lipophilic or hydrophilic analogues.152 
 
Following on the work done by Berners-Price et al.,6 a range of gold(I) and silver(I) 
complexes designed to have varying degrees of lipophilicities was described in the 
previous chapter (see Chapter 2). The testing for biological activity of these 
lipophilic cationic complexes is described here in. 
 
3.2 BIOLOGICAL SCREENING 
 
3.2.1 In Vitro Screening 
 
A range of thirteen compounds was found to be suitably chemically stable for 
biological screening (Table 3.1). Complexes with different aromatic substituents at 
the phosphorous centres of the chelating ligands were synthesised. The variations 
were generated to indroduce a range of different lipophilicities to allow for a 
structure/anti-tumour activity relationship to be formulated. Biological screening was 
carried out at the Department of Pharmacology at the University of Pretoria under 
the guidance of Prof. Connie Medlen, Dr. Gisella Joone and Mrs. Margo Nell. 
Further advice and guidance was also received from Prof. Denver Hendricks at the 
University of Cape Town. 
 
The screening assays allowed for the identification of the most selective compounds 
(i.e. the compounds most toxic to cancer cells and least toxic to normal cells). 
Furthermore, pharmacokinetic studies were undertaken to provide a broader 
understanding of the factors determining activity and selectivity. 
 
The range of compounds was screened against three cell lines, namely HeLa (Human 
cervix adenocarcinoma), Jurkat (Human T-cell carcinoma) and healthy lymphocytes 
from human blood. The HeLa cell line was selected due to it being the cancerous cell 
line most readily available and generally used in initial screening for activity. The 
cancerous Jurkat cell line was used to determine the toxicity of drugs to cancerous 
human T-cells, while normal lymphocytes, harvested from healthy human blood 
donors, were used to determine the toxicity of drugs to normal human T-cells. 
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A standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
assay was performed to determine IC50 values for the selected compounds. HeLa cells 
were examined under an inversion microscope to determine satisfactory growth and to 
check for possible infection. The cells were trypsinated to remove the adherent cells 
from the growth vessel. After trypsination the free floating cells were centrifuged to 
form an easily manageable pellet and to remove supernatant growth medium and 
trypsin.  
 
The cells were resuspended in 1 ml of growth medium and counted by suspending  
50 µl of the resuspended cells in white cell counting fluid. This was used to count 
cells utilising a Haemocytometer and a Reichert-Jung Microstar 110 microscope. 
Cells were diluted to a concentration of 2.5x104 cells/mL. A further 1:4 dilution was 
made and 100 µl of these cells loaded on 96 well plates preloaded with 80 µl growth 
medium and warmed to physiological temperature. The plates were left for 1 hour in 
the incubation oven to settle to the bottom of the plates and start adhering.  
 
After 1 hour the plates were loaded with 20 µl of drug dissolved in the growth 
medium. Drug solutions were made up by dissolving the compound of interest in 1 ml 
of DMSO to make up a 10 mM solution. This solution was dispensed into Eppendorf 
tubes in 50 µl portions and kept frozen until used. The drug-growth medium solution 
was made up just before administration by diluting the contents of one Eppendorf 
tube using the appropriate growth medium. Eight subsequent 1:1 dilutions of this 
solution were made up and added to the wells to give a final range of eight drug 
concentrations. Each drug concentration was administered to three wells to obtain 
triplicate results. 
 
The plates were placed in a covered (not closed) container with paper towels soaked 
with distilled water at the bottom to minimise evaporation of the growth medium in 
the wells. Containers were left for 7 days to incubate at 37 oC in a 5 % CO2 
atmosphere.  
 
After the 7 day incubation period the plates were removed from the incubator and  
20 µl of MTT solution were added to each well. The plates were placed back in the 
incubator for another 3 to 4 hours.  
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The plates were centrifuged and the supernatant in every well was removed separately 
and discarded. The cells were repeatedly washed with PBS (phosphate buffered 
saline) and left to dry completely overnight in a dark cupboard (due to the light 
sensitivity of the reagent). The next morning the purple crystals were dissolved in 
DMSO and an absorption intensity reading taken on a plate reader. IC50 values were 
calculated from the intensities as compared to the triple column of control cells (cells 
with no drug added) on each plate.  
 
A similar procedure was carried out for Jurkat cells, except that due to Jurkat cells 
being floating cells it was not necessary to trypsinate them. Jurkat cells were diluted 
to 3x104 cells/ml after counting compared to 2.5x104 cells/ml in the case of HeLa 
cells. 
 
For the isolation of normal lymphocytes, 30 ml of heparinised blood from a human 
donor was loaded onto 15 ml of Histopaque 1077. The suspension was centrifuged 
and the monolayer of plasma was removed and the layer of lymphocytes and 
monocytes was collected. The tube was filled with RPMI (Roswell Park Memorial 
Institute) growth medium and centrifuged to remove platelets. Sterile cold ammonium 
chloride was added and left on ice for 10 minutes to lyse remaining red cells. After 
centrifuging, the remaining pellet was resuspended in RPMI followed by centrifuging.  
 
The pellet was resuspended in 1 ml RPMI and subsequently counted, diluted to 2x106 
cells/ml and 100 µl of that solution was loaded onto the 96 well plates (preloaded with 
60 µl medium). 20 µl of PHA (Phytohaemaglutinine) were added to the stimulated 
lymphocyte assay while 20 µl RPMI were added to the resting lymphocyte assay. 
PHA was added to stimulate the lymphocytes in the same manner as an in vivo 
immune response. A procedure similar to the drug administration described for HeLa 
cells was followed for both resting and stimulated lymphocytes and the plates were 
incubated for 3 days after which MTT was added and readings were taken. 
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 Compound  Compound 
37 
Reference 
compound 
Ph2P PPh2
PPh2Ph2P
Au
+
Cl-
 
30 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
23 
N N
Et Et
Ph2P PPh2
Au 
Cl
Au
Cl
 
31 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
24 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
43 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag 
NO3
Ag
NO3
 
25 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
45 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Ag
+
NO3-
 
27 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
46 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
28 
NN
MeMe
PPh2Ph2P
N N
Me Me
Ph2P PPh2
Au
+
Cl-
 
47 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
29 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Au
+
Cl-
 
49 
NN
EtEt
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag
+
NO3-
 
Table 3.1: Compounds selected for biological screening. 
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3.2.2 Results from Activity Screening and Selectivity Determination 
 
IC50 values (i.e. the amount of drug delivered to cause 50% mortality to viable cells) 
were determined by performing the standard MTT assay on the following cell lines; 
i) HeLa cells; ii) Jurkat cells; iii) resting lymphocytes; and iv) stimulated 
lymphocytes. A series of results were obtained and the toxicology profile of each 
compound as pertaining to the tested cell lines is represented graphically (Appendix 
B, Graphs 3.1 – 3.56). Each point on these graphs is the result of three repetitions of 
the experiment. One experimental value is derived from the mean of three wells (per 
plate) containing the same concentration incubated under the same conditions.  
 
A summary of the IC50 values obtained from the cytotoxicity profiles is given in 
Table 3.2 reported as the mean value of three experimental results and given in µM 
concentrations of administered drug. 
 
Compound HeLa Jurkat 
Resting 
Lymphocyte 
Stimulated 
Lymphocyte 
37 (Ref) 0.747 ±0.273 0.030 ±0.049 0.325 ±0.324 0.131 ±0.101 
23 0.858 ±0.149 0.735 ±0.433 4.299 ±0.593 0.938 ±0.901 
24 1.009 ±0.330 1.014 ±.003 7.258 ±0.072 5.730 ±1.266 
25 5.470 ±2.499 0.440 ±1.416 7.522 ±4.031 12.805 ±0.298 
27 39.375 ±8.570 18.030 ±2.954 32.285 ±0.703 25.296 ±2.390 
28 4.570 ±0.336 2.500 ±1.542 1.536 ±0.584 1.098 ±0.318 
29 1.264 ±0.588 0.440 ±0.305 1.363 ±0.215 0.841 ±0.266 
30 0.736 ±0.662 0.305 ±0.175 0.776 ±0.255 0.646 ±0.127 
31 2.451 ±0.508 1.911 ±0.112 3.175 ±0.677 4.489 ±0.953 
43 0.563 ±0.051 1.822 ±0.285 3.240 ±0.257 2.911 ±0.103 
45 1.087 ±0.167 0.649 ±0.234 3.746 ±0.605 3.097 ±0.554 
46 0.705 ±0.595 0.380 ±0.157 1.954 ±0.126 6.516 ±0.298 
47 0.913 ±0.467 1.144 ±0.349 4.209 ±0.585 3.355 ±0.837 
49 1.738 ±0.528 3.126 ±0.580 10.246 ±0.905 4.892 ±1.043 
Table 3.2: IC50 (µM) of cells following treatment with experimental compounds 
(mean of three experiments). 
 102 
From the results obtained from the screening, specificity of the compounds was 
calculated (Table 3.3). Specificity was calculated as follows: the sum of the IC50 
values from normal cells (resting and stimulated lymphocytes in this case) divided 
by the sum of the IC50 values of the cancerous cells (HeLa and Jurkat cells in this 
case). The higher the specificity, the better the selectivity of the compound towards 
inhibiting the growth of cancerous cells, while not impeding the growth of normal 
cells. It has to be mentioned that this calculation is only a guide toward the 
effectiveness of these compounds. 
 
Compound Specificity Compound Specificity 
37 (Ref) 0.587 30 1.366 
23 3.288 31 1.757 
24 6.420 43 2.579 
25 3.439 45 3.942 
27 1.003 46 7.806 
28 0.373 47 3.677 
29 1.293 49 3.112 
Table 3.3: Specificity of compounds tested 
(lymphocytes IC50’s/Jurkat, HeLa IC50’s). 
 
Compounds 23, 24, 28, 31, 47 and 49 all showed a distinct exponential toxicity 
profile in the HeLa cell line with a dramatic increase in toxicity being observed with 
an increase in compound concentration. These compounds mostly showed acute 
toxicity for drug concentrations of 6 µM. Compounds 37, 29, 30, 43, 45 and 46, even 
though having more tapered graphical profiles had sharp increases in toxicity 
reaching acute toxicity at 3 µM. Compounds 25 and 27 had more moderate toxicity 
profiles with acute toxicity only setting in after 20 µM concentrations of the 
compound. 
 
Compounds 37, 24, 28, 43 and 49 showed exponential toxicity profiles in Jurkat 
cells with acute toxicity for about 3 µM concentrations with the exception of 37 
being extremely potent with acute toxicity at less than 0.5 µM. Compound 27 
displayed a more moderate profile with acute toxicity only after 20 µM 
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concentrations. The rest of the compounds showed more linear toxicity profiles with 
extreme toxicity, sometimes of less than 0.5 µM.  
 
The toxicity of these compounds in lymphocytes is of great importance. The 
selectivity of these compounds hinges on their ability to not eradicate healthy cells. 
A high IC50 value in resting and stimulated lymphocytes is thus preferable. 
Compounds 37 and 30 had very low IC50 values making them very toxic to the 
healthy cells and thus unsuitable as a potential drug. Compound 27 showed a very 
high IC50 making it less toxic but since this compound was also non-toxic to cancer 
cells it seemed ineffective. Compound 28 exhibited a low IC50 in lymphocytes and a 
higher IC50 in cancer cell lines, making it selectively toxic for healthy cells which is 
undesirable. Compounds 29 and 30 had low IC50 values and 31 and 43 had slightly 
higher IC50 values. These four compounds are not very selective with specificities 
close to 1. Compounds 23, 25, 45, 47 and 49 all had specificities of about 3, making 
them 3 times more potent against cancer cells than healthy lymphocytes. Compounds 
24 and 46 had good specificities of 6.4 and 7.8, respectively, making them roughly 7 
times more selective for cancer cells. 
 
3.3 MORE IN DEPTH IN VITRO EVALUATIONS 
 
Based on the specificity displayed by the compounds (Table 3.3), five potential 
inhibitors were chosen for further evaluation against other cancerous cell lines. The 
compounds displaying some of the highest specificity included: 
i) two bridged gold compounds; 
• ClAu((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2AuCl (24) 
• ClAu((4-MeO)Ph)2PN(Et)N(Et)P(Ph(4-OMe))2AuCl (25) 
ii) three bischelated silver compounds; 
• [(Ph2PN(Et)N(Et)PPh2)2 Ag]+.NO3- (45) 
• [(((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2)2 Ag]+.NO3- (46) 
• [(((4-Me2N)Ph)2PN(Et)N(Et)P(Ph(NMe2))2)2 Ag]+.NO3- (49) 
 
It can already be noted that compounds 24 and 46 show a ten fold higher specificity 
compared to the standard [Au(dppe)2]Cl (37). Both these complexes have the same 
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ligand, i.e. ((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2, but different metal centres, 
the bridged complex being a gold and the bischelated complex being a silver 
complex.  
 
Even though the bridged gold(I) compounds 24 and 25 showed high selectivity it is 
believed that the active agent is the corresponding bischelated complex. Studies by 
Berners-Price et al.71,129 have shown the bridged gold(I) compound, 
ClAu(dppe)AuCl, in blood was rapidly converted into the cationic species 
[Au(dppe)2]+. Similarly, the bridged gold complexes 24 and 25 are excpected to be 
converted to the bischelated species. 
 
It is known that bischelated silver(I) compounds similar to 45, 46 and 49 do not 
readily react with halides or other possible ligands that occur in biological fluids and 
thus may reach the intended target site without decomposition/metabolisation.6  
 
3.3.1 Activity Screening and Specificity Determination 
 
The five selected compounds were further tested on A2780 (Human ovarian cancer), 
A2780cis (Human ovarian cancer - cisplatin resistant), Colo 320 DM (Human colon 
cancer), MCF-7 (Human breast cancer) and MCF-12A (Immortalised human non-
cancerous breast cells) cell lines. A series of results were obtained and toxicity 
profiles are represented graphically (Appendix B, Graphs 3.57 – 3.85) and a 
summary of IC50 values obtained is given in Table 3.4. 
 
Compound A2780 A2780cis Colo 320 DM MCF-7 MCF-12A 
37 (Ref) 0.017 ±0.068 0.234 ±0.143 0.461 ±0.037 0.196 ±0.092 0.443 ±0.166 
24 0.284 ±0.408 1.877 ±0.323 1.344 ±0.024 0.786 ±0.361 1.596 ±0.254 
25 0.923 ±0.190 1.995 ±0.637 0.327 ±0.8016 1.120 ±0.068 0.762 ±0.221 
45 0.341 ±0.107 0.957 ±0.568 0.236 ±0.810 0.625 ±0.424 0.884 ±0.368 
46 0.028 ±0.190 5.541 ±0.637 0.507 ±0.245 0.962 ±0.068 12.665 ±0.221 
49 0.499 ±0.075 2.030 ±0.672 2.985 ±0.784 0.578 ±0.299 4.547 ±0.855 
Table 3.4. IC50 (µM) of cells following treatment with experimental compounds 
(mean of three experiments). 
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All five compounds showed low IC50 values for the three cancer cell lines A2780, 
Colo 320 DM and MCF-7. These complexes showed higher IC50 values in the 
cisplatin resistant A2780cis cell line. This might imply an overlap of mode of action 
of cell death or more likely show the vigorous growth of the cisplatin resistant cells. 
Only compounds 46 and 49 showed good selectivity for the cancerous MCF-7 cell 
line over the “healthy” MCF-12A cell line. MCF-12A is a cell line derived from 
normal breast epithelial cells.155 In order to keep this cell line viable in vitro it had to 
be immortalised, which is the key trademark of cancerous cells. It can thus be seen as 
a benign cancerous cell line. 
 
From the further assays done on these five compounds a broader selectivity profile 
was determined (Table 3.5). The broader specificity was calculated by taking the 
sum of the IC50 values from healthy cells (MCF-12A, resting and stimulated 
lymphocytes) divided by the sum of the IC50 values of the cancerous cells (HeLa, 
Jurkat, A2780, A2780cis, CoLo 320 DM and MCF-7). 
 
Compound Specificity Compound Specificity 
37 (Ref) 1.067 45 2.800 
24 4.305 46 5.767 
25 5.096 49 3.593 
Table 3.5: Specificity of compounds tested (lymphocytes, MCF-12A IC50’s/Jurkat, 
HeLa, Colo 320 DM, A2780, A2780cis, MCF-7 IC50’s). 
 
From these specificities it can be seen that the overall specificity of these five 
compounds is not ideal. The two compounds with the highest specificities (25 and 
46) showed a five times higher specificity if compared to the reference (37). Even 
though this is an improvement on the activity of the reference an even higher 
specificity is necessary for a good potential anti-tumour drug. 
 
                                               
155
 H.G.R. Thompson, J.W. Harris, B.J. Wold, F. Lin, J.P. Brody, Oncogene, 2003, 
22, 2322. 
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From the assay results in Tables 3.4 and 3.5, two compounds were chosen for further 
studies. The selected compounds, 25 and 46, were subjected to pharmacokinetic 
studies. Full discussion on the pharmacokinetic studies (mitochondrial membrane 
potential and apoptosis assay) follows. 
 
3.4 PHARMACOKINETIC STUDIES 
 
Recently it has become clear that mitochondria play a central role in both apoptotic 
and necrotic cell death.156 Cells can be considered to die by either necrotic or 
apoptotic pathways. Necrotic cell death occurs in response to acute damage and 
results in rapid, uncontrolled death with subsequent cell lysis and a damaging 
inflammatory response.157 Necrotic cell death follows ATP depletion and cellular 
calcium overloading, consequently extensive mitochondrial damage leads to necrotic 
cell death in situations such as heart attack and stroke.158 In contrast, during 
apoptotic cell death an endogenous cell death programme is activated that causes the 
ordered self-destruction of the cell, ending with its phagocytosis by surrounding cells 
without leakage of damaging contents and thus no inflammatory response.157 
Apoptosis occurs during development to remove superfluous cells and also in 
response to cell damage, viral infection or transformation.157 The distinction between 
apoptotic and necrotic cell death in response to cell damage is somewhat arbitrary as 
completion of the apoptotic programme requires ATP, and if the ATP level falls 
below a critical threshold after initiation of apoptosis the apoptotic programme is 
aborted and the cell dies by necrosis.159,160 
 
The understanding of the role of mitochondria in apoptosis is still developing, but it 
is clear that mitochondria are critically involved in deciding whether a cell 
undergoes apoptosis.156 By activation of caspases, cells irreversibly initiate 
                                               
156
 P.E. Bernardi, Biochim. Biophys. Acta, 1998, 1366, 1. 
157
 A.J. Hale, C.A. Smith, L.C. Sutherland, V.E.A. Stoneman, V.L. Longthorne, A.C. 
Culhane, G.T. Williams, Eur. J. Biochem., 1996, 236, 1. 
158
 P. Nicotera, G. Bellomo, S. Orrenius, Annu. Rev. Pharmacol. Toxicol., 1992, 32, 
449. 
159
 M. Leist, P. Nicotera, Exp. Cell Res., 1998, 239, 183. 
160
 M.P. Murphy, R.A.J. Smith, Adv. Drug Del. Rev., 2000, 41, 2, 235. 
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apoptosis.161 Caspases are cysteine proteases present in an inactive pro-form in the 
cytoplasm, that are activated by auto-proteolysis and then further proteolyse other 
pro-caspases leading to a self-amplifying caspase cascade and cell death.160,161  
 
The membrane potential of mitochondria in vitro has an inside negative value not 
larger than 180–200 mV. This is about the maximum a lipid bilayer can sustain 
without breaking down.162 Within living cells and organisms this potential is lower, 
usually about 130–150 mV, as a result of ATP synthesis and ion translocation.163 As 
the mitochondrial membrane potential is far larger than that of others areas of the 
cells, lipophilic cations accumulate selectively within mitochondria. Lipophilic 
cations can easily pass through the hydrophobic barrier of the lipid bilayer since their 
positive charge is shielded or delocalised over a large surface area.164  
 
The mitochondrial accumulation of lipophilic cations was first demonstrated by 
Skulachev et al.165 and lipophilic cations such as triphenylmethylphosphonium or 
tetraphenylphosphonium are now used routinely to measure the membrane potential 
of mitochondria within living cells.163 In addition, fluorescent lipophilic cations such 
as rhodamine and JC-1 are used to visualise mitochondria by fluorescence 
microscopy or to estimate mitochondrial energisation by flow cytometry.164  
 
Mitochondria accumulate most lipophilic cations to a greater or lesser extent 
depending on the degree of charge screening or delocalisation in these ions. The 
plasma membrane potential (typically 30–60 mV, negative inside) also drives cation 
accumulation in the cell and the cations are then further accumulated in the 
mitochondria. This process is so effective that 90–95% of the cations become 
localised in the mitochondria.160,166  
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166
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The ability of mitochondria to accumulate lipophilic cations has been researched as a 
potential therapy.164,167 The most widespread approach has been to use lipophilic 
cations to selectively kill cancer cells.167 This is possible because many cancer cells 
have an elevated mitochondrial membrane potential that leads to the accumulation of 
lipophilic cations in the cancer cells and thereby causes cell death by non-specific 
disruption of mitochondrial function.160,167  
 
If mitochondria targeting drugs derived from lipophilic cations are to be of use in 
vivo then their uptake and pharmacokinetics must be understood. Most lipophilic 
cations enter cells through the lipid bilayer of the plasma membrane and their uptake 
does not require specific carriers. This has been demonstrated for triphenylalkyl-
phosphonium cations, which are rapidly taken up into mitochondria of the isolated 
perfused heart and liver and are retained within the organs for several hours.168 
Similar rapid uptake and mitochondria localisation has been found for many other 
fluorescent lipophilic cations in perfused organs and intraventricular injection of 
lipophilic cations leads to their accumulation in neuronal mitochondria.169 
Furthermore, intraperitoneal or intravenous injection of triphenylalkylphosphonium 
cations leads to their rapid uptake into the heart and other organs.170 Most lipophilic 
cations are not rapidly metabolised. However, cells that acquire multi-drug 
resistance due to expression of P-glycoprotein, the MDR-1 gene product, can export 
lipophilic cations across the plasma membrane and this mechanism may be a 
problem for the use of lipophilic cations in cancer therapy.160,171  
 
3.4.1 Mitochondrial Membrane Potential Assay 
 
A mitochondrial membrane potential assay is used to determine whether the 
application of a drug lowers or increases the mitochondria membrane potential. This 
was done using the fluorescent probe JC-1 after a 24 hour incubation of the cells. 
There is a direct correlation between the fluorescent absorption of JC-1 and the 
membrane potential.  
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 109 
 
Mitochondria are seen as targets for discrete lipophilic cations and thus the 
depolarisation (lowering) of the mitochondrial membrane potential would indicate 
that the complexes under investigation cause cell death via a mitochondrial mode of 
action. Results of the assay on normal lymphocyte cells are displayed in Table 3.6. 
Valinomycin is used as positive control of the method as this is known to reduce the 
membrane potential of mitochondria. Concentrations used were taken at 1x, 2x, 5x 
and 10x the IC50 value previously obtained from cytotoxicity studies. Percentage of 
normal membrane activity is given as an easy comparison.  
 
 Concentration 
Absorption 
Ratio 
Absorption/Control 
x 100% 
Control  760 ±245 100% 
10µM 355 ±26 50% Valinomycin 
 0.1µM 390 ±25 55% 
1.0µM 464 ±110 62% 
0.5µM 517 ±173 68% 
0.2µM 606 ±240 79% 
37 (Ref) 
 
0.1µM 658 ±237 86% 
50.0µM 388 ±34 53% 
25.0µM 466 ±44 64% 
10.0µM 617 ±168 82% 
25 
 
5.0µM 701 ±228 92% 
66.0µM 315 ±89 42% 
33.0µM 316 ±138 41% 
13.2µM 271 ±38 38% 
46 
 
6.6µM 301 ±34 41% 
Table 3.6: Lymphocytes mitochondrial membrane potential at 1x, 2x, 5x and 10x 
IC50 value. (mean of three experiments). 
 
A clear trend is evident from the lymphocyte mitochondria membrane potential 
assay (Table 3.6). Complex 25 compares to the [Au(dppe)2]Cl reference compound 
(37) in that a decrease of the membrane potential is correlated to an increase in the 
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concentration of the drug. It was seen to be more effective than 37 in reducing 
membrane potential and therefore comparable to the known membrane potential 
reduction agent valinomycin. Compound 46 on the other hand showed a huge 
decrease in membrane potential independant of the concentration of the administered 
drug. This reduction (about 60%) of membrane potential was more than that 
observed for valinomycin (about 50%). The concentration dependence of 
compounds 37 and 25 implies a reversible interaction with the membrane while the 
concentration independence of compound 46 may imply a less labile or permanent 
interaction and disruption. 
 
The assay was repeated on the cancerous Jurkat cell line and the results are displayed 
in Table 3.7 
 
 Concentration 
Absorbtion 
Ratio 
Absorbtion/Control 
x 100% 
Control  486 ±76 100% 
10µM 365 ±23 75% Valinomycin 
 0.1µM 373 ±21 77% 
1.0µM 417 ±67 86% 
0.5µM 440 ±54 90% 
0.2µM 423 ±22 87% 
37 (Ref) 
 
0.1µM 416 ±7 85% 
10.0µM 482 ±127 99% 
5.0µM 451 ±52 93% 
2.0µM 459 ±86 94% 
25 
 
1.0µM 457 ±78 94% 
4.0µM 450 ±132 93% 
2.0µM 474 ±145 98% 
0.8µM 426 ±139 88% 
46 
 
0.4µM 484 ±140 99% 
Table 3.7: Jurkat mitochondrial membrane potential at 1x, 2x, 5x and 10x IC50 
value. (mean of four experiments). 
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The results obtained for the mitochondrial membrane potential of Jurkat cells allows 
no meaningful interpretation. No significant decrease in membrane potential could 
be observed for any of the drugs at a range of concentrations while the valinomycin 
control still showed a reasonable decrease in membrane potential (about 25%), 
although not as pronounced as in the healthy cells. 
 
3.4.2 Apoptosis and Necrosis Assay 
 
The apoptosis assay was carried out on the Jurkat cell line to determine whether cell 
death occurred via apoptosis or necrosis. The absorption of Annexin V and 
propidium iodide (PI) is measured and is directly indicative of apoptosis or necrosis. 
In the early phase of apoptosis, the integrity of cell membrane is maintained but the 
cells lose membrane phospholipid asymmetry. Phosphatidylserine (PS), a negatively 
charged phospholipid located in the inner leaflet of the plasma membrane, is then 
exposed at the cell surface. Annexin V, which is a calcium and phospholipid binding 
protein, binds preferentially to PS.172 Annexin V can, in the case of an apoptotic cell, 
bind to PS exposed on the outer cell membrane and gives an indication of cell death 
before cell lysing, while PI can only interact with cell DNA once the cell membranes 
are breached, making it possible for PI to move into cell (see also Table 3.8). 
Measurements were taken after 6, 24 and 48 hours, respectively. In order to clarify 
the apoptosis assay results, Figures 3.1, 3.2 and Table 3.8 have been constructed. 
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Figure 3.1: Legit of areas of distribution. 
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 www.beckmancoulter.com/eCatalog/CatalogItemDetails.do?productId=4745. 
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Figure 3.2: Example of a typical assay. 
 
Block  Expression Indication 
B1 High Annexin V, 
Low PI 
Early apoptosis 
B2 High Annexin V, 
High PI 
Late apoptosis, 
Early necrosis 
B3 Low Annexin V, 
Low PI 
Viable or healthy cells 
B4 Low Annexin V, 
High PI 
Late necrosis 
(i.e. cell fragments) 
Early  Early Apoptosis 
Late  Late Apoptosis 
Necrosis  Early Necrosis 
Table 3.8: Apoptosis or necrosis indication. 
 
Results were obtained after 6, 24 and 48 hours incubation after drug administration 
(Appendix C) and a summary of results obtained is given in Tables 3.9, 3.10 and 
3.11.  
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Apoptosis Assay after 6 Hours 
1 x IC50 2 x IC50  
Control 37 (Ref) 25 46 Control 
37 
(Ref) 25 46 
B1 23.47 
±15.82 
28.59 
±20.19 
31.31 
±12.65 
19.13 
±14.90 
20.04 
±5.84 
34.14 
±8.98 
34.72 
±9.35 
26.54 
±7.35 
B2 11.51 
±8.93 
14.12 
±10.51 
16.48 
±10.87 
8.84 
±6.03 
10.41 
±4.99 
18.17 
±7.83 
18.26 
±8.41 
14.35 
±6.49 
B3 64.55 
±23.63 
56.44 
±29.08 
52.04 
±21.68 
69.26 
±15.87 
69.13 
±9.17 
47.56 
±15.86 
46.83 
±15.53 
58.87 
±13.66 
B4 0.47 
±0.60 
0.85 
±1.55 
0.17 
±0.04 
2.77 
±5.08 
0.43 
±0.25 
0.13 
±0.08 
0.20 
±0.08 
0.26 
±0.14 
Early 37.71 
±25.55 
39.68 
±26.90 
48.78 
±14.74 
32.01 
±22.59 
36.47 
±9.60 
51.74 
±10.07 
53.51 
±8.91 
44.93 
±8.21 
Late 5.89 
±4.04 
9.59 
±7.07 
8.49 
±6.21 
4.10 
±3.22 
3.70 
±0.90 
10.56 
±3.84 
9.07 
±4.79 
6.18 
±3.51 
Necrosis 0.82 
±1.00 
1.79 
±2.61 
2.11 
±1.75 
1.23 
±1.53 
1.46 
±1.56 
1.97 
±1.67 
2.33 
±1.69 
2.00 
±1.65 
Table 3.9: Apoptosis results after a 6 hour incubation period  
(mean of four experiments). 
 
Apoptosis Assay after 24 Hours 
1 x IC50 2 x IC50  
Control 37 (Ref) 25 46 Control 
37 
(Ref) 25 46 
B1 14.11 
±4.37 
14.02 
±4.73 
12.06 
±9.67 
10.21 
±4.68 
12.85 
±13.27 
13.73 
±2.12 
12.98 
±6.98 
12.58 
±9.79 
B2 6.62 
±1.82 
7.22 
±2.94 
5.44 
±3.69 
5.81 
±2.71 
6.47 
±5.02 
7.17 
±2.04 
8.21 
±2.79 
6.47 
±4.70 
B3 78.57 
±3.33 
77.90 
±2.62 
81.28 
±11.24 
83.15 
±7.29 
80.11 
±18.19 
78.44 
±2.72 
78.10 
±9.11 
79.36 
±13.09 
B4 0.71 
±0.47 
0.87 
±0.82 
1.22 
±1.03 
0.83 
±0.41 
0.57 
±0.42 
0.66 
±0.49 
0.71 
±0.42 
1.59 
±1.48 
Early 27.83 
±6.18 
27.55 
±7.11 
22.95 
±16.47 
21.61 
±8.89 
23.82 
±21.45 
26.78 
±3.24 
25.43 
±11.81 
25.36 
±18.99 
Late 2.24 
±.046 
2.66 
±1.00 
1.74 
±1.17 
1.72 
±0.44 
2.45 
±1.83 
2.84 
±0.67 
3.55 
±1.50 
1.48 
±0.98 
Necrosis 0.87 
±0.42 
0.97 
±0.64 
0.83 
±0.76 
0.88 
±0.38 
0.64 
±0.55 
1.27 
±0.68 
1.12 
±0.46 
0.83 
±0.68 
Table 3.10: Apoptosis results after a 24 hour incubation period  
(mean of four experiments). 
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Apoptosis Assay after 48 Hours 
1 x IC50 2 x IC50  
Control 37 (Ref) 25 46 Control 
37 
(Ref) 25 46 
B1 10.06 
±4.80 
5.81 
±4.89 
6.39 
±3.70 
5.12 
±5.31 
5.01 
±6.07 
7.37 
±1.67 
6.52 
±4.48 
8.96 
±5.89 
B2 7.84 
±3.27 
5.33 
±3.47 
7.54 
±3.36 
5.85 
±5.27 
5.93 
±5.34 
8.83 
±4.05 
6.41 
±1.65 
5.85 
±3.41 
B3 81.14 
±7.61 
87.15 
±5.91 
84.89 
±6.98 
87.04 
±9.94 
87.16 
±10.39 
82.14 
±4.64 
85.01 
±3.25 
84.03 
±8.64 
B4 0.97 
±0.42 
1.71 
±1.44 
1.19 
±0.26 
1.99 
±1.08 
1.91 
±1.54 
1.67 
±0.75 
2.06 
±2.78 
1.16 
±0.42 
Early 24.85 
±9.33 
15.25 
±10.08 
18.24 
±8.87 
15.29 
±13.27 
13.87 
±14.70 
20.47 
±5.98 
16.38 
±7.29 
20.96 
±11.49 
Late 1.94 
±0.41 
1.61 
±1.19 
2.03 
±0.58 
1.18 
±0.85 
1.31 
±1.45 
2.65 
±1.03 
2.75 
±2.40 
1.44 
±1.01 
Necrosis 0.64 
±0.09 
0.71 
±0.74 
0.62 
±.032 
0.42 
±0.37 
0.39 
±0.46 
0.98 
±0.35 
0.53 
±0.40 
0.48 
±0.33 
Table 3.11: Apoptosis results after a 48 hour incubation period  
(mean of four experiments). 
 
No meaningful difference between treated cells and the untreated control could be 
established from the data obtained from the apoptosis assays. More work is needed 
to better understand the mode of cell death displayed by these compounds. 
 
3.5 . CONCLUSION 
 
Toxicity studies were carried out on thirteen metal complexes of silver(I) and gold(I) 
and related to results of the known anti-tumour agent [Au(dppe)2]Cl (37). The most 
active complexes were found to be bridged gold and tetrahedral silver complexes. 
Five complexes were tested against various other cell lines to obtain a better 
toxicology profile. The bisphosphine-bridged gold complexes ClAu((4-
MeO)Ph)2PN(Et)N(Et)P(Ph(4-OMe))2AuCl (25) and the bischelated silver complex 
[(((4-MeO)Ph)2PN(Me)N(Me)P(Ph(4-OMe))2)2 Ag]+.NO3- 46 were seen to exhibit 
the best specificities and subsequently were used in mitochondria membrane 
potential and apoptosis assays. These two assays, unfortunately, did not yield 
conclusive results. Although proving to be more selective than the reference 
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compound (37) the complexes tested did not exhibit profound selectivity and thus 
did not warrant further investigation. 
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Chapter 4 
 
Chemical Experimental Procedures  
 
4.1 GENERAL 
 
4.1.1 Solvents 
 
All solvents used were chemically pure or pre-purified. Solvents were distilled from 
drying agents and degassed. Solvents were stored under argon or nitrogen over 
molecular sieves. All other reagents were purchased analytically pure or synthetically 
pure. 
 
4.1.2 Group 11 Transition Metals 
 
Gold metal was obtained from Harmony Gold and further synthesis of gold precursors 
was done as described later in this chapter. Silver nitrate was obtained from Sigma 
Aldrich. 
 
4.1.3 Instrumentation 
 
4.1.3.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
NMR spectra were recorded on either a Bruker Avance 300MHz or a Bruker Avance 
DRX 400MHz spectrometer. All NMR spectra were obtained from solutions in 
deuterochloroform (CDCl3) or deutero dimethyl sulphoxide (d-DMSO). The peak 
multiplicity of the signals are abbreviated as follows: bs - broad singlet, d - doublet, 
dd - doublet of doublets, dt - doublet of triplets, t - triplet, td - triplet of doublets, p - 
pentet, q - quartet, m – multiplet, s - singlet. The coupling constants (J) is calculated 
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in Hertz and reported to the nearest 0.1 Hz. 
 
1H-NMR data are listed in order: Chemical shift (δ, reported in ppm and referenced to 
the residual solvent peak of CDCl3 [δ = 7.26 ppm] or d-DMSO [δ = 2.54 ppm]173), 
multiplicity, coupling constants, related compound proton assignment. Proton 
decoupled 13C-NMR data are reported in the order: Chemical shift (δ, reported in ppm 
and referenced to the residual solvent peak of CDCl3 [δ = 77.00 ppm] or d-DMSO [δ 
= 40.45 ppm]173), multiplicity (due to C-P spin coupling), coupling constants, related 
compound carbon assignment. 31P-NMR data are listed as chemical shift (δ, reported 
in ppm and referenced to phosphoric acid [δ = 0.00 ppm]). 
 
4.1.3.2 Single Crystal X-Ray Diffraction 
 
Intensity data were collected on a Bruker SMART 1K CCD area detector 
diffractometer with graphite monochromated Mo Kα radiation (40kV, 40mA). The 
collection method involved ω-scans of width 0.3°. Data reduction was carried out 
using the program SAINT+174 and absorption corrections were made using the 
program SADABS.174 
 
The crystal structures were solved by direct methods using SHELXTL.175 Non-
hydrogen atoms were first refined isotropically followed by anisotropic refinement by 
full matrix least-squares calculations based on F2 using SHELXTL. Hydrogen atoms 
were first located in the difference map then positioned geometrically and allowed to 
ride on their respective parent atoms. Diagrams and publication materials were 
generated using SHELXTL, PLATON,176 MERCURY177 and ORTEP178. 
                                               
173
 H.E.Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem., 1997, 62, 7512. 
174
 Bruker, SAINT-Plus, Version 6.02 (includes XPREP and SADABS), Bruker AXS 
Inc., Madison, Wisconsin, USA, 1999. 
175
 G.M. Sheldrick, SHELXL-97 release 97-2, University of Göttingen, Germany, 
1997. 
176
 A.L. Spek, Platon version 200905, Utrecht University, Padualaan 8, 3584 CH 
Utrecht, The Netherlands, Copyright © 1980-2006. 
177
 Mercury 1.4, The Cambridge Crystallographic Data Centre, 12 Union Road, 
Cambridge, CB2 1EZ, UK Copyright © 2004. 
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4.1.3.3 Mass Spectroscopy 
 
EI and FAB-MS spectra were collected using a VG70-SEQ mass spectrometer in 
positive ion mode. 
 
4.1.3.4 Elemental Analysis 
 
Elemental analyses were determined on either a Thermo Flash EA1112 CHNS-O 
elemental analyser by the University of Cape Town or by the Institute for Soil, 
Climate and Water, Pretoria, South Africa on a Carlo Erba NA1500 
Nitrogen/Carbon/Sulphur Analyser which has been modified to allow CHN analysis. 
 
4.2 LIGAND SYNTHESIS 
 
4.2.1 Ligand Precursor Synthesis 
 
Bis(dichlorophosphino)dimethylhydrazine (2)19,25 and bis(dichlorophosphino)-
diethylhydrazine (6)29 were synthesised by heating under reflux, 2g of 
dimethylhydrazine dihydrochloride or diethylhydrazine dihydrochloride in 25ml 
phosphorous trichloride. Heating under reflux conditions was discontinued when most 
of the starting material (white solid) had dissolved, but only small amounts of 
phosphorous oxides (orange solids) had formed. Reflux heating was carried out for 
periods between 8 to 48 hours. Excess phosphorous trichloride was removed by 
vacuum distillation and recycled. Dry ether was added to the liquid products and 
phosphorous oxides and the mixture left for 15 minutes to allow complete 
precipitation of all solids. The liquid phase was decanted and the ether removed in 
vacuo to afford the pure products as colourless liquids in >90% yield. The products 
were stored under argon. 
                                                                                                                                       
178
 L.J. Farrugia, ORTEP-3 for Windows version 1.08, Department of Chemistry, 
Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, Copyright © 
1997-2005. 
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4.2.1.1 Bis(dichlorophosphino)dimethylhydrazine (2) 
 
N N
Cl2P PCl2
Me Me
 
 
Properties: 
• Slightly milky, colourless or yellow liquid  
• Air sensitive with slow degradation 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 3.13 (t, CH3, 3J (H1-P31) = 3.7 Hz, 6H) 
13C NMR: (CDCl3, 75 MHz) δC 33.4 (d, CH3, 2J (C13-P31) = 1.8 Hz) 
31P NMR: (CDCl3, 162 MHz) δP 160.9 
 
4.2.1.2 Bis(dichlorophosphino)diethylhydrazine (6) 
 
N N
Cl2P PCl2
Et Et
 
 
Properties: 
• Colourless or slightly yellow liquid  
• Air sensitive with slow degradation 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 3.75 and 3.23 (m, CH2CH3, 4H), 1.27 (t, 
CH2CH3, 3J (1H-1H) = 7.1 Hz, 6H) 
13C NMR: (CDCl3, 75 MHz) δC 42.2 (s, CH2CH3), 14.0 (s, CH2CH3),  
31P NMR: (CDCl3, 162 MHz) δP 156.3   
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4.2.2 Grignard Reagents 
 
Magnesium shavings were activated by washing with diluted hydrochloric acid, 
followed by washing with ethanol and acetone and drying in vacuo. Activated 
magnesium was stored under argon. 
 
5 g of activated magnesium shavings were stirred in 75 ml dry ether or dry THF and 
an iodine crystal was added. 1 equivalent of either bromobenzene, 4-bromoanisole or 
4-bromo-N,N-dimethyl aniline dissolved in 25 ml was added drop-wise at a rate to 
keep the solution under constant reflux.179 The solution was left to stir overnight. The 
resulting Grignard reagent was stored under argon in the fridge without further 
filtration. 
 
4.2.2.1 Phenylmagnesium Bromide (53) 
 
Mg Br
 
 
Properties: 
• 2M solution in ether 
• Brown liquid  
• Air sensitive, pyrophoric 
• Stored in a Schlenk tube under argon in the fridge 
 
                                               
179
 J. March, Advanced Organic Chemistry, 4th Ed., Wiley-Interscience Publication, 
1992, 622. 
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4.2.2.2 4-Anisolmagnesium Bromide (54) 
 
Mg BrO
Me
 
 
Properties: 
• 2M solution in THF 
• Brown liquid  
• Air sensitive, pyrophoric 
• Stored in a Schlenk tube under argon in the fridge 
 
4.2.2.3 N,N-dimethyl-4-anilinemagnesium Bromide (55) 
 
Mg BrN
Me
Me
 
 
Properties: 
• 2M solution in THF 
• Brown liquid  
• Air sensitive, pyrophoric 
• Stored in a Schlenk tube under argon in the fridge 
 
4.2.3 Ligand Synthesis 
 
Ligands 13 - 18 were all synthesised in a similar manner to published methods.19,29  
1 equivalent of bis(dichlorophosphino)dimethylhydrazine (2) or bis(dichloro-
phosphino)diethylhydrazine (6) was dissolved in dry ether for 13 and 14, or dry THF 
for 15 - 18. The solution was cooled to 0 oC in an ice bath and 4.1 equivalents of the 
corresponding cold Grignard reagent were slowly added while stirring vigorously. 
The reaction mixture was left to warm to room temperature overnight. The reaction 
mixture was added to cold brine while stirring vigorously. The two phases were 
separated by means of a separation funnel and the organic phase was dried with 
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anhydrous magnesium sulphate, filtered and reduced in vacuo to yield the desired 
product. The product was stored under argon. 
 
4.2.3.1 Bis(diphenylphosphino)dimethylhydrazine (13) 
 
N N
Ph2P PPh2
Me Me
 
 
Reaction: 
• 2: 3.480 g (13.3 mmol) 
• 54: 27.2 ml (54,5 mmol) 
• Diethylether: 100 ml 
• Yield: 72 % 
 
Properties: 
• Sticky yellow liquid 
• Air sensitive with slow degradation 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.39 (bs, Arom, 8H), 7.23 (bs, Arom, 12H), 2.66 
(bs, CH3, 6H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (CDCl3, 162 MHz) δP 63.3 
MS:  429 (10%, M + H), 214 (43%, MeNPPh2), 185 (100%, PPh2) 
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4.2.3.2 Bis(diphenylphosphino)diethylhydrazine (14) 
 
 
N N
Ph2P PPh2
Et Et
 
 
Reaction: 
• 6: 2.957 g (10.2 mmol) 
• 54: 20.9 ml (41.8 mmol) 
• Diethyl ether: 100 ml 
• Yield: 86 % 
 
Properties: 
• Yellow sticky solid or crystalline flakes 
• Decomposes slowly in air  
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.54 (bs, Arom, 4H), 7.36 (bs, Arom, 4H), 7.26 
(m, Arom, 12H), 3.23 (m, CH2CH3, 4H), 0.79 (t, CH2CH3, 3J (1H-1H) 
= 7.0 Hz, 6H) 
13C NMR: (CDCl3, 75 MHz) δC 140.2 (m, Arom), 133.4 (m, o-Ph), 131.4 (s, 
Arom), 128.7 (s, Arom), 48.7 (t, CH2CH3, 2J (13C-31P) = 2.5 Hz), 14.3 
(d, CH2CH3, 3J (13C-31P) = 4.1 Hz) 
31P NMR: (CDCl3, 162 MHz) δP 63.4 
MS:  427 (9%, M – H), 214 (81%, MeNPPh2), 185 (100%, PPh2) 
MP:  95-96 oC 
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4.2.3.3 Bis(di(4-methoxyphenyl))dimethylhydrazine (15) 
 
N N
(MeO-4-Ph)2P P(Ph-4-OMe)2
Me Me
 
 
Reaction: 
• 2: 1.567 g (6.0 mmol) 
• 55: 12.3 ml (24.5 mmol) 
• THF: 75 ml 
• Yield: 74 % 
 
Properties: 
• Yellow sticky liquid 
• Air sensitive with slow degradation 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.32 (bs, Arom, 8H), 6.81 (d, Arom, 3J (1H-1H) 
= 8.4 Hz, 8H), 3.73 (s, OCH3, 12H), 2.60 (s, NCH3, 6H) 
13C NMR: (CDCl3, 75 MHz) δC 160.3 (s, Arom), 134.2 (m higher order, Arom), 
131.1 (bs, Arom), 114.2, (m, Arom), 55.5 (s, OCH3), 38.1 (m, NCH3) 
31P NMR: (CDCl3, 121 MHz) δP 61.4 
MS:  No useful information could be obtained 
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4.2.3.4 Bis(di(4-methoxyphenyl))diethylhydrazine (16) 
 
N N
(MeO-4-Ph)2P P(Ph-4-OMe)2
Et Et
 
 
Reaction: 
• 6: 2.341 g (8.1 mmol) 
• 55: 16.6 ml (33.1 mmol) 
• THF: 100 ml 
• Yield: 75 % 
 
Properties: 
• Yellow sticky liquid 
• Air sensitive 
• Stored under argon in a Schlenrok tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.44 (m, Arom, 4H), 7.26 (m, Arom, 4H), 6.80 
(m, Arom, 8H), 3.71 (s, OCH3, 12H), 2.99 (m, CH2CH3, 6H), 0.88 (t, 
CH2CH3, 3J (1H-1H) = 5.4 Hz, 4H) 
13C NMR: Due to sample break down 13C could not be done 
31P NMR: (CDCl3, 121 MHz) δP 61.0 
MS:  No useful information could be obtained 
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4.2.3.5 Bis(di(N,N-dimetyl-4-aminophenyl))dimethylhydrazine (17) 
 
N N
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Me Me
 
 
Reaction: 
• 2: 2.556 g (9.8 mmol) 
• 56: 20 ml (40.0 mmol) 
• THF: 100 ml 
• Yield: 82 % 
 
Properties: 
• Yellow sticky liquid 
• Air sensitive 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.44 (bs, Arom, 8H), 6.79 (d, Arom, 3J (1H-1H) 
= 8.3 Hz, 3J (1H-31P) = 17.5 Hz, 8H), 3.01 (s, N(CH3)2, 24H), 2.74 (bs, 
NCH3, 6H) 
13C NMR: Due to sample break down 13C could not be done 
31P NMR: (CDCl3, 162 MHz) δP 61.5 
MS:  271 (58%, P(PhNMe2)2), 120 (100%, PhNMe2) 
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4.2.3.6 Bis(di(N,N-dimetyl-4-aminophenyl))diethylhydrazine (18) 
 
N N
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Et Et
 
 
Reaction: 
• 6: 3.158 g (10.9 mmol) 
• 56: 20 ml (44.7 mmol) 
• THF: 100 ml 
• Yield: 90 % 
 
Properties: 
• Yellow sticky liquid 
• Air sensitive 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.52 (bs, Arom, 4H), 7.31 (bs, Arom, 4H), 6.70 
(t, J (1H-31P) = 6.0 Hz, Arom, 8H), 2.96 (m, N(CH3)2, 24H), 3.1 (m, 
CH2CH3, 4H), 0.92 (t, 3J (1H-1H) = 7.0 Hz, CH2CH3, 6H) 
13C NMR: (CDCl3, 75 MHz) δC 149.23 (m, Arom), 133.67 (m, Arom), 131.65 (m 
Arom), 111,01 (m, Arom), 46.9 (s, CH2CH3), 38.97 (m, N(CH3)2), 
13.41 (s, CH2CH3)  
31P NMR: (CDCl3, 162 MHz) δP 60.4 
MS:  271 (42%, P(PhNMe2)2), 120 (100%, PhNMe2) 
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4.3 GOLD PRECURSOR SYNTHESIS 
 
4.3.1 Auric acid hydrate (56) 
 
Gold pellets were dissolved in aqua regia overnight. The resulting solution was dried 
in vacuo, washed with HCl and dried again until bright yellow crystals of 
HAuCl4.4H2O remained.180,181 
 
4.3.2 Dimethylsuphidegold(I) chloride (57) 
 
Auric acid hydrate (56) (approx. 5 g) was dissolved in water and zinc powder was 
added until very finely divided gold particles precipitated. The excess zinc was 
dissolved with HCl. The solid gold particles were isolated by filtration and placed in a 
200 ml round bottomed flask. 50 ml of DMSO and 25 ml HCl were added and the 
mixture was stirred under reflux for 1 – 2 days. The mixture was cooled down to –20 
oC and the resulting white precipitate and the gold particles were removed by 
filtration. The white precipitate was dissolved in DCM and the solid gold particles 
filtered out. Hexane was added to the DCM solution to precipitate (SMe2)AuCl as a 
white micro-crystalline powder.180,182,183 
 
4.3.2 Tetrahydrothiophenegold(I) chloride (58) 
 
Auric acid hydrate (56) (approx. 2 g) was dissolved in ethanol. Tetrahydrothiophene 
(THT) was added dropwise to the stirred solution, until the yellow colour disappeared 
and only a white precipitate remained. The precipitate was left to settle and the 
ethanol-THT mixture was decanted. The complex was washed with ethanol and the 
precipitate was dried in vacuo to yield (THT)AuCl as a white powder.180,184 
 
                                               
180
 In-house publication, Project AuTEK Biomed, Mintek. 
181
 A. Haas, J. Helmbrecht, U. Niemann, in Handbuch der Präparativen 
Anorganischen Chemie, Ed. G Brauer, Verlag Stuttgart, Stuttgart 1978, 1014. 
182
 T.E. Müller, J.C. Green, D.M.P. Mingos, C.M. McPartlin, C. Wittingham, D.J. 
Williams, T.M. Woodroffe, J. Organomet. Chem., 1998, 551, 313. 
183
 K.C. Dash, H. Schmidbaur, Chem. Ber., 1973, 106, 1221. 
184
 R. Uson, A. Laguna, J. Vicente, J. Organomet. Chem., 1977, 131, 471. 
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4.4 COMPLEX SYNTHESIS 
 
4.4.1 Synthesis of Bridged-Gold Complexes 
 
Tetrahydrothiophenegold(I) chloride [(THT)AuCl] (57) or dimethylsulphide(I)gold 
chloride [(Me2S)AuCl] (58) (1 equivalent) was suspended in THF. 0.5 equivalents of 
ligand 13 or 14 dissolved in DCM was added to the stirred suspension. The 
suspension turned yellow and after a short time micro crystals started to form. The 
solvent was removed in vacuo to afford the products 22 and 23 as micro-crystalline 
powders, respectively. For ligands 15, 16 and 18 the reaction was carried out in DCM 
and afforded complexes 24, 25 and 27. By addition of a few drops of THF it was 
possible to grow crystals overnight. Complexation of gold to ligand 17 failed in both 
DCM and THF due to the breakdown of the ligand upon mixing with the gold 
precursor. 
 
4.4.1.1 Bis(diphenylphosphino)dimethylhydrazine di(gold chloride) (22) 
 
N N
Me Me
Ph2P PPh2
Au 
Cl
Au
Cl
 
 
Reaction: 
• 13: 146 mg (0.34 mmol) 
• 58: 200 mg (0.68 mmol) 
• THF: 2 ml 
• DCM: 5 ml 
• Yield: 89 % 
 
Properties: 
• Grey crystals or white precipitate 
• Stable in air 
• Crystals are insoluble in organic and highly polar solvents 
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Characterisation: 
1H NMR:  (CDCl3, 300 MHz) δH 7.85 (dd, Arom, J (1H-31P) = 13.2, J (1H-1H) = 
8.1), 7.52 (t, Arom, J (1H-1H) = 9.40 Hz), 7.40 (dd, Arom, J (1H-31P) = 
17.7, J (1H-1H) = 7.4), 2.76 (d, CH3, 3J = 7.8 Hz)  
13C NMR: Compound too insoluble in NMR solvents 
31P NMR: (CDCl3, 121 MHz) δP 87.1 
MS:  No useful information could be obtained 
EA: Calc: (Au2Cl2P2N2C26H26) C 34.96 %, H 2.93 %, N 3.14 %  
  Found: C 35.29 %, H 2.93 %, N 3.13 % 
MP:  228 - 230 oC 
 
4.4.1.2 Bis(diphenylphosphino)diethylhydrazine di(gold chloride) (23) 
 
N N
Et Et
Ph2P PPh2
Au 
Cl
Au
Cl
 
 
Reaction: 
• 14: 155 mg (0.34 mmol) 
• 58: 200 mg (0.68 mmol) 
• THF: 5 ml 
• Yield: 86 % 
 
Properties: 
• Colourless to grey crystals 
• Stable in air 
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Characterisation: 
1H NMR:  (d-DMSO, 300 MHz) 7.90 (dq, Arom, J (1H-31P) = 28.9, J (1H-1H) = 
7.1 Hz), 7.71 (d, Arom, J = 7.0 Hz), 7.60 (d, Arom, J = 7.1 Hz), 7.55 
(d, Arom, J (1H-1H) = 7.0 Hz), 3.33 (bs, CH2CH3), 0.43 (t, CH2CH3, 3J 
(1H-1H) = 6.6 Hz) 
13C NMR: (d-DMSO, 75 MHz) δC 132.3 (bs, Arom), 130.6 (m, Arom), 129.0 (s, 
Arom), 128.0 (bs, Arom), 43.6 (bs, CH2CH3), 14.1 (d, CH2CH3, 3J 
(13C-31P) = 16.1 Hz) 
31P NMR: (d-DMSO, 121 MHz) δP 87.7 
MS:  920 (2%, M), 885 (14%, M - Cl) 
EA:  Calc: (Au2Cl2P2N2C28H30) C 36.50 %, H 3.28 %, N 3.04 %  
  Found: C 35.42 %, H 3.44 %, N 2.64 % 
MP:  202 - 204 oC 
 
4.4.1.3 Bis(di(4-methoxyphenyl)phosphino)dimethylhydrazine di(gold chloride) (24) 
 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
 
Reaction: 
• 15: 167 mg (0.29 mmol) 
• 59: 200 mg (0.57 mmol) 
• DCM: 5 ml 
• THF: few drops 
• Yield: 75 % 
 
Properties: 
• Colourless to grey crystals 
• Stable in air 
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Characterisation: 
1H NMR:  (CDCl3, 300 MHz) δH 7.79 (t, Arom, J = 8.2 Hz, 4H) 7.41 (t, Arom, J 
= 8.2 Hz, 4H), 6.97 (d, Arom, J = 7.6 Hz, 4H), 6.81 (d, Arom, J = 7.6 
Hz, 4H), 3.86 (s, OMe, 6H), 3.81 (s, OMe, 6H), 2.69 (d, NCH3, 3J (1H-
31P) = 5.8 Hz, 6H) 
13C NMR:  (CDCl3, 75 MHz) δC 163.5 (d, Arom, J = 33.4 Hz), 135.9 (m, Arom), 
115.3 (m, Arom), 55.52 and 55.45 (s, OCH3), 35.1 (s, NCH3) 
31P NMR: (CDCl3, 121 MHz) δP 85.1 
MS: 977 (83 %, M - Cl), 245 (80%, P(PhOMe)2) 
EA: Calc: (Au2Cl2P2O4N2C30H34) C 35.56 %, H 3.38 %, N 2.76 % 
 Found: C 36.78 %, H 3.79 %, N 2.47 %  
MP:  166 – 170 oC 
 
4.4.1.4 Bis(di(4-methoxyphenyl)phosphino)diethylhydrazine di(gold chloride) (25) 
 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
 
Reaction: 
• 16: 159 mg (0.29 mmol) 
• 59: 200 mg (0.57 mmol) 
• DCM: 5 ml 
• THF: few drops 
• Yield: 80 % 
 
Properties: 
• Grey crystals or purple precipitate 
• Stable in air 
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Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.16 (m, Arom), 6.64 (m, Arom), 3.73 (s, 
OCH3), 2.58 (bs, CH2CH3, 4H), 1.78 (m, CH2CH3, 6H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (CDCl3, 121 MHz) δP 84.7 
MS: 1004 (100%, M - Cl) 
EA:  Calc: (Au2Cl2P2O4N2C32H38) C 36.91 %, H 3.68 %, N 2.69 % 
  Found: C 37.02 %, H 3.91 %, N 1.94 % 
MP:  96 – 97 oC 
 
4.4.1.5 Bis(di(N,N-dimetyl-4-aminophenyl)phosphino)dimethylhydrazine di(gold 
chloride) (26) 
 
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
 
The complex could not be prepared due to the breakdown of the ligand during 
complexation. 
 
4.4.1.6 Bis(di(N,N-dimetyl-4-aminophenyl)phosphino)diethylhydrazine di(gold 
chloride) (27) 
 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
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Reaction: 
• 18: 182 mg (0.29 mmol) 
• 59: 200 mg (0.57 mmol) 
• DCM: 5 ml 
• Yield: 86 % 
 
Properties: 
• Purple-blue in reaction solution 
• Green powder after solvent removal, becomes black over time 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR:  (d-DMSO, 400 MHz) δH 7.61 (m, Arom, 8H), 6.87 (d, 3J (1H-1H) = 7.6 
Hz, Arom, 4H), 6.72 (d, 3J (1H-1H) = 7.6 Hz, Arom, 4H), 3.16 (bs, 
CH2CH3, 4H), 3.01 and 2.96 (s, N(CH3)2, 24 H), 0.85 (t, 3J (1H-1H) = 
6.8 Hz, CH2CH3, 6H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (d-DMSO, 162 MHz) δP 83.5 
MS:  1057 (M - Cl), 271 (100%, P(PhNMe2)2) 
EA:  Calc: (Au2Cl2P2N6C36H50) C 39.54 %, H 4.61 %, N 7.68 %  
  Found: Large deviations from calculated where observed 
MP:  170 – 172 oC 
 
4.4.2 Synthesis of Bischelated Gold Complexes 
 
Tetrahydrothiophenegold(I) chloride [(THT)AuCl] (57) or dimethylsulphidegold(I) 
chloride [(Me2S)AuCl] (58) (1 equivalent) was suspended in THF. To the stirred 
suspension was added 2 equivalents of ligand (13 - 18) in THF or DCM. The 
suspension turned yellow (except for complexes 32 and 34, which turned bright red 
over time). The solvent was removed in vacuo to afford the products as solids. 
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4.4.2.1 Bis(bis(diphenylphosphino)dimethylhydrazine) gold chloride (28) 
 
NN
MeMe
PPh2Ph2P
N N
Me Me
Ph2P PPh2
Au
+
Cl-
 
Reaction: 
• 13: 291 mg (0.68 mmol) 
• 58: 100 mg (0.34 mmol) 
• THF: 2 ml 
• DCM: 5 ml 
• Yield: 86 % 
 
Properties: 
• Yellow solid 
• Decomposes slowly in air 
• Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR:  (CDCl3, 300 MHz) δH 7.33 (t, Arom, 3J (1H-1H) = 7.6 Hz, 8H), 7.21 (t, 
Arom, coupling not resolved, 16H), 7.12 (t, Arom, J (1H-1H) = 7.6 Hz, 
16H), 2.69 (t, coupling not resolved, NCH3, 12H) 
13C NMR: Due to sample break down, 13C could not be done 
31P NMR: (CDCl3, 121 MHz) δP 83.9 
MS:  1053 (100 %, M - Cl) 
EA:  Calc: (AuClP4N4C52H52) C 57.34 %, H 4.81 %, N 5.14 % 
  Found: Large deviations from calculated where observed 
MP:  84 - 86 oC 
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4.4.2.2 Bis(bis(diphenylphosphino)diethylhydrazine) gold chloride (29) 
 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Au
+
Cl-
 
 
Reaction: 
• 14: 310 mg (0.68 mmol) 
• 58: 100 mg (0.34 mmol) 
• THF: 5 ml 
• Yield: 92 % 
 
Properties: 
• Yellow Solid 
• Decomposes slowly in air 
• Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (d-DMSO, 300 MHz) δH 7.84 (m, Arom, 16H), 7.36 (m, Arom, 24H), 
2.94 (m, CH2CH3, 8H), 0.96 (t, CH2CH3, 3J (1H-1H) = 6.9 Hz, 12H) 
13C NMR: (d-DMSO, 100.6 MHz) δC 132.5 (m, Arom), 131.9 (m, Arom), 130.5 
(m, Arom), 128.7 (m, Arom), 46.3 (d, CH2CH3, 2J (13C-31P)= 22.5 Hz), 
14.1 (m, CH2CH3) 
31P NMR: (d-DMSO, 121 MHz) δP 86.5 
MS:  1109 (75 %, M - Cl) 
EA:  Calc: (AuClP4N4C52H52) C 58.72 %, H 5.28 %, N 4.89 %  
  Found: Large deviations from calculated where observed 
MP:  109 - 110 oC 
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4.4.2.3 Bis(bis(di(4-methoxyphenyl)phosphino)dimethylhydrazine) gold chloride 
(30) 
 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
Reaction: 
• 15: 310 mg (0.57 mmol) 
• 59: 100 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 83 % 
 
Properties: 
• Bright yellow solid 
• Decomposes slowly in air 
• Slightly Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.16 (d, 3J (1H-1H) = 7.6 Hz, Arom, 16H), 6.64 
(d, 3J (1H-1H) = 8.5 Hz, Arom, 16H), 3.73 (s, OCH3, 24H), 2.58 (bs, 
NCH3, 12H) 
13C NMR: (CDCl3, 75 MHz) δC 161.9 (BS, Arom), 134.2 (m, Arom), 126.0 (m, 
Arom), 114.6 (s, Arom), 55.6 (bs, OCH3), 37.4 (s, NCH3) 
31P NMR: (CDCl3, 121 MHz) δP 81.9 
MS: 1293 (85 %, M - Cl), 274 (54 %, MeNP(PhOMe)2), 245 (98 %, 
P(PhOMe)2), 138 (100 %, P(PhOMe)) 
EA:  Calc: (AuClP4O8N4C60H68) C 54.20 %, H 5.16 %, N 4.21 % 
  Found: C 51.10 %, H 4.96 %, N 3.72 % 
MP:  96 - 97 oC 
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4.4.2.4 Bis(bis(di(4-methoxyphenyl)phosphino)diethylhydrazine) gold chloride (31) 
 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au
+
Cl-
 
 
Reaction: 
• 16: 312 mg (0.57 mmol) 
• 59: 100 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 90 % 
 
Properties: 
• Bright orange solid 
• Decomposes slowly in air 
• Slightly Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR:  (CDCl3, 300 MHz) δH 7.73 (Arom, 4H), 6.95 (Arom, 4H); 3.84 and 
3.86 (s, OCH3, 6H), 3.46 (m, CH2CH3, 1H), 3.27 (m, CH2CH3, 1H) 
0.79 (t, CH3, 3H, J = 2.1 Hz) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (CDCl3, 121 MHz) δP 83.9 
MS:  1349 (25 %, M - Cl), 138 (100 %, P(PhOMe)) 
EA:  Calc: (AuClP4O8N4C62H72) C 55.48 %, H 5.53 %, N 4.04 % 
  Found: Large deviations from calculated where observed 
MP:  89 – 92 oC 
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4.4.2.5 Bis(bis(di(N,N-dimethyl-4-aminophenyl)phosphino)dimethylhydrazine) gold 
chloride (32) 
 
NN
MeMe
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au
+
Cl-
 
 
The complex could not be prepared due to the breakdown of ligand during 
complexation. 
 
4.4.2.6 Bis(bis(di(N,N-dimethyl-4-aminophenyl)phosphino)diethylhydrazine) gold 
chloride (33) 
 
NN
EtEt
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au
+
Cl-
 
 
Reaction: 
• 18: 358 mg (0.57 mmol) 
• 59: 100 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 90 % 
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Properties: 
• Yellow solid, turns red overtime 
• Decomposes slowly in air  
• Stored under argon in a Schlenk tube 
 
Characterisation: 
Yellow compound  
31P NMR: (CDCl3, 161.98 MHz) δP 84.9 
 
Red compound  
31P NMR: (CDCl3, 161.98 MHz) δP 96.5 
MS:  1491 (9%, M + 2), 825 (100%, L + Au) 
MP:  142 – 143 oC 
 
4.4.3 Synthesis of Bridged-Silver Complexes 
 
Silver nitrate (1 equivalent) was suspended in THF or dissolved in acetonitrile. To the 
stirred suspension were added 0.5 equivalents of ligand (13 - 18) in DCM. The 
suspension turned colourless or light brown except for 41 and 42, in which case a 
blue-green colour was observed. The solvent was removed in vacuo to afford the 
product as a solid. 
 
4.4.3.1 Bis(diphenylphosphino)dimethylhydrazine di(silver nitrate) (38) 
 
N N
Me Me
Ph2P PPh2
Ag 
NO3
Ag
NO3
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Reaction: 
• 13: 124 mg (0.29 mmol) 
• AgNO3: 100 mg (0.59 mmol) 
• THF: 2 ml 
• DCM: 2 ml 
 
Properties: 
• Unstable 
 
Characterisation: 
Too unstable to obtain pure sample. 
31P NMR: (d-DMSO, 121 MHz) δP 75.28 (d, 1J (107/109Ag-31P) = 764.2 Hz) 
 
4.4.3.2 Bis (diphenylphosphino)diethylhydrazine di(silver nitrate)(39) 
 
N N
Et Et
Ph2P PPh2
Ag 
NO3
Ag
NO3
 
 
Reaction: 
• 14: 132 mg (0.29 mmol) 
• AgNO3: 100 mg (0.59 mmol) 
• THF: 2 ml 
• DCM: 2 ml 
• Yield: 65 % 
 
Properties: 
• Colourless crystals or light brown powder 
• Decomposes slowly in air  
• Stored under argon in a Schlenk tube 
• Possibly light sensitive leading to decomposition 
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Characterisation: 
1H NMR:  (d-DMSO, 300 MHz) δH 7.79 (bs, Arom), 7.64 (bs, Arom), 7.54 (bs, 
Arom), 3.19 (m, CH2CH3), 0.57 (t, 3J (1H-1H) = 6.6 Hz, CH2CH3) 
13C NMR: (CDCl3, 100.6 MHz) δC 135.8 (s, Arom), 134.0 (Arom), 131.2 (m, 
Arom), 128.2 (s, Arom), 13C ethyl signals could not be seen 
31P NMR: (d-DMSO, 121 MHz) δP 77.14 (d, 1J (107/109Ag-31P) = 782.9 Hz) 
MS:  733 (M - NO3), 653 (L + Ag), 455 (L) 
EA:  Calc: (Ag2P2N4O6C28H30) C 42.24% H 3.80% N 7.04%  
Found: C 41.48% H 3.95% N 6.77% 
MP:  182 – 183 oC 
 
4.4.3.3 Bis(di(4-methoxyphenyl)phosphino)dimethylhydrazine di(silver nitrate) (40) 
 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag 
NO3
Ag
NO3
 
 
The complex could not be prepared due to the breakdown of ligand during 
complexation. 
 
4.4.3.4 Bis(di(4-methoxyphenyl)phosphino)diethylhydrazine di(silver nitrate) (41) 
 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag 
NO3
Ag
NO3
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Reaction: 
• 16: 167 mg (0.29 mmol) 
• AgNO3: 100 mg (0.59 mmol) 
• Acetonitrile: 2 ml 
• DCM: 2 ml 
• Yield: 70 % 
 
Properties: 
• White-grey powder 
• Decomposes slowly in air  
 
Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.54 (m, Arom, 8H), 7.00 (m, Arom, 8H), 3.85 
(s, OCH3, 12H), 3.41 and 3.18 (bs, CH2CH3, 4H), 1.02 (bs, CH2CH3, 
6H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (CDCl3, 162 MHz) δP 74.19 (d, 1J (107/109Ag-31P) = 834.2 Hz) 
MS:  826 (12 %, M – NO3), 138 (100 %, P(PhOMe)) 
EA:  Calc: (Ag2P2N4O10C32H38) C 43.60 % H 4.15 % N 6.78 % 
Found: Large deviations from calculated where observed 
MP:  91 – 92 oC 
 
4.4.3.5 Bis(di(N,N-dimetyl-4-aminophenyl)phosphino)dimethylhydrazine di(silver 
nitrate) (42) 
 
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag 
NO3
Ag
NO3
 
 
The complex could not be prepared due to the breakdown of ligand during 
complexation. 
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4.4.3.6 Bis(di(N,N-dimetyl-4-aminophenyl)phosphino)diethylhydrazine di(silver 
nitrate) (43) 
 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag 
NO3
Ag
NO3
 
Reaction: 
• 18: 182 mg (0.29 mmol) 
• AgNO3: 100 mg (0.59 mmol) 
• Acetonitrile: 2 ml 
• DCM: 2 ml 
• Yield: 74 % 
 
Properties: 
• Initial purple-blue colour in reaction solution  
• Green solid, turns black over time 
• Decomposes slowly in air  
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR:  (d-DMSO, 400 MHz) δH 7.43 (m, Arom), 6.78 (m, Arom), 3.11 (m, 
CH2CH3, 4H), 2.97 and 2.99 (s, N(CH3)2, 24H), 0.66 (t, 3J (1H-1H) = 
6.8 Hz, CH2CH3, 6H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (d-DMSO, 162 MHz) δP 74.46 (d, 1J (107/109Ag-31P) = 819.6 Hz) 
MS:  951 (10%, M – CH3, 10%), 751 (100 %, L + Ag + CH3/N) 
EA:  Calc: (Ag2P2N8O6C36H50) C 44.64 %, H 5.20 %, N 11.57 % 
  Found: C 44.14 %, H 5.23 %, N 10.60 % 
MP:  118 - 120 oC 
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4.4.4 Synthesis of Bischelated Silver Complexes 
 
Silver nitrate (1 equivalent) was suspended in THF. To the stirred suspension were 
added 2 equivalents of ligand (13 - 18) in THF or DCM. The suspension turned 
colourless (unless otherwise stated). THF was removed in vacuo to afford the product 
as a white solid (unless otherwise stated). 
 
4.4.4.1 Bis(bis(diphenylphosphino)dimethylhydrazine)silver nitrate (44) 
 
NN
MeMe
PPh2Ph2P
N N
Me Me
Ph2P PPh2
Ag
+
NO3-
 
 
Reaction: 
• 13: 252 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 2 ml 
• DCM: 2 ml 
• Yield: 76 % 
 
Properties: 
• White solid 
• Unstable 
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Characterisation: 
Complex was too unstable to obtain pure sample. The following characterisation was 
possible: 
1H NMR: (d-DMSO, 300 MHz) δH 7.51 (bs, Arom), 7.34 (bs, Arom), 2.73 (bs, 
CH3) 
31P NMR: (d-DMSO, 121 MHz) δP 68.42 (dd, 1J (107Ag-31P) = 245.7 Hz, 1J 
(109Ag-31P) = 283.5 Hz) 
MS:  963 (38%, M - NO3), 535 (58 %, Ligand + Ag), 214 (100 %, PPh) 
MP:  96 - 98 oC 
 
4.4.4.2 Bis(bis(diphenylphosphino)diethylhydrazine)silver nitrate (45) 
 
NN
EtEt
PPh2Ph2P
N N
Et Et
Ph2P PPh2
Ag
+
NO3-
 
 
Reaction: 
• 14: 269 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 84 % 
 
Properties: 
• White or grey solid 
• Decomposes slowly in air 
• Hygroscopic 
• Stored under argon in a Schlenk tube 
• Possibly light sensitive leading to decomposition 
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Characterisation: 
1H NMR: (CDCl3, 300 MHz) δH 7.39 (bs, Arom, 16H), 7.19 (bs, Arom, 24H), 
2.94 (unresolved q, CH2CH3, 8H), 0.85 (t, 3J (1H-1H) = 6.0 Hz, 
CH2CH3, 12H) 
13C NMR: (CDCl3, 75 MHz) δC 133.5 (Arom), 132.8 (Arom), 131.5 (Arom), 
128.9 (Arom), 48.9 (CH2CH3), 14.8 (CH2CH3) 
31P NMR: (CDCl3, 161.98 MHz) δP 69.06 (dd, 1J (107Ag-31P) = 248.1, 1J (109Ag-
31P) = 285.3Hz) 
MS:  1022 (45 %, M - NO3), 563 (56 %, L + Ag), 455 (47 %, L),  
EA:  Calc: (AgP4N5O3C56H60) C 62.11 %, H 5.58 %, N 6.47 %  
  Found: C 60.08 %, H 5.54%, N 5.85 % 
MP:  127 – 130 oC 
 
4.4.4.3 Bis(bis(di(4-methoxyphenyl)phosphino)dimethylhydrazine)silver nitrate (46) 
 
NN
MeMe
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
 
Reaction: 
• 15: 324 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 79 % 
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Properties: 
• Light yellow solid 
• Decomposes slowly in air  
• Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.21 (d, coupling not resolved, Arom, 16H), 
6.70 (d, 3J (1H-1H) = 8.4 Hz, Arom, 16H), 3.75 (OCH3, 24H), 2.54 
(NCH3, 12H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (CDCl3, 162 MHz) δP 66.18 (dd, 1J (107Ag-31P) = 246.9 Hz, 1J (109Ag-
31P) = 284.9Hz) 
MS:  1206 (36 %, M - NO3), 655 (34%, L + Ag), 245 (100%, P(PhOMe)2) 
EA:  Calc: (AgP4N5O11C60H68) C 56.88 %, H 5.41 %, N 5.53 %  
  Found: C 56.78%, H 5.51 %, N 4.84 % 
MP:  90 - 93 oC 
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4.4.4.4 Bis(bis(di(4-methoxyphenyl)phosphino)diethylhydrazine)silver nitrate (47) 
NN
EtEt
P(Ph-4-OMe)2(MeO-4-Ph)2P
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Ag
+
NO3-
 
 
Reaction: 
• 16: 341 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 83 % 
 
Properties: 
• Light yellow solid 
• Decomposes slowly in air  
• Hygroscopic 
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (CDCl3, 400 MHz) δH 7.53 (d, Arom, 3J (1H-1H) = 8.8Hz, 16H), 6.99 
(d, Arom, 3J (1H-1H) = 8.8Hz, 16H), 3.78 (OCH3, 24H), 2.90 (bs, 
CH2CH3, 8H), 0.85 (bs, CH2CH3, 12H) 
13C NMR: (CDCl3, 100.6 MHz) δC 161.8 (m, Arom), 132.8 (m, Arom), 113.2 (m, 
Arom), 52.6 (s, OCH3), 42.9 (m, CH2CH3), 13.2 (m, CH2CH3), 
31P NMR: (CDCl3, 162 MHz) δP 67.54 (dd, 1J (107Ag-31P) = 249.9, 1J (109Ag-31P) 
= 285.3 Hz) 
MS: 1261 (22 %, M - NO3), 683 (20 %, L + Ag), 245 (100 %, P(PhOMe)2) 
EA:  Calc: (AgP4N5O11C64H76) C 58.10 %, H 5.79 %, N 5.29 %  
  Found: C 58.27 %, H 5.96 %, N 4.88 % 
MP:  76 - 78 oC 
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4.4.4.5 Bis(bis(di(N,N-dimethyl-4-aminophenyl)phosphino)dimethylhydrazine)silver 
nitrate (48) 
 
NN
MeMe
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Me Me
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag
+
NO3-
 
 
Reaction: 
• 17: 354 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 5 ml 
 
The complex could not be fully characterised due to the breakdown of ligand during 
complexation 
 
Characterisation: 
31P NMR: (d-DMSO, 161.98 MHz) δP 66.56 (dd, 1J (107Ag-31P) = 246.4, 1J 
(109Ag-31P) = 284.2 Hz) 
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4.4.4.6 Bis(bis(di(N,N-dimethyl-4-aminophenyl)phosphino)diethylhydrazine)silver 
nitrate (49) 
 
NN
EtEt
P(Ph-4-NMe2)2(Me2N-4-Ph)2P
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Ag
+
NO3-
 
 
Reaction: 
• 17: 371 mg (0.59 mmol) 
• AgNO3: 50 mg (0.29 mmol) 
• THF: 5 ml 
• Yield: 76 % 
 
Properties: 
• Light brown solid 
• Decomposes slowly in air  
• Stored under argon in a Schlenk tube 
 
Characterisation: 
1H NMR: (d-DMSO, 400 MHz) δH 7.6 - 6.4 (various multiplets, Arom), 2.87 
(NCH3, 48H), 2.67 (m, CH2CH3, 8H), 0.88 (bs, CH2CH3, 12H) 
13C NMR: Due to sample breakdown 13C could not be done 
31P NMR: (d-DMSO, 162 MHz) δP 67.60 (dd, 1J (107Ag-31P) = 248.3, 1J (109Ag-
31P) = 286.1Hz) 
MS:  1365 (50 %, M - NO3), 735 (74 %, L + Ag), 271 (100 %, P(PhNMe2)2) 
EA:  Calc: (AgP4N13O3C72H100) C 60.58 %, H 7.06 %, N 12.76 %  
  Found: C 59.25 %, H 6.86 %, N 12.24 % 
MP:  125 - 127 oC 
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Chapter 5 
 
Biological Experimental Procedures 
 
5.1 GENERAL 
 
Experimental reagents were prepared according to in-house publications.185 
 
5.1.1 Experimental Conditions 
 
Plastic tips and tubes were autoclaved and kept in closed containers in laminar flow 
cabinets. Only sterile, disposable plastic-ware was used. Laminar flow cabinets were 
kept clean and sterile by wiping with 70% alcohol on a regular basis. 
 
5.1.2 Culture Medium 
 
Roswell Park Memorial Institute medium (RPMI), Eagle’s minimal essential medium 
(EMEM) and Dulbecco’s minimal essential medium (DMEM) culture media were 
commercially obtained (Sigma-Aldrich) and supplemented with 1% penstrep mixture 
(10 000 U penicillin/ml and 10 000 µg streptomycin/ml) (Adcock-Ingram) and 10% 
Heat Inactivated Foetal Calf Serum (HI FCS) (Adcock-Ingram). DMEM culture 
medium used for cultivating MCF-7 cell line was further supplemented with 2% non-
essential amino acids. Culture medium used for MCF-12 cell line was made up from a 
1:1 mixture of DMEM and Ham’s F12 medium and was supplemented with 
hydrocortisone (10 mg/ml), chlora toxin (1 mg/ml), insulin (20 mg/ml), 10% HI FCS 
and epidermal growth factor (100 mg/ml). All culture medium was stored at 4oC. 
 
                                               
185
 G. Joone, C.E. Medlen, In-house publications, Department of Pharmacology,  
University of Pretoria. 
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5.1.3 Heat Inactivated Foetal Calf Serum (HI FCS) 
 
A defrosted sealed bottle, containing 100 ml foetal calf serum (Adcock-Ingram), was 
incubated at 56 oC for 45 minutes in a water bath. The FCS was mixed periodically 
during incubation by gently swirling the container. The container was, after 
incubation, immediately divided into 2 sterile 50 ml centrifuge tubes and stored 
frozen until needed. 
 
5.1.4 White Cell Counting Fluid 
 
1 ml of a 0.1 % aqueous solution of Crystal Violet (Merck) was added to a solution of 
97 ml deionised water and 2 ml acetic acid. The resulting solution was stored at 4 oC. 
 
5.1.5 Phosphate Buffered Saline (PBS) 
 
FTA hemaglutination buffer (9.23 g) (The Scientific Group) was dissolved in 1 L of 
distilled water and the pH adjusted to 7.2 using either sodium hydroxide or 
hydrochloric acid. 
 
5.1.6 MTT Stain Solution 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (250 mg) 
(Sigma-Aldrich) was dissolved in 50 ml PBS and filter sterilised through a filter with 
a pore size of 0.2 µm. The solution was stored at 4 oC in the dark. 
 
5.1.7 Valinomycin 
 
Frozen Valinomycin stock solution (50 µl, 1 mM) was diluted to 100 µM and 1 µM 
concentrations. The final concentrations in mitochondrial membrane potential 
experiments after addition of 0.2 ml of the stock solution to flow cytometer tubes 
were 10 µM and 0.1 µM, respectively. 
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5.1.8 JC-1 
 
PBS (3900 µl) was added to 100 µl of a 1.5 mM frozen JC-1 [5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide] stock solution and mixed very 
well to minimise separation before use. 
 
5.1.9 Hepes Binding Buffer 
 
Into 100 ml of de-ionised water was dissolved Hepes buffering agent [4-(2-
hydroxyethyl)-1-piperazineethanesulphonic acid] (238.3 mg, 10 mM) (BD 
Bioscience), sodium chloride (876,6 mg, 150 mM), potassium chloride (37.3 mg, 5 
mM), calcium chloride (26.5 mg, 1.8 mM) and magnesium chloride (9.5 mg, 1 mM). 
The pH was adjusted to 7.4 using either sodium hydroxide or hydrochloric acid and 
stored at 4 oC. 
 
5.1.10 Propidium Iodide (PI) 
 
Propidium iodide (2.5 g) was dissolved in 50 ml PBS. The solution was stored at 4 oC 
in the dark. 
 
5.1.11 Ammonium Chloride Solution 
 
Ammonium chloride (8.3 g), sodium bicarbonate (1 g) and EDTA [ethylenediamine-
tetraaceticacid] (74 mg)  (Sigma-Aldrich) were dissolved in distilled water (1 L). The 
solution was filter sterilised through a 0.2 µm pore size filter and stored at 4 oC in the 
dark. 
 
5.1.12 Phytohaemaglutinine (PHA) 
 
Sterile distilled water (5 ml) was added to the freeze dried content of a bottle of 
commercial PHA (BIOWEB) and mixed gently. 0.2 ml aliquots were dispensed into 
sterile tubes, which were then stored at -20 oC. 
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5.1.13 Heparin 
 
Commercial Heparin (sodium salt) (90 mg) (Sigma-Aldrich) was dissolved in distilled 
water (30 ml), that was sterislised before use, and the solution was stored at 4 oC. 
 
5.1.14 Cell Cultures 
 
The following cell cultures were used: 
 
Code Description ATCC code 
Culture 
medium 
HeLa 
Human adenocarcinoma of the 
cervix 
CCL-2 EMEM 
CoLo 320 DM Human colon cancer CCL-220 RPMI 
Jurkat Human T-cell cancer NRBM 0062 RPMI 
A2780 Human ovarian cancer EACC 93112519 RPMI 
A2780cis 
Human ovarian cancer 
(cisplatin resistant) 
EACC 93112519 
exposed to cisplatin 
RPMI 
MCF-7 Human breast cancer HTB 22 DMEM 
MCF-12A 
Modified human non-
cancerous breast cells 
CRL 10782 DMEM 
Table 5.1: Summary of the cell cultures used in biological studies. American Type 
Culture Collection (ATCC) codes are also provided. 
 
5.2 INSTRUMENTATION 
 
5.2.1 Microplate Reader 
 
MTT assays were performed using a BIO-TEK Instruments, ELx800 UV Universal 
microplate reader. 
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5.2.2 Flowcytometer 
 
Mitochondria and apoptosis assays were performed on a Beckman Coulter Cytomics 
FC 500 flowcytometer equipped with a 488nm argon laser. 
 
5.3 BIOLOGICAL STUDIES 
 
Procedures were carried out following in-house procedures.185 
 
5.3.1 Maintenance of Cultures 
 
Viable cells in appropriate media were kept in a culture flask at 37 oC in an 
atmosphere of 5 % CO2 in air. The media were replaced 2 to 3 times a week. The lid 
of the culture flask was not tightened completely to allow for pH regulation by the 
inflow of CO2. 
 
5.3.2 Trypsination of Adherent Cell Lines 
 
This applies to the following cell lines: HeLa, A2780, A2780cis, MCF-7 and MCF-
12A. Cells were examined under an invert microscope to determine satisfactory 
growth (cells should not reach confluency) and to check for possible infection.  
 
The medium was removed and washed with Trypsin/Versene solution (0.25% Trypsin 
and 0.05 % EDTA solution in Ca2+ and Mg2+ free Dulbecco buffer, commercially 
obtained) (approx. 5 ml) to remove all traces of culture medium as this inhibits the 
activity of Trypsin. Enough Trypsin/Versene (approx. 3 ml) was added to cover the 
cells on the bottom of the flask. The cells were incubated for approx. 10 minutes at  
37 oC until the cells detached themselves from the bottom of the flask. The cells were 
aspirated into a centrifuge tube (15 ml) and culture medium was added to fill the tube. 
Culture medium was added as it contains proteins that prevent cell damage caused by 
Trypsin and EDTA. The tube was centrifuged for 5 minutes at 1000 rpm and 
supernatant liquid was discarded. The remaining cell pellet was resuspended in 1 ml 
of culture medium. The resuspended cells were used for cell population counting and 
with appropriate dilution were loaded onto a 96 well plate. 
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5.3.3 Lymphocyte Preparation 
 
Heparinised blood (30 ml, 5 units/ml blood) from a healthy adult human volunteer 
was carefully loaded onto 15 ml Histopaque 1077. The suspension was centrifuged 
for 25 minutes at 1800 rpm. The top plasma layer was removed and the 
lymphocytes/monocyte layer was transferred to a sterile 50 ml tube. The 50 ml tube 
was filled with RPMI medium and centrifuged for 15 minutes at 1000 rpm to remove 
contaminating platelets. The supernatant fluid was discarded and the tube refilled with 
RPMI. The suspension was centrifuged for 10 minutes at 1000 rpm. The supernatant 
fluid was discarded and the tube filled with cold ammonium chloride solution. The 
suspension was left on ice for 10 minutes to lyse contaminating red cells. The tube 
was centrifuged for 10 minutes at 1000 rpm and the supernatant liquid discarded. The 
remaining pellet was resuspended in RPMI medium followed by centrifuging for 10 
minutes at 1000 rpm. The supernatant liquid was discarded and the pellet resuspended 
in 1 ml RPMI with 10 % FCS. Cells were counted and diluted for use. 
 
5.3.4 Counting of Cells 
 
The resuspended pellet (50 µl) was added to white cell counting fluid (450 µl) and 
thoroughly mixed. A small amount of the suspension was put on a Haemocytometer 
and counted using a Reichert-Jung Microstar 110 microscope at a magnification of 
10x. Final concentrations required for a 96 well plate were made up by dilution of the 
1 ml resuspended cell pellet (Table 5.2).  
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Cell Line Cell Concentration Needed 
HeLa 1:4 dilution of 2.5 x 104  
CoLo 320 DM 1:4 dilution of 2 x 104  
Jurkat 1:4 dilution of 3 x 104  
A2780 1:4 dilution of 2.5 x 104  
A2780cis 1:4 dilution of 2.5 x 104  
MCF-7 1:4 dilution of 2 x 104  
MCF-12A 1:4 dilution of 2 x 104  
Lymphocytes 2 x 106  
Table 5.2: Cell concentrations for loading onto plates. 
 
5.3.5 IC50 Toxicity Tests 
 
This procedure applies to all cell lines except lymphocytes. Culture medium (80 µl) 
was dispensed into the 96 wells of the plate and left to warm to 37 oC in the 
incubation oven while cells were prepared. A cell suspension (100 µl) of the 
appropriate concentration was dispensed into wells and the plate was left to incubate 
for one hour at 37 oC in an atmosphere of 5 % CO2. The drug solution (20 µl) or the 
culture medium (in the case of the control experiments) was dispensed into wells 
(triple experiments) and incubated for 7 days. Plates are incubated in a closed (not 
sealed) container with a kitchen towel soaked with sterile water at the bottom to 
minimise edge effect from evaporation of culture medium. 
 
5.3.6 IC50 Drug Toxicity Testing for Lymphocytes 
 
Culture medium (60 µl) was dispensed into the 96 wells of the plate and left to warm 
to 37 oC in the incubation oven while cells were prepared. 100 µl of cell suspension at 
the appropriate concentration were dispensed into wells and the plate was left to 
incubate for 1 hour at 37 oC in a 5 % CO2 atmosphere. The drug solution (20 µl) or 
the culture medium (in the case of the control experiments) were dispensed into wells 
(triple experiments). After 5 minutes PHA (20 µl) was added to stimulate 
lymphocytes in one set of experiments, while culture medium (20 µl) was added to 
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the set of resting lymphocyte experiments. The plates were incubated for 3 days. 
Plates were incubated in a closed (not sealed) container with a kitchen towel soaked 
with sterile water at the bottom to minimise edge effect from evaporation of culture 
medium. 
 
5.3.7 Drug Preparation 
 
Stock solutions (10 mM) of the drugs were prepared by dissolving the drug in DMSO 
(1 ml). The stock solutions were dispensed in 50 µl aliquots into Eppendorf tubes and 
stored at -20 oC. Dilutions of the stock solutions were made directly before they were 
administered to stabilised cells in 96 well plates. Eight dilutions of the drugs in 
question were prepared from the stock solution by subsequent dilution in a ratio of 1:1 
(see example below). The final percentage DMSO solvent per well was less than  
0.5 %. 
 
Example of stock dilutions for plate loading: 
 
50 µl 10 mM stock solution 
50 µl stock solution + 450 µl medium → 500 µl 1 mM drug solution 
100 µl 1 mM solution + 100 µl medium → 200 µl 500 µM drug solution 
 
1:1 dilutions (100 µl of previous solution + 100 µl medium) 
500 µM = first drug dose → 20 µl per well to give a final conc. of 50.00 µM 
250 µM = second drug dose → 20 µl per well to give a final conc. of 25.00 µM 
125 µM = third drug dose → 20 µl per well to give a final conc. of 12.50 µM 
62.5 µM = fourth drug dose → 20 µl per well to give a final conc. of 6.25 µM 
31.3 µM = fifth drug dose → 20 µl per well to give a final conc. of 3.13 µM 
15.6 µM = sixth drug dose → 20 µl per well to give a final conc. of 1.56 µM 
7.8 µM = seventh drug dose → 20 µl per well to give a final conc. of 0.78 µM 
3.9 µM = eighth drug dose → 20 µl per well to give a final conc. of 0.39 µM 
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5.3.8 MTT Assay 
 
MTT stain solution (20 µl) was added to each well after the 7 day incubation period 
of the respective cells. The plate was re-incubated for another 3½ to 4 hours for viable 
cell staining. The plate was centrifuged for 10 minutes at 2000 rpm. The supernatant 
fluid was discarded without disturbing the pellet and the cells were washed with  
150 µl PBS, followed by 10 minuntes centrifugation of the mixture at 2000 rpm. The 
supernatant liquid was discarded and the pellet left to dry overnight in the dark. The 
next morning 100 µl DMSO were added and the plates were placed on a shaker for 
approximately 2 hours to facilitate dissolution of the purple formazan crystals formed 
from MTT by viable cells. The absorbance of viable and proliferating cells was 
analysed with a 900 Micro-ELISA reader. 
 
5.3.9 Determination of the Cell Membrane Potential of Mitochondria 
 
Jurkat or lymphocyte cells (1.8 ml) at appropriate concentrations (Table 5.2) were 
incubated for 1 hour in flow cytometer tubes. To this was added the appropriate drug 
dilution (0.2 ml) for Jurkat cells and for lymphocyte cells (0.22 ml). All experiments 
were carried out in the same manner using a control sample (no addition of toxin) and 
multiples (1x, 2x, 5x, 10x) of the IC50 value of the drug as determined in previous 
toxicological experiments. For the lymphocyte experiment the cells were stimulated 
with PHA (0.2 ml) 5 minutes after dispension of the drug. The cells were left to 
incubate for 24 hours. Two tubes that were incubated without drug were treated with 
0.1 mM (0.2 ml) and 10 mM (0.2 ml) Valinomycin (known to decrease mitochondrial 
membrane potential), respectively and incubated for 10 minutes. The tubes were 
centrifuged for 5 minutes at 1800 rpm. The obtained pellet was resuspended in the 
appropriate supplemented medium (900 µl) and JC-1 (100 µl) was added. The tubes 
were left in the dark for 20 minutes and then centrifuged for 5 minutes at 1800 rpm. 
The isolated pellet was washed with PBS (approximately 3 ml), the mixture was 
centrifuged for 5 minutes at 1800 rpm and the supernatant liquid was discarded. The 
obtained pellet was resuspended in PBS (1 ml) supplemented with 10 % FCS and 
analysed using the flowcytometer. 
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5.3.10 Apoptosis Test 
 
Jurkat cells of the appropriate concentration (Table 5.2) were incubated for 1 hour in 
culture flasks (45 ml cell solution per 250 ml flask). All experiments were carried out 
in the same manner using a control sample (no addition of toxin) and multiples (1x, 
2x) of the concentration related to the IC50 value of the drug as determined in previous 
toxicological experiments. The flasks were incubated for 48 hours and after 6, 24 and 
48 hours 15 ml aliquots were removed from each flask for analyses.  
 
Centrifuge tubes (15 ml) were filled with samples from the 250 ml culture flasks and 
centrifuged for 7 minutes at 800 rpm. The supernatant liquid was discarded and the 
remaining pellet was washed twice with PBS (2 ml) containing 1% FCS. It was then 
centrifuged again for 7 minutes at 800 rpm and the supernatant liquid was discarded. 
The isolated pellet was resuspended in Hepes binding buffer (1 ml) and two flow 
cytometer tubes were filled with 100 µl aliquots of each of the cell suspensions. One 
of the tubes was left unstained while PI (10 µl) and Annexin V-FITC (Fluorescence 
conjugated Annexin-V) (5 µl) was added to the second tube. The tubes were left for 
15 minutes in the dark (Annexin-V is light sensitive). Hepes binding buffer (400 µl) 
was added to each tube and the suspended cells analysed using the flowcytometer. 
 
5.3.11 Statistical Analysis 
 
The results of the assays are expressed as the mean percentage (%) of ±SEM. The 
statistical program GRAPHPAD was used to determine the IC50 concentration of the 
drug treated groups.  
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Appendix A 
 
Molecular Structures 
 
Bis(diphenylphosphino)diethylhydrazine (14) 
 
N N
Ph2P PPh2
Et Et
 
 
Table 1: Crystal data and structure refinement for 14. 
 
Empirical formula  P2N2C28H30  
Formula weight  456.48 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 14.623(5) Å α = 90° 
 b = 13.085(4) Å β = 108.2(6)° 
 c = 13.494(4) Å γ = 90° 
Volume 2453.1(13) Å3 
Z 4 
Density (calculated) 1.236 Mg/m3 
Absorption coefficient 0.196 mm-1 
F(000) 968 
Crystal size 0.44 x 0.17 x 0.17 mm3 
Theta range for data collection 1.47 to 26.00° 
Index ranges -16<=h<=18, -12<=k<=16, -16<=l<=14 
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Reflections collected 13465 
Independent reflections 4813 [R(int) = 0.0490] 
Completeness to theta = 26.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9675 and 0.9189 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 4813/0/291 
Goodness-of-fit on F2 1.014 
Final R indices [I>2sigma(I)] R1 = 0.0508, wR2 = 0.1188 
R indices (all data) R1 = 0.0860, wR2 = 0.1371 
Largest diff. peak and hole 0.787 and -0.419 e.Å-3 
 
Table 2: Bond lengths [Å] and angles [°] for 14. 
 
N(1)-N(2)  1.427(3) 
N(1)-C(1)  1.471(3) 
N(1)-P(1)  1.710(2) 
N(2)-C(3)  1.466(3) 
N(2)-P(2)  1.692(2) 
P(1)-C(21)  1.832(3) 
P(1)-C(11)  1.846(3) 
P(2)-C(41)  1.835(3) 
P(2)-C(31)  1.847(3) 
C(1)-C(2)  1.510(4) 
C(3)-C(4)  1.511(4) 
C(11)-C(16)  1.394(4) 
C(11)-C(12)  1.394(4) 
C(12)-C(13)  1.388(4) 
C(13)-C(14)  1.375(4) 
C(14)-C(15)  1.381(4) 
C(15)-C(16)  1.383(4) 
C(21)-C(26)  1.396(4) 
C(21)-C(22)  1.404(4) 
C(22)-C(23)  1.385(4) 
C(23)-C(24)  1.386(4) 
C(24)-C(25)  1.378(4) 
C(25)-C(26)  1.390(4) 
C(31)-C(36)  1.394(4) 
C(31)-C(32)  1.399(4) 
C(32)-C(33)  1.391(4) 
C(33)-C(34)  1.377(4) 
C(34)-C(35)  1.383(4) 
C(35)-C(36)  1.385(4) 
C(41)-C(42)  1.395(4) 
C(41)-C(46)  1.398(4) 
C(42)-C(43)  1.382(4) 
C(43)-C(44)  1.381(4) 
C(44)-C(45)  1.376(4) 
C(45)-C(46)  1.387(4) 
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N(2)-N(1)-C(1) 114.65(19) 
N(2)-N(1)-P(1) 116.47(16) 
C(1)-N(1)-P(1) 122.01(17) 
N(1)-N(2)-C(3) 114.49(19) 
N(1)-N(2)-P(2) 118.43(16) 
C(3)-N(2)-P(2) 126.88(17) 
N(1)-P(1)-C(21) 102.16(11) 
N(1)-P(1)-C(11) 104.85(11) 
C(21)-P(1)-C(11) 99.34(12) 
N(2)-P(2)-C(41) 105.91(11) 
N(2)-P(2)-C(31) 105.31(11) 
C(41)-P(2)-C(31) 98.32(11) 
N(1)-C(1)-C(2) 113.7(2) 
N(2)-C(3)-C(4) 114.7(2) 
C(16)-C(11)-C(12) 117.5(3) 
C(16)-C(11)-P(1) 125.0(2) 
C(12)-C(11)-P(1) 117.4(2) 
C(13)-C(12)-C(11) 120.7(3) 
C(14)-C(13)-C(12) 121.0(3) 
C(13)-C(14)-C(15) 119.0(3) 
C(14)-C(15)-C(16) 120.3(3) 
C(15)-C(16)-C(11) 121.5(3) 
C(26)-C(21)-C(22) 117.5(2) 
C(26)-C(21)-P(1) 124.5(2) 
C(22)-C(21)-P(1) 118.0(2) 
C(23)-C(22)-C(21) 121.3(3) 
C(22)-C(23)-C(24) 120.2(3) 
C(25)-C(24)-C(23) 119.6(3) 
C(24)-C(25)-C(26) 120.5(3) 
C(25)-C(26)-C(21) 121.1(3) 
C(36)-C(31)-C(32) 118.2(2) 
C(36)-C(31)-P(2) 124.81(19) 
C(32)-C(31)-P(2) 116.9(2) 
C(33)-C(32)-C(31) 120.6(3) 
C(34)-C(33)-C(32) 120.1(3) 
C(33)-C(34)-C(35) 120.0(3) 
C(34)-C(35)-C(36) 120.1(3) 
C(35)-C(36)-C(31) 120.9(3) 
C(42)-C(41)-C(46) 117.6(2) 
C(42)-C(41)-P(2) 116.7(2) 
C(46)-C(41)-P(2) 125.8(2) 
C(43)-C(42)-C(41) 121.4(3) 
C(44)-C(43)-C(42) 120.2(3) 
C(45)-C(44)-C(43) 119.3(3) 
C(44)-C(45)-C(46) 120.9(3) 
C(45)-C(46)-C(41) 120.5(3) 
 
 
Table 3: Torsion angles [°] for 14. 
 
C(1)-N(1)-N(2)-C(3) -113.0(2) 
P(1)-N(1)-N(2)-C(3) 95.3(2) 
C(1)-N(1)-N(2)-P(2) 71.9(2) 
P(1)-N(1)-N(2)-P(2) -79.7(2) 
N(2)-N(1)-P(1)-C(21) -131.65(17) 
C(1)-N(1)-P(1)-C(21) 79.0(2) 
N(2)-N(1)-P(1)-C(11) 125.12(18) 
C(1)-N(1)-P(1)-C(11) -24.3(2) 
N(1)-N(2)-P(2)-C(41) -123.64(18) 
C(3)-N(2)-P(2)-C(41) 62.0(2) 
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N(1)-N(2)-P(2)-C(31) 132.83(18) 
C(3)-N(2)-P(2)-C(31) -41.6(2) 
N(2)-N(1)-C(1)-C(2) 57.0(3) 
P(1)-N(1)-C(1)-C(2) -153.1(2) 
N(1)-N(2)-C(3)-C(4) -60.6(3) 
P(2)-N(2)-C(3)-C(4) 113.9(2) 
N(1)-P(1)-C(11)-C(16) 105.1(2) 
C(21)-P(1)-C(11)-C(16) -0.2(3) 
N(1)-P(1)-C(11)-C(12) -78.5(2) 
C(21)-P(1)-C(11)-C(12) 176.1(2) 
C(16)-C(11)-C(12)-C(13) -0.5(4) 
P(1)-C(11)-C(12)-C(13) -177.1(3) 
C(11)-C(12)-C(13)-C(14) 1.0(5) 
C(12)-C(13)-C(14)-C(15) -0.2(5) 
C(13)-C(14)-C(15)-C(16) -1.0(5) 
C(14)-C(15)-C(16)-C(11) 1.5(4) 
C(12)-C(11)-C(16)-C(15) -0.7(4) 
P(1)-C(11)-C(16)-C(15) 175.6(2) 
N(1)-P(1)-C(21)-C(26) 0.9(2) 
C(11)-P(1)-C(21)-C(26) 108.4(2) 
N(1)-P(1)-C(21)-C(22) 178.7(2) 
C(11)-P(1)-C(21)-C(22) -73.8(2) 
C(26)-C(21)-C(22)-C(23) -1.7(4) 
P(1)-C(21)-C(22)-C(23) -179.7(2) 
C(21)-C(22)-C(23)-C(24) 0.2(4) 
C(22)-C(23)-C(24)-C(25) 1.2(4) 
C(23)-C(24)-C(25)-C(26) -1.0(4) 
C(24)-C(25)-C(26)-C(21) -0.6(4) 
C(22)-C(21)-C(26)-C(25) 1.9(4) 
P(1)-C(21)-C(26)-C(25) 179.7(2) 
N(2)-P(2)-C(31)-C(36) 85.1(2) 
C(41)-P(2)-C(31)-C(36) -24.0(2) 
N(2)-P(2)-C(31)-C(32) -98.2(2) 
C(41)-P(2)-C(31)-C(32) 152.7(2) 
C(36)-C(31)-C(32)-C(33) 0.2(4) 
P(2)-C(31)-C(32)-C(33) -176.7(2) 
C(31)-C(32)-C(33)-C(34) -0.7(4) 
C(32)-C(33)-C(34)-C(35) -0.1(4) 
C(33)-C(34)-C(35)-C(36) 1.2(4) 
C(34)-C(35)-C(36)-C(31) -1.7(4) 
C(32)-C(31)-C(36)-C(35) 0.9(4) 
P(2)-C(31)-C(36)-C(35) 177.6(2) 
N(2)-P(2)-C(41)-C(42) 176.14(19) 
C(31)-P(2)-C(41)-C(42) -75.2(2) 
N(2)-P(2)-C(41)-C(46) -3.5(3) 
C(31)-P(2)-C(41)-C(46) 105.1(2) 
C(46)-C(41)-C(42)-C(43) -1.9(4) 
P(2)-C(41)-C(42)-C(43) 178.4(2) 
C(41)-C(42)-C(43)-C(44) 0.5(4) 
C(42)-C(43)-C(44)-C(45) 1.0(4) 
C(43)-C(44)-C(45)-C(46) -1.0(4) 
C(44)-C(45)-C(46)-C(41) -0.4(4) 
C(42)-C(41)-C(46)-C(45) 1.9(4) 
P(2)-C(41)-C(46)-C(45) -178.4(2) 
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Di(phenylphosphino)cyclotetramethyldihydrazine (52) 
 
PhP
N N
PPh
NN
Me Me
Me Me
 
 
Table 4: Crystal data and structure refinement for 52. 
 
Empirical formula  P2N4C16H22 
Formula weight  332.32 
Temperature  193(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 13.2879(16) Å α = 90° 
 b = 7.5426(9) Å β = 90° 
 c = 17.125(2) Å γ = 90° 
Volume 1716.4(4) Å3 
Z 4 
Density (calculated) 1.286 Mg/m3 
Absorption coefficient 0.255 mm
-1
 
F(000) 704 
Crystal size 0.38 x 0.27 x 0.26 mm
3
 
Theta range for data collection 2.38 to 27.00° 
Index ranges -15<=h<=16, -7<=k<=9, -21<=l<=21 
Reflections collected 10040 
Independent reflections 1873 [R(int) = 0.0313] 
Completeness to theta = 27.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9366 and 0.9092 
Refinement method Full-matrix least-squares on F2 
 167 
Data/restraints/parameters 1873/0/100 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0302, wR2 = 0.0888 
R indices (all data) R1 = 0.0370, wR2 = 0.0935 
Largest diff. peak and hole 0.318 and -0.248 e.Å-3 
 
Table 5: Bond lengths [Å] and angles [°] for 52. 
 
C(1)-N(1)  1.4583(18) 
C(2)-N(2)  1.4605(17) 
C(11)-C(16)  1.398(2) 
C(11)-C(12)  1.400(2) 
C(11)-P(1)  1.8412(15) 
C(12)-C(13)  1.393(2) 
C(13)-C(14)  1.384(2) 
C(14)-C(15)  1.389(2) 
C(15)-C(16)  1.395(2) 
N(1)-N(2)#1  1.4321(17) 
N(1)-P(1)  1.6953(14) 
N(2)-N(1)#1  1.4321(17) 
N(2)-P(1)  1.6984(12) 
 
 
C(16)-C(11)-C(12) 118.12(13) 
C(16)-C(11)-P(1) 121.12(11) 
C(12)-C(11)-P(1) 119.90(11) 
C(13)-C(12)-C(11) 121.04(14) 
C(14)-C(13)-C(12) 120.08(14) 
C(13)-C(14)-C(15) 119.73(14) 
C(14)-C(15)-C(16) 120.24(14) 
C(15)-C(16)-C(11) 120.72(14) 
N(2)#1-N(1)-C(1) 114.56(12) 
N(2)#1-N(1)-P(1) 120.94(9) 
C(1)-N(1)-P(1) 121.23(10) 
N(1)#1-N(2)-C(2) 114.43(11) 
N(1)#1-N(2)-P(1) 120.04(9) 
C(2)-N(2)-P(1) 119.18(10) 
N(1)-P(1)-N(2) 106.49(6) 
N(1)-P(1)-C(11) 101.67(6) 
N(2)-P(1)-C(11) 100.84(6) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y,-z. 
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Table 6: Torsion angles [°] for 52. 
 
C(16)-C(11)-C(12)-C(13) -2.7(2) 
P(1)-C(11)-C(12)-C(13) -172.18(11) 
C(11)-C(12)-C(13)-C(14) 0.5(2) 
C(12)-C(13)-C(14)-C(15) 1.3(2) 
C(13)-C(14)-C(15)-C(16) -1.0(2) 
C(14)-C(15)-C(16)-C(11) -1.3(2) 
C(12)-C(11)-C(16)-C(15) 3.1(2) 
P(1)-C(11)-C(16)-C(15) 172.42(12) 
N(2)#1-N(1)-P(1)-N(2) 38.17(13) 
C(1)-N(1)-P(1)-N(2) -120.30(12) 
N(2)#1-N(1)-P(1)-C(11) -66.99(11) 
C(1)-N(1)-P(1)-C(11) 134.55(11) 
N(1)#1-N(2)-P(1)-N(1) -37.75(13) 
C(2)-N(2)-P(1)-N(1) 112.73(11) 
N(1)#1-N(2)-P(1)-C(11) 68.00(11) 
C(2)-N(2)-P(1)-C(11) -141.52(11) 
C(16)-C(11)-P(1)-N(1) 148.76(12) 
C(12)-C(11)-P(1)-N(1) -42.10(12) 
C(16)-C(11)-P(1)-N(2) 39.20(13) 
C(12)-C(11)-P(1)-N(2) -151.65(11) 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y,-z. 
 
Bis(diphenylphosphino)dimethylhydrazine di(gold chloride) (22) 
 
N N
Me Me
Ph2P PPh2
Au 
Cl
Au
Cl
 
 
Table 7: Crystal data and structure refinement for 22. 
 
Empirical formula  Au2Cl2P2N2C26H26 
Formula weight  893.26 
Temperature  193(2) K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  P41212 
Unit cell dimensions a = 10.6720(14) Å α = 90° 
 b = 10.6720(14) Å β = 90° 
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 c = 23.439(4) Å γ = 90° 
Volume 2669.5(7) Å3 
Z 4 
Density (calculated) 2.223 Mg/m3 
Absorption coefficient 11.317 mm
-1
 
F(000) 1672 
Crystal size 18 x 10 x 8 mm
3
 
Theta range for data collection 2.10 to 28.29° 
Index ranges -14<=h<=14, -11<=k<=14, -31<=l<=31 
Reflections collected 25347 
Independent reflections 3312 [R(int) = 0.0906] 
Completeness to theta = 28.29° 99.9 %  
Absorption correction Integration 
Max. and min. transmission 0.4566 and 0.2936 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 3312/0/154 
Goodness-of-fit on F2 0.975 
Final R indices [I>2sigma(I)] R1 = 0.0296, wR2 = 0.0531 
R indices (all data) R1 = 0.0467, wR2 = 0.0560 
Absolute structure parameter 0.011(10) 
Largest diff. peak and hole 1.443 and -0.767 e.Å-3 
 
Table 8: Bond lengths [Å] and angles [°] for 22. 
 
Au-P  2.2318(16) 
Au-Cl  2.2976(17) 
P-N  1.702(5) 
P-C(21)  1.805(6) 
P-C(11)  1.811(6) 
N-N#1  1.425(10) 
N-C(1)  1.455(8) 
C(21)-C(22)  1.393(8) 
C(21)-C(26)  1.394(9) 
C(11)-C(12)  1.394(8) 
C(11)-C(16)  1.402(9) 
C(23)-C(24)  1.379(10) 
C(23)-C(22)  1.388(8) 
C(16)-C(15)  1.386(9) 
C(25)-C(26)  1.349(9) 
C(25)-C(24)  1.404(9) 
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C(15)-C(14)  1.372(9) 
C(13)-C(12)  1.373(9) 
C(13)-C(14)  1.374(9) 
 
 
P-Au-Cl 176.34(6) 
N-P-C(21) 110.1(3) 
N-P-C(11) 103.8(3) 
C(21)-P-C(11) 106.0(3) 
N-P-Au 108.89(18) 
C(21)-P-Au 114.4(2) 
C(11)-P-Au 113.1(2) 
N#1-N-C(1) 115.9(4) 
N#1-N-P 113.3(5) 
C(1)-N-P 121.9(4) 
C(22)-C(21)-C(26) 118.9(6) 
C(22)-C(21)-P 118.2(5) 
C(26)-C(21)-P 122.9(5) 
C(12)-C(11)-C(16) 118.1(6) 
C(12)-C(11)-P 120.4(5) 
C(16)-C(11)-P 120.9(5) 
C(24)-C(23)-C(22) 119.1(6) 
C(15)-C(16)-C(11) 119.9(6) 
C(26)-C(25)-C(24) 120.3(7) 
C(14)-C(15)-C(16) 120.8(6) 
C(12)-C(13)-C(14) 120.5(6) 
C(23)-C(22)-C(21) 120.8(6) 
C(13)-C(12)-C(11) 120.9(6) 
C(23)-C(24)-C(25) 120.0(6) 
C(25)-C(26)-C(21) 120.8(6) 
C(15)-C(14)-C(13) 119.6(6) 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -y+1,-x+1,-z+1/2. 
 
Table 9: Torsion angles [°] for 22. 
 
C(21)-P-N-N#1 -89.2(4) 
C(11)-P-N-N#1 157.7(3) 
Au-P-N-N#1 37.0(4) 
C(21)-P-N-C(1) 56.8(6) 
C(11)-P-N-C(1) -56.3(6) 
Au-P-N-C(1) -177.0(5) 
N-P-C(21)-C(22) 110.1(5) 
C(11)-P-C(21)-C(22) -138.3(5) 
Au-P-C(21)-C(22) -13.0(6) 
N-P-C(21)-C(26) -69.0(6) 
C(11)-P-C(21)-C(26) 42.7(6) 
Au-P-C(21)-C(26) 168.0(5) 
N-P-C(11)-C(12) -42.6(6) 
C(21)-P-C(11)-C(12) -158.7(5) 
Au-P-C(11)-C(12) 75.2(5) 
N-P-C(11)-C(16) 145.7(5) 
C(21)-P-C(11)-C(16) 29.7(6) 
Au-P-C(11)-C(16) -96.5(5) 
C(12)-C(11)-C(16)-C(15) -0.2(10) 
P-C(11)-C(16)-C(15) 171.6(5) 
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C(11)-C(16)-C(15)-C(14) 0.9(10) 
C(24)-C(23)-C(22)-C(21) -2.1(9) 
C(26)-C(21)-C(22)-C(23) -0.9(9) 
P-C(21)-C(22)-C(23) 180.0(5) 
C(14)-C(13)-C(12)-C(11) -0.5(10) 
C(16)-C(11)-C(12)-C(13) 0.0(9) 
P-C(11)-C(12)-C(13) -171.8(5) 
C(22)-C(23)-C(24)-C(25) 4.1(10) 
C(26)-C(25)-C(24)-C(23) -3.1(10) 
C(24)-C(25)-C(26)-C(21) 0.0(10) 
C(22)-C(21)-C(26)-C(25) 2.0(10) 
P-C(21)-C(26)-C(25) -179.0(5) 
C(16)-C(15)-C(14)-C(13) -1.3(11) 
C(12)-C(13)-C(14)-C(15) 1.1(11) 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -y+1,-x+1,-z+1/2. 
 
Bis(diphenylphosphino)diethylhydrazine di(gold chloride) (23) 
 
N N
Et Et
Ph2P PPh2
Au 
Cl
Au
Cl
 
 
Table 10: Crystal data and structure refinement for 23. 
 
Empirical formula  Au2Cl2P2N2O2C36H46 
Formula weight  1065.52 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pccn 
Unit cell dimensions a = 12.3275(18) Å α = 90° 
 b = 17.200(3) Å β = 90° 
 c = 18.173(3) Å γ = 90° 
Volume 3853.4(10) Å3 
Z 4 
Density (calculated) 1.837 Mg/m3 
Absorption coefficient 7.860 mm-1 
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F(000) 2056 
Crystal size 0.48 x 0.23 x 0.14 mm3 
Theta range for data collection 2.03 to 27.00° 
Index ranges -11<=h<=15, -21<=k<=21, -22<=l<=23 
Reflections collected 23024 
Independent reflections 4199 [R(int) = 0.0450] 
Completeness to theta = 27.00° 99.8 %  
Absorption correction Integration 
Max. and min. transmission 0.3395 and 0.1191 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 4199/0/209 
Goodness-of-fit on F2 1.063 
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0485 
R indices (all data) R1 = 0.0417, wR2 = 0.0518 
Largest diff. peak and hole 0.523 and -1.219 e.Å-3 
 
Table 11: Bond lengths [Å] and angles [°] for 23. 
 
Au(1)-P(1)  2.2331(11) 
Au(1)-Cl(1)  2.3021(10) 
Au(1)-Au(1)#1  3.1310(5) 
N(1)-N(1)#1  1.416(6) 
N(1)-C(1)  1.481(5) 
N(1)-P(1)  1.679(3) 
P(1)-C(21)  1.810(4) 
P(1)-C(11)  1.820(4) 
C(1)-C(2)  1.526(6) 
C(11)-C(12)  1.386(6) 
C(11)-C(16)  1.397(5) 
C(12)-C(13)  1.388(6) 
C(13)-C(14)  1.377(6) 
C(14)-C(15)  1.361(6) 
C(15)-C(16)  1.394(6) 
C(21)-C(22)  1.399(6) 
C(21)-C(26)  1.400(6) 
C(22)-C(23)  1.383(6) 
C(23)-C(24)  1.385(7) 
C(24)-C(25)  1.367(6) 
C(25)-C(26)  1.369(6) 
O(1)-C(31)  1.340(9) 
O(1)-C(34)  1.349(8) 
C(31)-C(32)  1.497(9) 
C(32)-C(33)  1.491(9) 
C(33)-C(34)  1.479(8) 
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P(1)-Au(1)-Cl(1) 179.22(4) 
P(1)-Au(1)-Au(1)#1 86.37(3) 
Cl(1)-Au(1)-Au(1)#1 94.01(3) 
N(1)#1-N(1)-C(1) 117.4(3) 
N(1)#1-N(1)-P(1) 118.4(3) 
C(1)-N(1)-P(1) 123.1(2) 
N(1)-P(1)-C(21) 104.36(17) 
N(1)-P(1)-C(11) 108.90(18) 
C(21)-P(1)-C(11) 103.71(18) 
N(1)-P(1)-Au(1) 110.68(11) 
C(21)-P(1)-Au(1) 113.12(13) 
C(11)-P(1)-Au(1) 115.30(14) 
N(1)-C(1)-C(2) 113.1(3) 
C(12)-C(11)-C(16) 118.9(4) 
C(12)-C(11)-P(1) 122.2(3) 
C(16)-C(11)-P(1) 118.8(3) 
C(11)-C(12)-C(13) 120.0(4) 
C(14)-C(13)-C(12) 120.6(4) 
C(15)-C(14)-C(13) 120.0(4) 
C(14)-C(15)-C(16) 120.4(4) 
C(15)-C(16)-C(11) 120.0(4) 
C(22)-C(21)-C(26) 118.0(4) 
C(22)-C(21)-P(1) 122.5(3) 
C(26)-C(21)-P(1) 119.5(3) 
C(23)-C(22)-C(21) 119.7(4) 
C(22)-C(23)-C(24) 120.6(5) 
C(25)-C(24)-C(23) 120.3(5) 
C(24)-C(25)-C(26) 119.6(5) 
C(25)-C(26)-C(21) 121.7(4) 
C(31)-O(1)-C(34) 112.3(6) 
O(1)-C(31)-C(32) 110.3(7) 
C(33)-C(32)-C(31) 102.4(6) 
C(34)-C(33)-C(32) 106.3(6) 
O(1)-C(34)-C(33) 108.3(6) 
 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,-y+1/2,z. 
 
Table 12: Torsion angles [°] for 23. 
 
N(1)#1-N(1)-P(1)-C(21) -155.3(2) 
C(1)-N(1)-P(1)-C(21) 37.0(3) 
N(1)#1-N(1)-P(1)-C(11) 94.4(3) 
C(1)-N(1)-P(1)-C(11) -73.3(3) 
N(1)#1-N(1)-P(1)-Au(1) -33.3(3) 
C(1)-N(1)-P(1)-Au(1) 159.0(3) 
Au(1)#1-Au(1)-P(1)-N(1) -38.27(13) 
Au(1)#1-Au(1)-P(1)-C(21) 78.44(14) 
Au(1)#1-Au(1)-P(1)-C(11) -162.42(14) 
N(1)#1-N(1)-C(1)-C(2) 90.6(4) 
P(1)-N(1)-C(1)-C(2) -101.6(4) 
N(1)-P(1)-C(11)-C(12) 11.5(4) 
C(21)-P(1)-C(11)-C(12) -99.2(4) 
Au(1)-P(1)-C(11)-C(12) 136.5(3) 
N(1)-P(1)-C(11)-C(16) -168.9(3) 
C(21)-P(1)-C(11)-C(16) 80.4(3) 
Au(1)-P(1)-C(11)-C(16) -43.8(4) 
C(16)-C(11)-C(12)-C(13) -1.2(6) 
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P(1)-C(11)-C(12)-C(13) 178.4(3) 
C(11)-C(12)-C(13)-C(14) -0.6(7) 
C(12)-C(13)-C(14)-C(15) 1.6(7) 
C(13)-C(14)-C(15)-C(16) -0.8(7) 
C(14)-C(15)-C(16)-C(11) -0.9(7) 
C(12)-C(11)-C(16)-C(15) 1.9(6) 
P(1)-C(11)-C(16)-C(15) -177.7(3) 
N(1)-P(1)-C(21)-C(22) -95.7(4) 
C(11)-P(1)-C(21)-C(22) 18.3(4) 
Au(1)-P(1)-C(21)-C(22) 144.0(3) 
N(1)-P(1)-C(21)-C(26) 83.6(4) 
C(11)-P(1)-C(21)-C(26) -162.4(3) 
Au(1)-P(1)-C(21)-C(26) -36.8(4) 
C(26)-C(21)-C(22)-C(23) -1.4(7) 
P(1)-C(21)-C(22)-C(23) 177.8(4) 
C(21)-C(22)-C(23)-C(24) 0.5(8) 
C(22)-C(23)-C(24)-C(25) 0.0(9) 
C(23)-C(24)-C(25)-C(26) 0.5(8) 
C(24)-C(25)-C(26)-C(21) -1.6(8) 
C(22)-C(21)-C(26)-C(25) 2.0(7) 
P(1)-C(21)-C(26)-C(25) -177.3(4) 
C(34)-O(1)-C(31)-C(32) -2.4(12) 
O(1)-C(31)-C(32)-C(33) 5.2(11) 
C(31)-C(32)-C(33)-C(34) -5.8(9) 
C(31)-O(1)-C(34)-C(33) -1.6(11) 
C(32)-C(33)-C(34)-O(1) 4.9(10) 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,-y+1/2,z. 
 
Bis(di(4-methoxyphenyl))dimethylhydrazine di(gold chloride) (24) 
 
N N
Me Me
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
 
Table 13: Crystal data and structure refinement for 24. 
 
Empirical formula  Au2Cl2P2N2O6C38H50 
Formula weight  1157.57 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
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Unit cell dimensions a = 23.208(5) Å α = 90° 
 b = 9.080(5) Å β = 92.4(5)° 
 c = 20.220(5) Å γ = 90° 
Volume 4257(3) Å3 
Z 4 
Density (calculated) 1.806 Mg/m3 
Absorption coefficient 7.129 mm
-1
 
F(000) 2248 
Crystal size 0.58 x 0.45 x 0.10 mm3 
Theta range for data collection 1.76 to 28.29° 
Index ranges -30<=h<=30, -12<=k<=11, -25<=l<=26 
Reflections collected 33198 
Independent reflections 5264 [R(int) = 0.0400] 
Completeness to theta = 28.29° 99.6 %  
Absorption correction Integration 
Max. and min. transmission 0.5670 and 0.0436 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 5264/0/235 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0193, wR2 = 0.0460 
R indices (all data) R1 = 0.0249, wR2 = 0.0486 
Largest diff. peak and hole 1.077 and -0.795 e.Å-3 
 
Table 14: Bond lengths [Å] and angles [°] for 24. 
 
C(1)-N  1.460(3) 
C(11)-C(16)  1.382(4) 
C(11)-C(12)  1.395(4) 
C(11)-P  1.803(2) 
C(12)-C(13)  1.376(4) 
C(13)-C(14)  1.388(4) 
C(14)-O(1)  1.362(3) 
C(14)-C(15)  1.378(4) 
C(15)-C(16)  1.391(3) 
C(17)-O(1)  1.419(4) 
C(21)-C(22)  1.382(4) 
C(21)-C(26)  1.391(4) 
C(21)-P  1.807(2) 
C(22)-C(23)  1.396(4) 
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C(23)-C(24)  1.380(4) 
C(24)-O(2)  1.365(3) 
C(24)-C(25)  1.393(4) 
C(25)-C(26)  1.378(4) 
C(27)-O(2)  1.430(4) 
C(31)-O(3)  1.371(6) 
C(31)-C(32)  1.495(7) 
C(32)-C(33)  1.449(9) 
C(33)-C(34)  1.361(9) 
C(34)-O(3)  1.366(7) 
N-N#1  1.417(4) 
N-P  1.678(2) 
P-Au  2.2238(11) 
Cl-Au  2.2905(11) 
Au-Au#1  3.1222(7) 
 
 
C(16)-C(11)-C(12) 118.8(2) 
C(16)-C(11)-P 119.45(19) 
C(12)-C(11)-P 121.61(19) 
C(13)-C(12)-C(11) 120.4(3) 
C(12)-C(13)-C(14) 120.1(3) 
O(1)-C(14)-C(15) 124.4(3) 
O(1)-C(14)-C(13) 115.2(3) 
C(15)-C(14)-C(13) 120.4(2) 
C(14)-C(15)-C(16) 119.1(3) 
C(11)-C(16)-C(15) 121.2(2) 
C(22)-C(21)-C(26) 118.8(2) 
C(22)-C(21)-P 119.4(2) 
C(26)-C(21)-P 121.73(19) 
C(21)-C(22)-C(23) 121.0(3) 
C(24)-C(23)-C(22) 119.2(3) 
O(2)-C(24)-C(23) 124.8(3) 
O(2)-C(24)-C(25) 114.8(3) 
C(23)-C(24)-C(25) 120.4(2) 
C(26)-C(25)-C(24) 119.6(3) 
C(25)-C(26)-C(21) 120.9(2) 
O(3)-C(31)-C(32) 105.7(5) 
C(33)-C(32)-C(31) 105.2(5) 
C(34)-C(33)-C(32) 104.1(6) 
C(33)-C(34)-O(3) 113.0(6) 
N#1-N-C(1) 116.05(18) 
N#1-N-P 115.65(17) 
C(1)-N-P 126.33(17) 
C(14)-O(1)-C(17) 117.6(3) 
C(24)-O(2)-C(27) 117.0(3) 
C(34)-O(3)-C(31) 105.4(5) 
N-P-C(11) 102.26(11) 
N-P-C(21) 109.71(12) 
C(11)-P-C(21) 104.57(11) 
N-P-Au 110.83(8) 
C(11)-P-Au 116.63(9) 
C(21)-P-Au 112.20(9) 
P-Au-Cl 175.68(3) 
P-Au-Au#1 88.241(19) 
Cl-Au-Au#1 94.74(2) 
 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+1/2. 
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Table 15: Torsion angles [°] for 24. 
 
C(16)-C(11)-C(12)-C(13) -1.9(4) 
P-C(11)-C(12)-C(13) 174.3(2) 
C(11)-C(12)-C(13)-C(14) 1.0(5) 
C(12)-C(13)-C(14)-O(1) -178.9(3) 
C(12)-C(13)-C(14)-C(15) 0.6(5) 
O(1)-C(14)-C(15)-C(16) 178.3(3) 
C(13)-C(14)-C(15)-C(16) -1.3(5) 
C(12)-C(11)-C(16)-C(15) 1.3(4) 
P-C(11)-C(16)-C(15) -175.0(2) 
C(14)-C(15)-C(16)-C(11) 0.3(4) 
C(26)-C(21)-C(22)-C(23) 1.4(4) 
P-C(21)-C(22)-C(23) -175.7(2) 
C(21)-C(22)-C(23)-C(24) -1.3(4) 
C(22)-C(23)-C(24)-O(2) -179.7(3) 
C(22)-C(23)-C(24)-C(25) 0.1(4) 
O(2)-C(24)-C(25)-C(26) -179.3(2) 
C(23)-C(24)-C(25)-C(26) 0.9(4) 
C(24)-C(25)-C(26)-C(21) -0.7(4) 
C(22)-C(21)-C(26)-C(25) -0.5(4) 
P-C(21)-C(26)-C(25) 176.63(19) 
O(3)-C(31)-C(32)-C(33) 14.1(8) 
C(31)-C(32)-C(33)-C(34) 1.1(10) 
C(32)-C(33)-C(34)-O(3) -16.7(13) 
C(15)-C(14)-O(1)-C(17) -9.2(5) 
C(13)-C(14)-O(1)-C(17) 170.4(3) 
C(23)-C(24)-O(2)-C(27) -5.4(5) 
C(25)-C(24)-O(2)-C(27) 174.8(3) 
C(33)-C(34)-O(3)-C(31) 26.4(12) 
C(32)-C(31)-O(3)-C(34) -23.6(9) 
N#1-N-P-C(11) -165.00(15) 
C(1)-N-P-C(11) 31.7(3) 
N#1-N-P-C(21) 84.44(16) 
C(1)-N-P-C(21) -78.9(3) 
N#1-N-P-Au -40.01(16) 
C(1)-N-P-Au 156.7(2) 
C(16)-C(11)-P-N 76.7(2) 
C(12)-C(11)-P-N -99.5(2) 
C(16)-C(11)-P-C(21) -168.9(2) 
C(12)-C(11)-P-C(21) 14.9(3) 
C(16)-C(11)-P-Au -44.4(2) 
C(12)-C(11)-P-Au 139.4(2) 
C(22)-C(21)-P-N -162.70(19) 
C(26)-C(21)-P-N 20.2(2) 
C(22)-C(21)-P-C(11) 88.3(2) 
C(26)-C(21)-P-C(11) -88.8(2) 
C(22)-C(21)-P-Au -39.0(2) 
C(26)-C(21)-P-Au 143.88(19) 
N-P-Au-Cl 101.1(3) 
C(11)-P-Au-Cl -142.5(3) 
C(21)-P-Au-Cl -21.9(4) 
N-P-Au-Au#1 -32.68(8) 
C(11)-P-Au-Au#1 83.74(9) 
C(21)-P-Au-Au#1 -155.70(9) 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+1/2. 
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Bis(di(4-methoxyphenyl))diethylhydrazine di(gold chloride) (25) 
 
N N
Et Et
(MeO-4-Ph)2P P(Ph-4-OMe)2
Au 
Cl
Au
Cl
 
 
Table 16: Crystal data and structure refinement for 25. 
 
Empirical formula  Au2Cl2P2N2O6C40H54  
Formula weight  1185.63 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 23.638(5) Å α = 90° 
 b = 9.126(5) Å β = 94.0(5)° 
 c = 20.227(5) Å γ = 90° 
Volume 4353(3) Å3 
Z 4 
Density (calculated) 1.809 Mg/m3 
Absorption coefficient 6.975 mm
-1
 
F(000) 2312 
Crystal size 0.36 x 0.20 x 0.07 mm
3
 
Theta range for data collection 1.73 to 35.26° 
Index ranges -38<=h<=36, -14<=k<=14, -32<=l<=32 
Reflections collected 52013 
Independent reflections 9147 [R(int) = 0.1649] 
Completeness to theta = 35.26° 93.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 9147/0/245 
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Goodness-of-fit on F2 1.003 
Final R indices [I>2sigma(I)] R1 = 0.0522, wR2 = 0.1322 
R indices (all data) R1 = 0.0638, wR2 = 0.1379 
Largest diff. peak and hole 7.150 and -3.416 e.Å-3 
 
Table 17: Bond lengths [Å] and angles [°] for 25. 
 
C(1)-N(1)  1.474(5) 
C(1)-C(2)  1.527(6) 
C(11)-C(12)  1.395(5) 
C(11)-C(16)  1.400(5) 
C(11)-P(1)  1.813(4) 
C(12)-C(13)  1.392(6) 
C(13)-C(14)  1.395(6) 
C(14)-O(1)  1.347(5) 
C(14)-C(15)  1.393(6) 
C(15)-C(16)  1.387(6) 
C(17)-O(1)  1.434(8) 
C(21)-C(26)  1.389(5) 
C(21)-C(22)  1.398(5) 
C(21)-P(1)  1.805(4) 
C(22)-C(23)  1.372(6) 
C(23)-C(24)  1.394(6) 
C(24)-O(2)  1.365(5) 
C(24)-C(25)  1.393(6) 
C(25)-C(26)  1.397(6) 
C(27)-O(2)  1.414(7) 
N(1)-N(1)#1  1.405(6) 
N(1)-P(1)  1.685(3) 
P(1)-Au(1)  2.2267(13) 
Cl(1)-Au(1)  2.2935(14) 
Au(1)-Au(1)#1  3.1408(7) 
O(3)-C(34)  1.426(8) 
O(3)-C(31)  1.626(11) 
C(34)-C(33)  1.487(13) 
C(33)-C(32)  1.377(16) 
C(31)-C(32)  1.430(18) 
 
 
N(1)-C(1)-C(2) 113.7(3) 
C(12)-C(11)-C(16) 119.0(4) 
C(12)-C(11)-P(1) 119.3(3) 
C(16)-C(11)-P(1) 121.7(3) 
C(13)-C(12)-C(11) 120.7(4) 
C(12)-C(13)-C(14) 119.8(4) 
O(1)-C(14)-C(15) 115.3(4) 
O(1)-C(14)-C(13) 124.8(4) 
C(15)-C(14)-C(13) 119.8(4) 
C(16)-C(15)-C(14) 120.2(4) 
C(15)-C(16)-C(11) 120.5(4) 
C(26)-C(21)-C(22) 118.4(4) 
C(26)-C(21)-P(1) 119.5(3) 
C(22)-C(21)-P(1) 121.9(3) 
C(23)-C(22)-C(21) 121.0(4) 
C(22)-C(23)-C(24) 120.1(4) 
O(2)-C(24)-C(25) 124.0(4) 
O(2)-C(24)-C(23) 115.8(4) 
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C(25)-C(24)-C(23) 120.2(4) 
C(24)-C(25)-C(26) 118.8(4) 
C(21)-C(26)-C(25) 121.4(4) 
N(1)#1-N(1)-C(1) 117.4(3) 
N(1)#1-N(1)-P(1) 117.5(2) 
C(1)-N(1)-P(1) 123.2(2) 
C(14)-O(1)-C(17) 116.6(4) 
C(24)-O(2)-C(27) 118.1(4) 
N(1)-P(1)-C(21) 102.36(16) 
N(1)-P(1)-C(11) 109.44(17) 
C(21)-P(1)-C(11) 104.93(17) 
N(1)-P(1)-Au(1) 111.61(11) 
C(21)-P(1)-Au(1) 115.65(11) 
C(11)-P(1)-Au(1) 112.19(13) 
P(1)-Au(1)-Cl(1) 175.99(4) 
P(1)-Au(1)-Au(1)#1 87.78(3) 
Cl(1)-Au(1)-Au(1)#1 95.56(3) 
C(34)-O(3)-C(31) 97.3(5) 
O(3)-C(34)-C(33) 114.5(6) 
C(32)-C(33)-C(34) 106.3(9) 
C(32)-C(31)-O(3) 107.5(8) 
C(33)-C(32)-C(31) 109.9(11) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+3/2. 
 
Table 18: Torsion angles [°] for 25. 
 
C(16)-C(11)-C(12)-C(13) -0.4(6) 
P(1)-C(11)-C(12)-C(13) 179.5(3) 
C(11)-C(12)-C(13)-C(14) 1.2(7) 
C(12)-C(13)-C(14)-O(1) 178.8(4) 
C(12)-C(13)-C(14)-C(15) -0.7(7) 
O(1)-C(14)-C(15)-C(16) 179.8(4) 
C(13)-C(14)-C(15)-C(16) -0.6(6) 
C(14)-C(15)-C(16)-C(11) 1.4(6) 
C(12)-C(11)-C(16)-C(15) -1.0(6) 
P(1)-C(11)-C(16)-C(15) 179.2(3) 
C(26)-C(21)-C(22)-C(23) 2.3(7) 
P(1)-C(21)-C(22)-C(23) -173.4(4) 
C(21)-C(22)-C(23)-C(24) 0.3(8) 
C(22)-C(23)-C(24)-O(2) 177.4(5) 
C(22)-C(23)-C(24)-C(25) -2.2(8) 
O(2)-C(24)-C(25)-C(26) -178.1(5) 
C(23)-C(24)-C(25)-C(26) 1.5(7) 
C(22)-C(21)-C(26)-C(25) -3.1(6) 
P(1)-C(21)-C(26)-C(25) 172.8(3) 
C(24)-C(25)-C(26)-C(21) 1.2(7) 
C(2)-C(1)-N(1)-N(1)#1 -94.3(4) 
C(2)-C(1)-N(1)-P(1) 102.0(4) 
C(15)-C(14)-O(1)-C(17) -179.0(6) 
C(13)-C(14)-O(1)-C(17) 1.4(8) 
C(25)-C(24)-O(2)-C(27) 11.0(8) 
C(23)-C(24)-O(2)-C(27) -168.6(6) 
N(1)#1-N(1)-P(1)-C(21) 161.0(2) 
C(1)-N(1)-P(1)-C(21) -35.3(3) 
N(1)#1-N(1)-P(1)-C(11) -88.1(3) 
C(1)-N(1)-P(1)-C(11) 75.6(3) 
N(1)#1-N(1)-P(1)-Au(1) 36.7(3) 
C(1)-N(1)-P(1)-Au(1) -159.6(3) 
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C(26)-C(21)-P(1)-N(1) -80.2(3) 
C(22)-C(21)-P(1)-N(1) 95.5(4) 
C(26)-C(21)-P(1)-C(11) 165.5(3) 
C(22)-C(21)-P(1)-C(11) -18.8(4) 
C(26)-C(21)-P(1)-Au(1) 41.3(4) 
C(22)-C(21)-P(1)-Au(1) -143.0(3) 
C(12)-C(11)-P(1)-N(1) 163.0(3) 
C(16)-C(11)-P(1)-N(1) -17.1(4) 
C(12)-C(11)-P(1)-C(21) -87.8(3) 
C(16)-C(11)-P(1)-C(21) 92.1(3) 
C(12)-C(11)-P(1)-Au(1) 38.5(3) 
C(16)-C(11)-P(1)-Au(1) -141.6(3) 
N(1)-P(1)-Au(1)-Cl(1) -111.8(6) 
C(21)-P(1)-Au(1)-Cl(1) 131.7(6) 
C(11)-P(1)-Au(1)-Cl(1) 11.4(6) 
N(1)-P(1)-Au(1)-Au(1)#1 34.73(12) 
C(21)-P(1)-Au(1)-Au(1)#1 -81.73(14) 
C(11)-P(1)-Au(1)-Au(1)#1 157.97(13) 
C(31)-O(3)-C(34)-C(33) 15.6(11) 
O(3)-C(34)-C(33)-C(32) -5.6(17) 
C(34)-O(3)-C(31)-C(32) -20.6(12) 
C(34)-C(33)-C(32)-C(31) -9.5(19) 
O(3)-C(31)-C(32)-C(33) 19.4(18) 
 
Symmetry transformations used to generate equivalent atoms: 
#1 -x+1,y,-z+3/2. 
 
Bis(di(N,N-dimetyl-4-aminophenyl))diethylhydrazine di(gold chloride) (27) 
 
N N
Et Et
(Me2N-4-Ph)2P P(Ph-4-NMe2)2
Au 
Cl
Au
Cl
 
 
Table 19: Crystal data and structure refinement for 27. 
 
Empirical formula  Au2Cl2P2N4C30H30 
Formula weight  973.35 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 13.9122(13) Å α = 90° 
 b = 14.9533(15) Å β = 96.9(6)° 
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 c = 23.806(2) Å γ = 90° 
Volume 4916.7(8) Å3 
Z 6 
Density (calculated) 1.972 Mg/m3 
Absorption coefficient 9.228 mm
-1
 
F(000) 2760 
Crystal size 0.16 x 0.08 x 0.04 mm
3
 
Theta range for data collection 1.47 to 28.00° 
Index ranges -16<=h<=18, -19<=k<=19, -31<=l<=31 
Reflections collected 41431 
Independent reflections 11865 [R(int) = 0.3658] 
Completeness to theta = 28.00° 100.0 %  
Absorption correction Integration 
Max. and min. transmission 0.7091 and 0.3199 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 11865/0/449 
Goodness-of-fit on F2 0.921 
Final R indices [I>2sigma(I)] R1 = 0.0845, wR2 = 0.1890 
R indices (all data) R1 = 0.2862, wR2 = 0.2727 
Largest diff. peak and hole 2.503 and -2.498 e.Å-3 
 
Table 20: Bond lengths [Å] and angles [°] for 27. 
 
C(1)-N(1)  1.46(2) 
C(1)-C(2)  1.52(3) 
C(3)-N(2)  1.43(3) 
C(3)-C(4)  1.51(3) 
C(11)-C(12)  1.39(3) 
C(11)-C(16)  1.40(3) 
C(11)-P(1)  1.82(2) 
C(12)-C(13)  1.37(3) 
C(13)-C(14)  1.42(3) 
C(14)-N(3)  1.37(3) 
C(14)-C(15)  1.39(3) 
C(15)-C(16)  1.39(3) 
C(17)-N(3)  1.47(3) 
C(18)-N(3)  1.44(3) 
C(21)-C(22)  1.42(3) 
C(21)-C(26)  1.40(3) 
C(21)-P(1)  1.76(2) 
C(22)-C(23)  1.41(3) 
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C(23)-C(24)  1.38(3) 
C(24)-N(4)  1.38(3) 
C(24)-C(25)  1.39(3) 
C(25)-C(26)  1.38(3) 
C(27)-N(4)  1.40(3) 
C(28)-N(4)  1.44(3) 
C(31)-C(36)  1.40(3) 
C(31)-C(32)  1.42(3) 
C(31)-P(2)  1.814(19) 
C(32)-C(33)  1.42(3) 
C(33)-C(34)  1.41(3) 
C(34)-N(5)  1.37(3) 
C(34)-C(35)  1.44(3) 
C(35)-C(36)  1.35(3) 
C(37)-N(5)  1.47(3) 
C(38)-N(5)  1.40(4) 
C(41)-C(46)  1.38(3) 
C(41)-C(42)  1.44(3) 
C(41)-P(2)  1.79(2) 
C(42)-C(43)  1.35(3) 
C(43)-C(44)  1.38(3) 
C(44)-N(6)  1.35(3) 
C(44)-C(45)  1.44(3) 
C(45)-C(46)  1.42(3) 
C(47)-N(6)  1.45(3) 
C(48)-N(6)  1.51(3) 
C(98)-C(99)  1.78(11) 
C(98)-Cl(98)  1.84(5) 
C(99)-Cl(99)  1.59(10) 
C(99)-Cl(98)  2.14(10) 
N(1)-N(2)  1.43(2) 
N(1)-P(1)  1.683(17) 
N(2)-P(2)  1.667(18) 
P(1)-Au(1)  2.238(5) 
P(2)-Au(2)  2.239(6) 
Cl(1)-Au(1)  2.313(5) 
Cl(2)-Au(2)  2.313(7) 
Au(1)-Au(2)  3.1860(13) 
 
 
N(1)-C(1)-C(2) 111.8(18) 
N(2)-C(3)-C(4) 116(2) 
C(12)-C(11)-C(16) 116.7(19) 
C(12)-C(11)-P(1) 123.3(15) 
C(16)-C(11)-P(1) 119.8(15) 
C(13)-C(12)-C(11) 123.1(19) 
C(12)-C(13)-C(14) 119.3(19) 
N(3)-C(14)-C(15) 121.7(19) 
N(3)-C(14)-C(13) 119.8(19) 
C(15)-C(14)-C(13) 118.5(19) 
C(16)-C(15)-C(14) 120.4(18) 
C(15)-C(16)-C(11) 122.0(18) 
C(22)-C(21)-C(26) 114.5(19) 
C(22)-C(21)-P(1) 120.6(15) 
C(26)-C(21)-P(1) 124.7(18) 
C(21)-C(22)-C(23) 123(2) 
C(24)-C(23)-C(22) 120(2) 
N(4)-C(24)-C(25) 119(2) 
N(4)-C(24)-C(23) 122(3) 
C(25)-C(24)-C(23) 118(2) 
C(24)-C(25)-C(26) 121(2) 
C(25)-C(26)-C(21) 123(2) 
C(36)-C(31)-C(32) 116.8(18) 
C(36)-C(31)-P(2) 120.3(15) 
C(32)-C(31)-P(2) 122.9(14) 
C(31)-C(32)-C(33) 123(2) 
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C(34)-C(33)-C(32) 118(2) 
N(5)-C(34)-C(33) 120(2) 
N(5)-C(34)-C(35) 122(2) 
C(33)-C(34)-C(35) 118(2) 
C(36)-C(35)-C(34) 121(2) 
C(35)-C(36)-C(31) 123(2) 
C(46)-C(41)-C(42) 114.2(18) 
C(46)-C(41)-P(2) 124.2(15) 
C(42)-C(41)-P(2) 121.6(15) 
C(43)-C(42)-C(41) 123.1(19) 
C(42)-C(43)-C(44) 122.4(19) 
N(6)-C(44)-C(43) 122.5(18) 
N(6)-C(44)-C(45) 120(2) 
C(43)-C(44)-C(45) 117.6(19) 
C(46)-C(45)-C(44) 118(2) 
C(41)-C(46)-C(45) 125(2) 
C(99)-C(98)-Cl(98) 72(4) 
C(98)-C(99)-Cl(99) 143(8) 
C(98)-C(99)-Cl(98) 55(3) 
Cl(99)-C(99)-Cl(98) 106(6) 
N(2)-N(1)-C(1) 116.6(16) 
N(2)-N(1)-P(1) 119.2(12) 
C(1)-N(1)-P(1) 123.2(14) 
N(1)-N(2)-C(3) 119.0(16) 
N(1)-N(2)-P(2) 117.7(13) 
C(3)-N(2)-P(2) 122.7(15) 
C(14)-N(3)-C(18) 121.0(19) 
C(14)-N(3)-C(17) 119.1(18) 
C(18)-N(3)-C(17) 117.0(19) 
C(24)-N(4)-C(27) 124(2) 
C(24)-N(4)-C(28) 118(2) 
C(27)-N(4)-C(28) 118(2) 
C(34)-N(5)-C(38) 120(2) 
C(34)-N(5)-C(37) 121(2) 
C(38)-N(5)-C(37) 118(2) 
C(44)-N(6)-C(47) 120.2(19) 
C(44)-N(6)-C(48) 120.7(19) 
C(47)-N(6)-C(48) 119.0(18) 
N(1)-P(1)-C(21) 105.1(9) 
N(1)-P(1)-C(11) 108.3(9) 
C(21)-P(1)-C(11) 104.2(10) 
N(1)-P(1)-Au(1) 111.4(6) 
C(21)-P(1)-Au(1) 113.6(7) 
C(11)-P(1)-Au(1) 113.6(6) 
N(2)-P(2)-C(41) 107.6(9) 
N(2)-P(2)-C(31) 110.0(9) 
C(41)-P(2)-C(31) 102.8(9) 
N(2)-P(2)-Au(2) 113.4(7) 
C(41)-P(2)-Au(2) 111.9(7) 
C(31)-P(2)-Au(2) 110.6(6) 
C(98)-Cl(98)-C(99) 53(3) 
P(1)-Au(1)-Cl(1) 176.6(2) 
P(1)-Au(1)-Au(2) 86.16(14) 
Cl(1)-Au(1)-Au(2) 97.14(16) 
P(2)-Au(2)-Cl(2) 175.9(3) 
P(2)-Au(2)-Au(1) 85.13(14) 
Cl(2)-Au(2)-Au(1) 99.0(2) 
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Table 21: Torsion angles [°] for 27. 
 
C(16)-C(11)-C(12)-C(13) 0(3) 
P(1)-C(11)-C(12)-C(13) 175.1(16) 
C(11)-C(12)-C(13)-C(14) 2(3) 
C(12)-C(13)-C(14)-N(3) 176.2(18) 
C(12)-C(13)-C(14)-C(15) -2(3) 
N(3)-C(14)-C(15)-C(16) -177.7(18) 
C(13)-C(14)-C(15)-C(16) 0(3) 
C(14)-C(15)-C(16)-C(11) 2(3) 
C(12)-C(11)-C(16)-C(15) -2(3) 
P(1)-C(11)-C(16)-C(15) -176.9(15) 
C(26)-C(21)-C(22)-C(23) 0(3) 
P(1)-C(21)-C(22)-C(23) 175.4(16) 
C(21)-C(22)-C(23)-C(24) -1(3) 
C(22)-C(23)-C(24)-N(4) 178(2) 
C(22)-C(23)-C(24)-C(25) 3(3) 
N(4)-C(24)-C(25)-C(26) 180(2) 
C(23)-C(24)-C(25)-C(26) -5(4) 
C(24)-C(25)-C(26)-C(21) 4(4) 
C(22)-C(21)-C(26)-C(25) -2(3) 
P(1)-C(21)-C(26)-C(25) -176.9(19) 
C(36)-C(31)-C(32)-C(33) 4(3) 
P(2)-C(31)-C(32)-C(33) -173.5(16) 
C(31)-C(32)-C(33)-C(34) -3(3) 
C(32)-C(33)-C(34)-N(5) -178(2) 
C(32)-C(33)-C(34)-C(35) -1(3) 
N(5)-C(34)-C(35)-C(36) -179(2) 
C(33)-C(34)-C(35)-C(36) 4(4) 
C(34)-C(35)-C(36)-C(31) -2(4) 
C(32)-C(31)-C(36)-C(35) -2(3) 
P(2)-C(31)-C(36)-C(35) 176.1(19) 
C(46)-C(41)-C(42)-C(43) 6(3) 
P(2)-C(41)-C(42)-C(43) -175.5(17) 
C(41)-C(42)-C(43)-C(44) -3(3) 
C(42)-C(43)-C(44)-N(6) -179(2) 
C(42)-C(43)-C(44)-C(45) 0(3) 
N(6)-C(44)-C(45)-C(46) 180(2) 
C(43)-C(44)-C(45)-C(46) 1(3) 
C(42)-C(41)-C(46)-C(45) -5(3) 
P(2)-C(41)-C(46)-C(45) 176.4(18) 
C(44)-C(45)-C(46)-C(41) 2(4) 
Cl(98)-C(98)-C(99)-Cl(99) -69(12) 
C(2)-C(1)-N(1)-N(2) -90(2) 
C(2)-C(1)-N(1)-P(1) 101(2) 
C(1)-N(1)-N(2)-C(3) -77(2) 
P(1)-N(1)-N(2)-C(3) 92(2) 
C(1)-N(1)-N(2)-P(2) 94.3(18) 
P(1)-N(1)-N(2)-P(2) -96.4(15) 
C(4)-C(3)-N(2)-N(1) -87(2) 
C(4)-C(3)-N(2)-P(2) 103(2) 
C(15)-C(14)-N(3)-C(18) -159(2) 
C(13)-C(14)-N(3)-C(18) 22(3) 
C(15)-C(14)-N(3)-C(17) 1(3) 
C(13)-C(14)-N(3)-C(17) -177(2) 
C(25)-C(24)-N(4)-C(27) -1(4) 
C(23)-C(24)-N(4)-C(27) -177(2) 
C(25)-C(24)-N(4)-C(28) -176(2) 
C(23)-C(24)-N(4)-C(28) 8(4) 
C(33)-C(34)-N(5)-C(38) -169(3) 
C(35)-C(34)-N(5)-C(38) 15(4) 
C(33)-C(34)-N(5)-C(37) -1(4) 
C(35)-C(34)-N(5)-C(37) -178(2) 
C(43)-C(44)-N(6)-C(47) -7(4) 
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C(45)-C(44)-N(6)-C(47) 175(2) 
C(43)-C(44)-N(6)-C(48) 170(3) 
C(45)-C(44)-N(6)-C(48) -8(4) 
N(2)-N(1)-P(1)-C(21) 155.7(14) 
C(1)-N(1)-P(1)-C(21) -35.8(19) 
N(2)-N(1)-P(1)-C(11) -93.4(15) 
C(1)-N(1)-P(1)-C(11) 75.1(18) 
N(2)-N(1)-P(1)-Au(1) 32.3(15) 
C(1)-N(1)-P(1)-Au(1) -159.2(14) 
C(22)-C(21)-P(1)-N(1) -83.3(18) 
C(26)-C(21)-P(1)-N(1) 91.6(19) 
C(22)-C(21)-P(1)-C(11) 162.8(16) 
C(26)-C(21)-P(1)-C(11) -22(2) 
C(22)-C(21)-P(1)-Au(1) 38.7(19) 
C(26)-C(21)-P(1)-Au(1) -146.4(16) 
C(12)-C(11)-P(1)-N(1) -15(2) 
C(16)-C(11)-P(1)-N(1) 159.3(15) 
C(12)-C(11)-P(1)-C(21) 96.0(18) 
C(16)-C(11)-P(1)-C(21) -89.2(17) 
C(12)-C(11)-P(1)-Au(1) -139.8(15) 
C(16)-C(11)-P(1)-Au(1) 34.9(18) 
N(1)-N(2)-P(2)-C(41) 156.1(13) 
C(3)-N(2)-P(2)-C(41) -32.9(19) 
N(1)-N(2)-P(2)-C(31) -92.6(14) 
C(3)-N(2)-P(2)-C(31) 78.4(18) 
N(1)-N(2)-P(2)-Au(2) 31.8(15) 
C(3)-N(2)-P(2)-Au(2) -157.2(15) 
C(46)-C(41)-P(2)-N(2) 86.0(19) 
C(42)-C(41)-P(2)-N(2) -92.7(18) 
C(46)-C(41)-P(2)-C(31) -30(2) 
C(42)-C(41)-P(2)-C(31) 151.1(17) 
C(46)-C(41)-P(2)-Au(2) -148.8(17) 
C(42)-C(41)-P(2)-Au(2) 32.5(19) 
C(36)-C(31)-P(2)-N(2) 164.7(17) 
C(32)-C(31)-P(2)-N(2) -17.8(19) 
C(36)-C(31)-P(2)-C(41) -81.0(19) 
C(32)-C(31)-P(2)-C(41) 96.5(18) 
C(36)-C(31)-P(2)-Au(2) 38.6(19) 
C(32)-C(31)-P(2)-Au(2) -143.9(15) 
Cl(99)-C(99)-Cl(98)-C(98) 144(8) 
N(1)-P(1)-Au(1)-Cl(1) -154(3) 
C(21)-P(1)-Au(1)-Cl(1) 88(4) 
C(11)-P(1)-Au(1)-Cl(1) -31(4) 
N(1)-P(1)-Au(1)-Au(2) 38.9(7) 
C(21)-P(1)-Au(1)-Au(2) -79.5(8) 
C(11)-P(1)-Au(1)-Au(2) 161.6(8) 
N(2)-P(2)-Au(2)-Cl(2) -148(3) 
C(41)-P(2)-Au(2)-Cl(2) 90(3) 
C(31)-P(2)-Au(2)-Cl(2) -23(3) 
N(2)-P(2)-Au(2)-Au(1) 38.3(7) 
C(41)-P(2)-Au(2)-Au(1) -83.7(7) 
C(31)-P(2)-Au(2)-Au(1) 162.4(7) 
P(1)-Au(1)-Au(2)-P(2) -65.7(2) 
Cl(1)-Au(1)-Au(2)-P(2) 115.1(2) 
P(1)-Au(1)-Au(2)-Cl(2) 114.8(2) 
Cl(1)-Au(1)-Au(2)-Cl(2) -64.5(2) 
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Bis(bis(di(N,N-dimetyl-4-aminophenyl))diethylhydrazine)gold trinitrate (35) 
 
N N
Et Et
P(Ph-4-NMe2)2(MeN-4-Ph)2P
N N
Et Et
P(Ph-4-NMe2)2(MeN-4-Ph)2P
Au
+
NO3-
 
 
Table 22: Crystal data and structure refinement for 35. 
 
Empirical formula  AuP4N14O6C86H100  
Formula weight  1746.65 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pban 
Unit cell dimensions a = 15.8970(8) Å α = 90° 
 b = 16.3239(8) Å β = 90° 
 c = 15.4379(8) Å γ = 90° 
Volume 4006.2(3) Å3 
Z 2 
Density (calculated) 1.448 Mg/m3 
Absorption coefficient 1.992 mm
-1
 
F(000) 1802 
Crystal size 0.37 x 0.27 x 0.03 mm
3
 
Theta range for data collection 1.79 to 28.00° 
Index ranges -21<=h<=21, -21<=k<=20, -18<=l<=20 
Reflections collected 39748 
Independent reflections 4849 [R(int) = 0.1031] 
Completeness to theta = 28.00° 100.0 %  
Absorption correction Integration 
Max. and min. transmission 0.9427 and 0.5260 
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Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 4849/0/254 
Goodness-of-fit on F2 0.979 
Final R indices [I>2sigma(I)] R1 = 0.0320, wR2 = 0.0754 
R indices (all data) R1 = 0.0613, wR2 = 0.0850 
Largest diff. peak and hole 0.940 and -0.833 e.Å-3 
 
 
Table 23: Bond lengths [Å] and angles [°] for 35. 
 
C(1)-N(1)  1.460(4) 
C(1)-C(2)  1.518(5) 
C(11)-C(16)  1.394(5) 
C(11)-C(12)  1.403(5) 
C(11)-P(1)  1.766(3) 
C(12)-C(13)  1.372(5) 
C(13)-C(14)  1.403(5) 
C(14)-N(2)  1.369(5) 
C(14)-C(15)  1.408(5) 
C(15)-C(16)  1.370(5) 
C(17)-N(2)  1.462(6) 
C(18)-N(2)  1.423(5) 
C(21)-C(22)  1.393(5) 
C(21)-C(26)  1.399(5) 
C(21)-P(1)  1.774(3) 
C(22)-C(23)  1.379(5) 
C(23)-C(24)  1.412(5) 
C(24)-N(3)  1.358(5) 
C(24)-C(25)  1.408(5) 
C(25)-C(26)  1.368(5) 
C(27)-N(3)  1.437(5) 
C(28)-N(3)  1.466(5) 
N(1)-N(1)#1  1.429(6) 
N(1)-P(1)  1.683(3) 
N(4)-O(1)  1.208(7) 
N(4)-O(2)#2  1.264(5) 
N(4)-O(2)  1.264(5) 
N(5)-O(4)#3  1.163(11) 
N(5)-O(4)  1.163(11) 
N(5)-O(3)  1.32(3) 
N(6)-O(5)#4  1.69(2) 
N(6)-O(5)  1.69(2) 
P(1)-Au(1)  2.3865(8) 
Au(1)-P(1)#5  2.3865(8) 
Au(1)-P(1)#1  2.3865(8) 
Au(1)-P(1)#6  2.3865(8) 
 
 
N(1)-C(1)-C(2) 112.2(3) 
C(16)-C(11)-C(12) 117.2(3) 
C(16)-C(11)-P(1) 121.7(3) 
C(12)-C(11)-P(1) 120.6(3) 
C(13)-C(12)-C(11) 121.7(3) 
C(12)-C(13)-C(14) 120.8(4) 
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N(2)-C(14)-C(13) 121.1(4) 
N(2)-C(14)-C(15) 121.2(4) 
C(13)-C(14)-C(15) 117.7(3) 
C(16)-C(15)-C(14) 120.8(3) 
C(15)-C(16)-C(11) 121.9(4) 
C(22)-C(21)-C(26) 118.1(3) 
C(22)-C(21)-P(1) 121.8(3) 
C(26)-C(21)-P(1) 119.7(3) 
C(23)-C(22)-C(21) 121.6(3) 
C(22)-C(23)-C(24) 120.3(4) 
N(3)-C(24)-C(25) 121.5(3) 
N(3)-C(24)-C(23) 120.9(4) 
C(25)-C(24)-C(23) 117.6(3) 
C(26)-C(25)-C(24) 121.4(3) 
C(25)-C(26)-C(21) 121.0(4) 
N(1)#1-N(1)-C(1) 117.9(2) 
N(1)#1-N(1)-P(1) 111.02(17) 
C(1)-N(1)-P(1) 128.8(3) 
C(14)-N(2)-C(18) 123.0(4) 
C(14)-N(2)-C(17) 119.5(4) 
C(18)-N(2)-C(17) 117.5(4) 
C(24)-N(3)-C(27) 121.0(3) 
C(24)-N(3)-C(28) 120.8(4) 
C(27)-N(3)-C(28) 118.2(3) 
O(1)-N(4)-O(2)#2 120.4(3) 
O(1)-N(4)-O(2) 120.4(3) 
O(2)#2-N(4)-O(2) 119.1(6) 
O(4)#3-N(5)-O(4) 125(2) 
O(4)#3-N(5)-O(3) 117.7(12) 
O(4)-N(5)-O(3) 117.7(12) 
O(5)#4-N(6)-O(5) 148(3) 
N(1)-P(1)-C(11) 112.43(16) 
N(1)-P(1)-C(21) 105.21(15) 
C(11)-P(1)-C(21) 110.85(17) 
N(1)-P(1)-Au(1) 100.37(11) 
C(11)-P(1)-Au(1) 114.92(12) 
C(21)-P(1)-Au(1) 112.25(13) 
P(1)#5-Au(1)-P(1)#1 172.54(4) 
P(1)#5-Au(1)-P(1)#6 83.50(4) 
P(1)#1-Au(1)-P(1)#6 96.99(4) 
P(1)#5-Au(1)-P(1) 96.99(4) 
P(1)#1-Au(1)-P(1) 83.50(4) 
P(1)#6-Au(1)-P(1) 172.54(4) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y,-z+1; 
#2 x,-y+1/2,-z+1; 
#3 -x+3/2,y,-z; 
#4 x,-y+1/2,-z; 
#5 -x+1/2,-y+3/2,z; 
#6 x,-y+3/2,-z+1. 
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Table 24: Torsion angles [°] for 35. 
 
C(16)-C(11)-C(12)-C(13) 2.2(6) 
P(1)-C(11)-C(12)-C(13) 174.1(3) 
C(11)-C(12)-C(13)-C(14) -0.5(7) 
C(12)-C(13)-C(14)-N(2) 178.0(4) 
C(12)-C(13)-C(14)-C(15) -1.9(6) 
N(2)-C(14)-C(15)-C(16) -177.2(4) 
C(13)-C(14)-C(15)-C(16) 2.8(6) 
C(14)-C(15)-C(16)-C(11) -1.1(6) 
C(12)-C(11)-C(16)-C(15) -1.3(6) 
P(1)-C(11)-C(16)-C(15) -173.2(3) 
C(26)-C(21)-C(22)-C(23) 2.5(6) 
P(1)-C(21)-C(22)-C(23) 175.7(3) 
C(21)-C(22)-C(23)-C(24) 0.0(6) 
C(22)-C(23)-C(24)-N(3) 179.1(4) 
C(22)-C(23)-C(24)-C(25) -1.7(6) 
N(3)-C(24)-C(25)-C(26) -179.9(4) 
C(23)-C(24)-C(25)-C(26) 0.9(6) 
C(24)-C(25)-C(26)-C(21) 1.7(6) 
C(22)-C(21)-C(26)-C(25) -3.3(6) 
P(1)-C(21)-C(26)-C(25) -176.6(3) 
C(2)-C(1)-N(1)-N(1)#1 -64.3(5) 
C(2)-C(1)-N(1)-P(1) 134.6(3) 
C(13)-C(14)-N(2)-C(18) 177.7(4) 
C(15)-C(14)-N(2)-C(18) -2.4(7) 
C(13)-C(14)-N(2)-C(17) -5.1(7) 
C(15)-C(14)-N(2)-C(17) 174.9(4) 
C(25)-C(24)-N(3)-C(27) -177.9(4) 
C(23)-C(24)-N(3)-C(27) 1.3(7) 
C(25)-C(24)-N(3)-C(28) 0.4(6) 
C(23)-C(24)-N(3)-C(28) 179.6(4) 
N(1)#1-N(1)-P(1)-C(11) -74.8(3) 
C(1)-N(1)-P(1)-C(11) 87.3(3) 
N(1)#1-N(1)-P(1)-C(21) 164.5(3) 
C(1)-N(1)-P(1)-C(21) -33.4(3) 
N(1)#1-N(1)-P(1)-Au(1) 47.8(3) 
C(1)-N(1)-P(1)-Au(1) -150.1(3) 
C(16)-C(11)-P(1)-N(1) 92.9(3) 
C(12)-C(11)-P(1)-N(1) -78.7(4) 
C(16)-C(11)-P(1)-C(21) -149.7(3) 
C(12)-C(11)-P(1)-C(21) 38.7(4) 
C(16)-C(11)-P(1)-Au(1) -21.1(4) 
C(12)-C(11)-P(1)-Au(1) 167.3(3) 
C(22)-C(21)-P(1)-N(1) 146.3(3) 
C(26)-C(21)-P(1)-N(1) -40.6(3) 
C(22)-C(21)-P(1)-C(11) 24.5(4) 
C(26)-C(21)-P(1)-C(11) -162.4(3) 
C(22)-C(21)-P(1)-Au(1) -105.5(3) 
C(26)-C(21)-P(1)-Au(1) 67.6(3) 
N(1)-P(1)-Au(1)-P(1)#5 173.54(11) 
C(11)-P(1)-Au(1)-P(1)#5 -65.61(14) 
C(21)-P(1)-Au(1)-P(1)#5 62.26(13) 
N(1)-P(1)-Au(1)-P(1)#1 -13.95(10) 
C(11)-P(1)-Au(1)-P(1)#1 106.89(14) 
C(21)-P(1)-Au(1)-P(1)#1 -125.24(13) 
N(1)-P(1)-Au(1)-P(1)#6 80.24(10) 
C(11)-P(1)-Au(1)-P(1)#6 -158.92(14) 
C(21)-P(1)-Au(1)-P(1)#6 -31.05(13) 
 
_____________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y,-z+1; 
#2 x,-y+1/2,-z+1; 
#3 -x+3/2,y,-z; 
#4 x,-y+1/2,-z; 
#5 -x+1/2,-y+3/2,z; 
#6 x,-y+3/2,-z+1. 
 
Bis(diphenylphosphino)diethylhydrazine di(silver nitrate) (39) 
 
N N
Et Et
Ph2P PPh2
Ag 
NO3
Ag
NO3
 
 
Table 25: Crystal data and structure refinement for 39. 
 
Empirical formula  Ag2P2N4O6C28H30 
Formula weight  796.24 
Temperature  193(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna21 
Unit cell dimensions a = 16.3320(10) Å α = 90° 
 b = 20.6486(13) Å β = 90° 
 c = 9.0164(5) Å γ = 90° 
Volume 3040.6(3) Å3 
Z 4 
Density (calculated) 1.739 Mg/m3 
Absorption coefficient 1.441 mm
-1
 
F(000) 1592 
Crystal size 0.22 x 0.08 x 0.07 mm
3
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Theta range for data collection 1.59 to 30.48° 
Index ranges -20<=h<=23, -10<=k<=29, -12<=l<=12 
Reflections collected 13103 
Independent reflections 8801 [R(int) = 0.0508] 
Completeness to theta = 30.48° 99.5 %  
Absorption correction Integration 
Max. and min. transmission 0.9069 and 0.7877 
Refinement method Full-matrix least-squares on F2 
Data/restraints/parameters 8801/1/379 
Goodness-of-fit on F2 1.011 
Final R indices [I>2sigma(I)] R1 = 0.0472, wR2 = 0.1134 
R indices (all data) R1 = 0.0825, wR2 = 0.1620 
Absolute structure parameter 0.52(4) 
Largest diff. peak and hole 0.590 and -0.731 e.Å-3 
 
Table 26: Bond lengths [Å] and angles [°] for 39. 
 
C(1)-C(2)  1.464(13) 
C(1)-N(1)  1.488(9) 
C(3)-N(2)  1.464(9) 
C(3)-C(4)  1.570(11) 
C(11)-C(16)  1.375(11) 
C(11)-C(12)  1.408(10) 
C(11)-P(1)  1.807(8) 
C(12)-C(13)  1.410(12) 
C(13)-C(14)  1.366(13) 
C(14)-C(15)  1.412(14) 
C(15)-C(16)  1.357(14) 
C(21)-C(22)  1.364(10) 
C(21)-C(26)  1.392(10) 
C(21)-P(1)  1.837(7) 
C(22)-C(23)  1.416(11) 
C(22)-H(22)  0.9300 
C(23)-C(24)  1.348(12) 
C(24)-C(25)  1.376(11) 
C(25)-C(26)  1.394(11) 
C(31)-C(32)  1.393(10) 
C(31)-C(36)  1.425(9) 
C(31)-P(2)  1.810(7) 
C(32)-C(33)  1.390(10) 
C(33)-C(34)  1.415(11) 
C(34)-C(35)  1.371(14) 
C(35)-C(36)  1.362(11) 
C(41)-C(42)  1.407(11) 
C(41)-C(46)  1.409(10) 
C(41)-P(2)  1.840(7) 
C(42)-C(43)  1.381(11) 
C(43)-C(44)  1.388(12) 
C(44)-C(45)  1.388(13) 
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C(45)-C(46)  1.364(11) 
N(1)-N(2)  1.406(8) 
N(1)-P(1)  1.699(6) 
N(2)-P(2)  1.705(6) 
N(3)-O(3)  1.198(8) 
N(3)-O(2)  1.260(7) 
N(3)-O(1)  1.287(8) 
N(4)-O(6)  1.226(9) 
N(4)-O(5)  1.247(8) 
N(4)-O(4)  1.275(9) 
O(1)-Ag(1)  2.302(5) 
O(1)-Ag(2)#1  2.592(5) 
O(2)-Ag(2)#2  2.314(5) 
O(2)-Ag(1)#1  2.553(5) 
O(4)-Ag(1)#3  2.506(5) 
O(4)-Ag(2)  2.548(5) 
P(1)-Ag(1)  2.3340(18) 
P(2)-Ag(2)  2.3491(18) 
Ag(1)-O(4)#1  2.506(5) 
Ag(1)-O(2)#3  2.553(5) 
Ag(2)-O(2)#4  2.314(5) 
Ag(2)-O(1)#3  2.592(5) 
 
 
C(2)-C(1)-N(1) 118.5(8) 
N(2)-C(3)-C(4) 113.4(6) 
C(16)-C(11)-C(12) 116.1(7) 
C(16)-C(11)-P(1) 125.8(6) 
C(12)-C(11)-P(1) 118.1(5) 
C(11)-C(12)-C(13) 121.4(7) 
C(14)-C(13)-C(12) 120.2(8) 
C(13)-C(14)-C(15) 118.1(8) 
C(16)-C(15)-C(14) 120.8(8) 
C(15)-C(16)-C(11) 123.2(9) 
C(22)-C(21)-C(26) 118.8(7) 
C(22)-C(21)-P(1) 123.8(5) 
C(26)-C(21)-P(1) 117.4(6) 
C(21)-C(22)-C(23) 120.1(7) 
C(24)-C(23)-C(22) 120.0(7) 
C(23)-C(24)-C(25) 121.2(7) 
C(24)-C(25)-C(26) 118.8(7) 
C(25)-C(26)-C(21) 121.0(7) 
C(32)-C(31)-C(36) 118.8(7) 
C(32)-C(31)-P(2) 121.6(5) 
C(36)-C(31)-P(2) 118.6(5) 
C(33)-C(32)-C(31) 119.6(7) 
C(32)-C(33)-C(34) 120.9(8) 
C(35)-C(34)-C(33) 118.3(8) 
C(36)-C(35)-C(34) 122.2(8) 
C(35)-C(36)-C(31) 120.0(8) 
C(42)-C(41)-C(46) 117.4(6) 
C(42)-C(41)-P(2) 118.6(5) 
C(46)-C(41)-P(2) 123.9(5) 
C(43)-C(42)-C(41) 120.6(7) 
C(42)-C(43)-C(44) 119.6(8) 
C(43)-C(44)-C(45) 121.3(7) 
C(46)-C(45)-C(44) 118.4(7) 
C(45)-C(46)-C(41) 122.6(7) 
N(2)-N(1)-C(1) 118.9(6) 
N(2)-N(1)-P(1) 117.7(4) 
C(1)-N(1)-P(1) 123.3(5) 
N(1)-N(2)-C(3) 115.8(5) 
N(1)-N(2)-P(2) 116.9(4) 
C(3)-N(2)-P(2) 122.2(4) 
O(3)-N(3)-O(2) 122.6(6) 
O(3)-N(3)-O(1) 121.6(6) 
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O(2)-N(3)-O(1) 115.8(6) 
O(6)-N(4)-O(5) 120.8(7) 
O(6)-N(4)-O(4) 122.2(7) 
O(5)-N(4)-O(4) 116.9(6) 
N(3)-O(1)-Ag(1) 114.6(4) 
N(3)-O(1)-Ag(2)#1 132.6(4) 
Ag(1)-O(1)-Ag(2)#1 97.92(18) 
N(3)-O(2)-Ag(2)#2 116.2(4) 
N(3)-O(2)-Ag(1)#1 143.5(4) 
Ag(2)#2-O(2)-Ag(1)#1 98.70(18) 
N(4)-O(4)-Ag(1)#3 116.8(5) 
N(4)-O(4)-Ag(2) 101.5(4) 
Ag(1)#3-O(4)-Ag(2) 93.96(17) 
N(1)-P(1)-C(11) 104.8(3) 
N(1)-P(1)-C(21) 108.9(3) 
C(11)-P(1)-C(21) 102.0(3) 
N(1)-P(1)-Ag(1) 114.0(2) 
C(11)-P(1)-Ag(1) 113.7(2) 
C(21)-P(1)-Ag(1) 112.5(2) 
N(2)-P(2)-C(31) 104.0(3) 
N(2)-P(2)-C(41) 111.0(3) 
C(31)-P(2)-C(41) 101.3(3) 
N(2)-P(2)-Ag(2) 118.8(2) 
C(31)-P(2)-Ag(2) 106.6(2) 
C(41)-P(2)-Ag(2) 113.1(2) 
O(1)-Ag(1)-P(1) 164.67(13) 
O(1)-Ag(1)-O(4)#1 71.71(19) 
P(1)-Ag(1)-O(4)#1 116.32(14) 
O(1)-Ag(1)-O(2)#3 67.25(18) 
P(1)-Ag(1)-O(2)#3 126.75(13) 
O(4)#1-Ag(1)-O(2)#3 72.65(17) 
O(2)#4-Ag(2)-P(2) 154.16(13) 
O(2)#4-Ag(2)-O(4) 75.93(19) 
P(2)-Ag(2)-O(4) 118.77(12) 
O(2)#4-Ag(2)-O(1)#3 66.38(17) 
P(2)-Ag(2)-O(1)#3 137.65(12) 
O(4)-Ag(2)-O(1)#3 66.56(16) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y,z+1/2; 
#2 x,y,z+1; 
#3 -x,-y,z-1/2; 
#4 x,y,z-1. 
 
Table 27: Torsion angles [°] for 39. 
 
C(16)-C(11)-C(12)-C(13) 5.2(12) 
P(1)-C(11)-C(12)-C(13) -174.2(7) 
C(11)-C(12)-C(13)-C(14) -5.6(14) 
C(12)-C(13)-C(14)-C(15) 2.8(17) 
C(13)-C(14)-C(15)-C(16) 0(2) 
C(14)-C(15)-C(16)-C(11) 0(2) 
C(12)-C(11)-C(16)-C(15) -2.3(16) 
P(1)-C(11)-C(16)-C(15) 177.1(10) 
C(26)-C(21)-C(22)-C(23) -4.1(12) 
P(1)-C(21)-C(22)-C(23) 177.9(7) 
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C(21)-C(22)-C(23)-C(24) 3.9(14) 
C(22)-C(23)-C(24)-C(25) -0.9(14) 
C(23)-C(24)-C(25)-C(26) -1.8(13) 
C(24)-C(25)-C(26)-C(21) 1.5(13) 
C(22)-C(21)-C(26)-C(25) 1.4(12) 
P(1)-C(21)-C(26)-C(25) 179.6(6) 
C(36)-C(31)-C(32)-C(33) 3.7(11) 
P(2)-C(31)-C(32)-C(33) 172.0(6) 
C(31)-C(32)-C(33)-C(34) -3.0(13) 
C(32)-C(33)-C(34)-C(35) 2.6(13) 
C(33)-C(34)-C(35)-C(36) -3.1(14) 
C(34)-C(35)-C(36)-C(31) 4.0(13) 
C(32)-C(31)-C(36)-C(35) -4.2(11) 
P(2)-C(31)-C(36)-C(35) -172.8(6) 
C(46)-C(41)-C(42)-C(43) 1.3(10) 
P(2)-C(41)-C(42)-C(43) -175.9(5) 
C(41)-C(42)-C(43)-C(44) -2.8(11) 
C(42)-C(43)-C(44)-C(45) 4.2(12) 
C(43)-C(44)-C(45)-C(46) -4.0(12) 
C(44)-C(45)-C(46)-C(41) 2.5(11) 
C(42)-C(41)-C(46)-C(45) -1.1(10) 
P(2)-C(41)-C(46)-C(45) 175.9(6) 
C(2)-C(1)-N(1)-N(2) 82.7(10) 
C(2)-C(1)-N(1)-P(1) -100.9(9) 
C(1)-N(1)-N(2)-C(3) 71.4(8) 
P(1)-N(1)-N(2)-C(3) -105.2(6) 
C(1)-N(1)-N(2)-P(2) -83.9(7) 
P(1)-N(1)-N(2)-P(2) 99.5(5) 
C(4)-C(3)-N(2)-N(1) 68.1(8) 
C(4)-C(3)-N(2)-P(2) -138.0(6) 
O(3)-N(3)-O(1)-Ag(1) -16.4(8) 
O(2)-N(3)-O(1)-Ag(1) 165.2(5) 
O(3)-N(3)-O(1)-Ag(2)#1 -145.2(6) 
O(2)-N(3)-O(1)-Ag(2)#1 36.4(9) 
O(3)-N(3)-O(2)-Ag(2)#2 -7.7(9) 
O(1)-N(3)-O(2)-Ag(2)#2 170.7(4) 
O(3)-N(3)-O(2)-Ag(1)#1 -169.2(6) 
O(1)-N(3)-O(2)-Ag(1)#1 9.2(11) 
O(6)-N(4)-O(4)-Ag(1)#3 -67.3(9) 
O(5)-N(4)-O(4)-Ag(1)#3 114.0(6) 
O(6)-N(4)-O(4)-Ag(2) -167.7(8) 
O(5)-N(4)-O(4)-Ag(2) 13.5(7) 
N(2)-N(1)-P(1)-C(11) -141.3(5) 
C(1)-N(1)-P(1)-C(11) 42.3(7) 
N(2)-N(1)-P(1)-C(21) 110.2(5) 
C(1)-N(1)-P(1)-C(21) -66.2(7) 
N(2)-N(1)-P(1)-Ag(1) -16.4(5) 
C(1)-N(1)-P(1)-Ag(1) 167.2(6) 
C(16)-C(11)-P(1)-N(1) -89.0(8) 
C(12)-C(11)-P(1)-N(1) 90.4(6) 
C(16)-C(11)-P(1)-C(21) 24.5(9) 
C(12)-C(11)-P(1)-C(21) -156.1(6) 
C(16)-C(11)-P(1)-Ag(1) 145.9(8) 
C(12)-C(11)-P(1)-Ag(1) -34.8(7) 
C(22)-C(21)-P(1)-N(1) 10.2(7) 
C(26)-C(21)-P(1)-N(1) -167.9(6) 
C(22)-C(21)-P(1)-C(11) -100.2(7) 
C(26)-C(21)-P(1)-C(11) 81.7(6) 
C(22)-C(21)-P(1)-Ag(1) 137.6(6) 
C(26)-C(21)-P(1)-Ag(1) -40.5(6) 
N(1)-N(2)-P(2)-C(31) -150.4(5) 
C(3)-N(2)-P(2)-C(31) 56.0(6) 
N(1)-N(2)-P(2)-C(41) 101.4(5) 
C(3)-N(2)-P(2)-C(41) -52.2(7) 
N(1)-N(2)-P(2)-Ag(2) -32.2(5) 
C(3)-N(2)-P(2)-Ag(2) 174.2(5) 
C(32)-C(31)-P(2)-N(2) 29.7(7) 
C(36)-C(31)-P(2)-N(2) -162.0(5) 
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C(32)-C(31)-P(2)-C(41) 144.9(6) 
C(36)-C(31)-P(2)-C(41) -46.8(6) 
C(32)-C(31)-P(2)-Ag(2) -96.6(6) 
C(36)-C(31)-P(2)-Ag(2) 71.7(6) 
C(42)-C(41)-P(2)-N(2) -118.9(5) 
C(46)-C(41)-P(2)-N(2) 64.1(6) 
C(42)-C(41)-P(2)-C(31) 131.2(5) 
C(46)-C(41)-P(2)-C(31) -45.8(6) 
C(42)-C(41)-P(2)-Ag(2) 17.5(6) 
C(46)-C(41)-P(2)-Ag(2) -159.5(5) 
N(3)-O(1)-Ag(1)-P(1) 20.2(9) 
Ag(2)#1-O(1)-Ag(1)-P(1) 164.8(4) 
N(3)-O(1)-Ag(1)-O(4)#1 -103.9(5) 
Ag(2)#1-O(1)-Ag(1)-O(4)#1 40.70(17) 
N(3)-O(1)-Ag(1)-O(2)#3 177.8(5) 
Ag(2)#1-O(1)-Ag(1)-O(2)#3 -37.65(16) 
N(1)-P(1)-Ag(1)-O(1) 60.7(6) 
C(11)-P(1)-Ag(1)-O(1) -179.2(6) 
C(21)-P(1)-Ag(1)-O(1) -63.9(6) 
N(1)-P(1)-Ag(1)-O(4)#1 179.4(3) 
C(11)-P(1)-Ag(1)-O(4)#1 -60.5(3) 
C(21)-P(1)-Ag(1)-O(4)#1 54.7(3) 
N(1)-P(1)-Ag(1)-O(2)#3 -93.2(3) 
C(11)-P(1)-Ag(1)-O(2)#3 26.9(3) 
C(21)-P(1)-Ag(1)-O(2)#3 142.1(3) 
N(2)-P(2)-Ag(2)-O(2)#4 91.3(4) 
C(31)-P(2)-Ag(2)-O(2)#4 -151.9(4) 
C(41)-P(2)-Ag(2)-O(2)#4 -41.4(4) 
N(2)-P(2)-Ag(2)-O(4) -148.9(3) 
C(31)-P(2)-Ag(2)-O(4) -32.1(3) 
C(41)-P(2)-Ag(2)-O(4) 78.4(3) 
N(2)-P(2)-Ag(2)-O(1)#3 -63.0(3) 
C(31)-P(2)-Ag(2)-O(1)#3 53.9(3) 
C(41)-P(2)-Ag(2)-O(1)#3 164.3(3) 
N(4)-O(4)-Ag(2)-O(2)#4 85.6(5) 
Ag(1)#3-O(4)-Ag(2)-O(2)#4 -32.80(18) 
N(4)-O(4)-Ag(2)-P(2) -71.5(5) 
Ag(1)#3-O(4)-Ag(2)-P(2) 170.15(9) 
N(4)-O(4)-Ag(2)-O(1)#3 155.6(5) 
Ag(1)#3-O(4)-Ag(2)-O(1)#3 37.23(16) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y,z+1/2; 
#2 x,y,z+1; 
#3 -x,-y,z-1/2; 
#4 x,y,z-1. 
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Bis(bis(diphenylphosphino)diethylhydrazine)silver nitrate (45) 
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Table 28: Crystal data and structure refinement for 45. 
 
Empirical formula  AgP4N5O4C60H65 
Formula weight  1151.92 
Temperature  193(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P
-1 
Unit cell dimensions a = 11.912(5) Å α = 81.1(5)° 
 b = 14.954(5) Å β = 85.4 (5)° 
 c = 15.795(5) Å γ = 84.2 (5)° 
Volume 2759.5(17) Å3 
Z 2 
Density (calculated) 1.386 Mg/m3 
Absorption coefficient 0.533 mm
-1
 
F(000) 1198 
Crystal size 0.42 x 0.07 x 0.02 mm
3
 
Theta range for data collection 1.31 to 28.37° 
Index ranges -15<=h<=15, -19<=k<=19, -20<=l<=20 
Reflections collected 27916 
Independent reflections 13642 [R(int) = 0.1465] 
Completeness to theta = 28.37° 98.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
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Data/restraints/parameters 13642/0/667 
Goodness-of-fit on F2 1.423 
Final R indices [I>2sigma(I)] R1 = 0.1825, wR2 = 0.4667 
R indices (all data) R1 = 0.2927, wR2 = 0.5069 
Largest diff. peak and hole 5.731 and -1.801 e.Å-3 
 
 
Table 29: Bond lengths [Å] and angles [°] for 45. 
 
C(1)-C(2)  1.51(3) 
C(1)-N(1)  1.49(2) 
C(3)-N(2)  1.433(19) 
C(3)-C(4)  1.51(2) 
C(5)-N(3)  1.468(19) 
C(5)-C(6)  1.49(3) 
C(7)-N(4)  1.44(2) 
C(7)-C(8)  1.67(3) 
C(11)-C(12)  1.38(3) 
C(11)-C(16)  1.41(3) 
C(11)-P(1)  1.82(2) 
C(12)-C(13)  1.36(3) 
C(13)-C(14)  1.44(3) 
C(14)-C(15)  1.43(3) 
C(15)-C(16)  1.33(3) 
C(21)-C(26)  1.38(3) 
C(21)-C(22)  1.40(2) 
C(21)-P(1)  1.792(18) 
C(22)-C(23)  1.40(3) 
C(23)-C(24)  1.47(3) 
C(24)-C(25)  1.31(4) 
C(25)-C(26)  1.37(3) 
C(31)-C(32)  1.41(2) 
C(31)-C(36)  1.43(2) 
C(31)-P(2)  1.821(16) 
C(32)-C(33)  1.33(3) 
C(33)-C(34)  1.42(3) 
C(34)-C(35)  1.37(3) 
C(35)-C(36)  1.43(2) 
C(41)-C(46)  1.39(2) 
C(41)-C(42)  1.42(2) 
C(41)-P(2)  1.798(16) 
C(42)-C(43)  1.39(2) 
C(43)-C(44)  1.39(3) 
C(44)-C(45)  1.39(3) 
C(45)-C(46)  1.42(3) 
C(51)-C(56)  1.36(2) 
C(51)-C(52)  1.39(2) 
C(51)-P(3)  1.836(17) 
C(52)-C(53)  1.36(2) 
C(53)-C(54)  1.41(3) 
C(54)-C(55)  1.34(3) 
C(55)-C(56)  1.43(3) 
C(61)-C(66)  1.40(2) 
C(61)-C(62)  1.38(2) 
C(61)-P(3)  1.798(16) 
C(62)-C(63)  1.37(2) 
C(63)-C(64)  1.37(3) 
 199 
C(64)-C(65)  1.40(3) 
C(65)-C(66)  1.43(2) 
C(71)-C(72)  1.37(3) 
C(71)-C(76)  1.40(3) 
C(71)-P(4)  1.814(19) 
C(72)-C(73)  1.38(3) 
C(73)-C(74)  1.37(3) 
C(74)-C(75)  1.32(3) 
C(75)-C(76)  1.38(3) 
C(81)-C(82)  1.39(3) 
C(81)-C(86)  1.38(3) 
C(81)-P(4)  1.788(18) 
C(82)-C(83)  1.47(3) 
C(83)-C(84)  1.31(3) 
C(84)-C(85)  1.36(3) 
CC(85)-C(86)  1.32(3) 
N(1)-N(2)  1.474(18) 
N(1)-P(1)  1.729(15) 
N(2)-P(2)  1.684(13) 
N(3)-N(4)  1.42(2) 
N(3)-P(3)  1.696(13) 
N(4)-P(4)  1.739(17) 
N(5)-O(2)  1.18(3) 
N(5)-O(3)  1.19(3) 
N(5)-O(1)  1.21(4) 
P(1)-Ag(1)  2.531(5) 
P(2)-Ag(1)  2.526(4) 
P(3)-Ag(1)  2.513(4) 
P(4)-Ag(1)  2.528(4) 
C(8)-C(7)1  1.67(3) 
O(4)-C(91)  1.32(6) 
O(4)-C(94)  1.53(6) 
C(91)-C(92)  1.32(6) 
C(94)-C(93)  1.46(6) 
C(93)-C(92)  1.54(6) 
 
C(2)-C(1)-N(1) 115.3(19) 
N(2)-C(3)-C(4) 116.7(14) 
N(3)-C(5)-C(6) 116.6(15) 
N(4)-C(7)-C(8) 99.5(19) 
C(12)-C(11)-C(16) 118.4(19) 
C(12)-C(11)-P(1) 119.2(15) 
C(16)-C(11)-P(1) 122.4(15) 
C(11)-C(12)-C(13) 123(2) 
C(12)-C(13)-C(14) 118(2) 
C(15)-C(14)-C(13) 118.1(19) 
C(16)-C(15)-C(14) 121(2) 
C(15)-C(16)-C(11) 121(2) 
C(26)-C(21)-C(22) 117.2(17) 
C(26)-C(21)-P(1) 123.9(15) 
C(22)-C(21)-P(1) 118.9(14) 
C(23)-C(22)-C(21) 124(2) 
C(22)-C(23)-C(24) 113(2) 
C(25)-C(24)-C(23) 122(2) 
C(24)-C(25)-C(26) 122(3) 
C(25)-C(26)-C(21) 121(2) 
C(32)-C(31)-C(36) 118.4(15) 
C(32)-C(31)-P(2) 119.8(12) 
C(36)-C(31)-P(2) 121.7(13) 
C(33)-C(32)-C(31) 121.1(17) 
C(32)-C(33)-C(34) 121.6(18) 
C(35)-C(34)-C(33) 120.2(17) 
C(34)-C(35)-C(36) 118.9(17) 
C(35)-C(36)-C(31) 119.7(17) 
C(46)-C(41)-C(42) 117.6(16) 
C(46)-C(41)-P(2) 120.3(13) 
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C(42)-C(41)-P(2) 121.2(12) 
C(43)-C(42)-C(41) 121.6(16) 
C(42)-C(43)-C(44) 120.4(18) 
C(43)-C(44)-C(45) 118.7(18) 
C(46)-C(45)-C(44) 121(2) 
C(41)-C(46)-C(45) 120.4(19) 
C(56)-C(51)-C(52) 118.2(16) 
C(56)-C(51)-P(3) 116.6(13) 
C(52)-C(51)-P(3) 124.7(13) 
C(53)-C(52)-C(51) 122.1(18) 
C(52)-C(53)-C(54) 120.2(17) 
C(55)-C(54)-C(53) 118.2(18) 
C(54)-C(55)-C(56) 121.4(18) 
C(51)-C(56)-C(55) 119.5(18) 
C(66)-C(61)-C(62) 117.8(15) 
C(66)-C(61)-P(3) 123.4(13) 
C(62)-C(61)-P(3) 118.5(12) 
C(63)-C(62)-C(61) 122.9(17) 
C(64)-C(63)-C(62) 120.0(18) 
C(63)-C(64)-C(65) 120.2(16) 
C(64)-C(65)-C(66) 118.8(16) 
C(61)-C(66)-C(65) 120.3(16) 
C(72)-C(71)-C(76) 118.5(18) 
C(72)-C(71)-P(4) 123.8(15) 
C(76)-C(71)-P(4) 117.7(13) 
C(71)-C(72)-C(73) 121(2) 
C(74)-C(73)-C(72) 120.1(19) 
C(75)-C(74)-C(73) 117.8(18) 
C(74)-C(75)-C(76) 125.3(19) 
C(75)-C(76)-C(71) 116.8(17) 
C(82)-C(81)-C(86) 117.6(18) 
C(82)-C(81)-P(4) 122.8(18) 
C(86)-C(81)-P(4) 119.6(15) 
C(81)-C(82)-C(83) 119(2) 
C(84)-C(83)-C(82) 118(2) 
C(83)-C(84)-C(85) 122(3) 
C(86)-C(85)-C(84) 121(3) 
C(85)-C(86)-C(81) 122(2) 
N(2)-N(1)-C(1) 108.1(13) 
N(2)-N(1)-P(1) 106.5(10) 
C(1)-N(1)-P(1) 114.2(11) 
C(3)-N(2)-N(1) 112.5(12) 
C(3)-N(2)-P(2) 125.5(11) 
N(1)-N(2)-P(2) 120.1(9) 
N(4)-N(3)-C(5) 114.1(12) 
N(4)-N(3)-P(3) 120.0(10) 
C(5)-N(3)-P(3) 123.3(12) 
N(3)-N(4)-C(7) 116.8(16) 
N(3)-N(4)-P(4) 108.3(10) 
C(7)-N(4)-P(4) 113.1(12) 
O(2)-N(5)-O(3) 109(4) 
O(2)-N(5)-O(1) 121(4) 
O(3)-N(5)-O(1) 129(3) 
N(1)-P(1)-C(21) 102.7(8) 
N(1)-P(1)-C(11) 101.5(7) 
C(21)-P(1)-C(11) 103.7(8) 
N(1)-P(1)-Ag(1) 101.0(5) 
C(21)-P(1)-Ag(1) 129.6(6) 
C(11)-P(1)-Ag(1) 114.2(6) 
N(2)-P(2)-C(41) 104.9(7) 
N(2)-P(2)-C(31) 107.4(7) 
C(41)-P(2)-C(31) 103.3(7) 
N(2)-P(2)-Ag(1) 102.7(4) 
C(41)-P(2)-Ag(1) 111.1(5) 
C(31)-P(2)-Ag(1) 125.8(5) 
N(3)-P(3)-C(61) 104.1(7) 
N(3)-P(3)-C(51) 107.3(7) 
C(61)-P(3)-C(51) 102.6(7) 
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N(3)-P(3)-Ag(1) 102.5(5) 
C(61)-P(3)-Ag(1) 109.7(5) 
C(51)-P(3)-Ag(1) 128.5(6) 
N(4)-P(4)-C(81) 101.7(8) 
N(4)-P(4)-C(71) 104.0(8) 
C(81)-P(4)-C(71) 106.0(9) 
N(4)-P(4)-Ag(1) 99.3(5) 
C(81)-P(4)-Ag(1) 114.9(7) 
C(71)-P(4)-Ag(1) 127.1(6) 
P(3)-Ag(1)-P(2) 129.03(15) 
P(3)-Ag(1)-P(4) 79.35(14) 
P(2)-Ag(1)-P(4) 128.83(15) 
P(3)-Ag(1)-P(1) 125.94(15) 
P(2)-Ag(1)-P(1) 79.22(14) 
P(4)-Ag(1)-P(1) 121.34(16) 
C(91)-O(4)-C(94) 103(5) 
O(4)-C(91)-C(92) 112(6) 
C(93)-C(94)-O(4) 101(5) 
C(94)-C(93)-C(92) 104(5) 
C(93)-C(92)-C(91) 104(6) 
 
_____________________________________________________________________ 
 
Table 30: Torsion angles [°] for 45. 
 
C(16)-C(11)-C(12)-C(13) 0(3) 
P(1)-C(11)-C(12)-C(13) 179.5(17) 
C(11)-C(12)-C(13)-C(14) 0(3) 
C(12)-C(13)-C(14)-C(15) -1(3) 
C(13)-C(14)-C(15)-C(16) 1(3) 
C(14)-C(15)-C(16)-C(11) -2(3) 
C(12)-C(11)-C(16)-C(15) 1(3) 
P(1)-C(11)-C(16)-C(15) -178.8(16) 
C(26)-C(21)-C(22)-C(23) 7(3) 
P(1)-C(21)-C(22)-C(23) -173.7(18) 
C(21)-C(22)-C(23)-C(24) -4(3) 
C(22)-C(23)-C(24)-C(25) -2(4) 
C(23)-C(24)-C(25)-C(26) 5(5) 
C(24)-C(25)-C(26)-C(21) -2(5) 
C(22)-C(21)-C(26)-C(25) -4(4) 
P(1)-C(21)-C(26)-C(25) 177(2) 
C(36)-C(31)-C(32)-C(33) 3(3) 
P(2)-C(31)-C(32)-C(33) -174.1(15) 
C(31)-C(32)-C(33)-C(34) -4(3) 
C(32)-C(33)-C(34)-C(35) 2(3) 
C(33)-C(34)-C(35)-C(36) 0(3) 
C(34)-C(35)-C(36)-C(31) -1(3) 
C(32)-C(31)-C(36)-C(35) 0(2) 
P(2)-C(31)-C(36)-C(35) 176.5(14) 
C(46)-C(41)-C(42)-C(43) -3(2) 
P(2)-C(41)-C(42)-C(43) -172.1(12) 
C(41)-C(42)-C(43)-C(44) 2(2) 
C(42)-C(43)-C(44)-C(45) 0(3) 
C(43)-C(44)-C(45)-C(46) -1(3) 
C(42)-C(41)-C(46)-C(45) 2(2) 
P(2)-C(41)-C(46)-C(45) 171.4(14) 
C(44)-C(45)-C(46)-C(41) 0(3) 
C(56)-C(51)-C(52)-C(53) 3(3) 
P(3)-C(51)-C(52)-C(53) 175.1(16) 
C(51)-C(52)-C(53)-C(54) 2(3) 
C(52)-C(53)-C(54)-C(55) -5(3) 
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C(53)-C(54)-C(55)-C(56) 3(3) 
C(52)-C(51)-C(56)-C(55) -4(3) 
P(3)-C(51)-C(56)-C(55) -177.3(15) 
C(54)-C(55)-C(56)-C(51) 1(3) 
C(66)-C(61)-C(62)-C(63) 1(2) 
P(3)-C(61)-C(62)-C(63) 174.2(14) 
C(61)-C(62)-C(63)-C(64) -2(3) 
C(62)-C(63)-C(64)-C(65) 1(3) 
C(63)-C(64)-C(65)-C(66) 1(3) 
C(62)-C(61)-C(66)-C(65) 1(2) 
P(3)-C(61)-C(66)-C(65) -171.9(13) 
C(64)-C(65)-C(66)-C(61) -2(3) 
C(76)-C(71)-C(72)-C(73) -1(5) 
P(4)-C(71)-C(72)-C(73) -179(3) 
C(71)-C(72)-C(73)-C(74) -1(6) 
C(72)-C(73)-C(74)-C(75) 2(5) 
C(73)-C(74)-C(75)-C(76) -1(4) 
C(74)-C(75)-C(76)-C(71) 0(4) 
C(72)-C(71)-C(76)-C(75) 1(3) 
P(4)-C(71)-C(76)-C(75) 179.7(15) 
C(86)-C(81)-C(82)-C(83) 1(3) 
P(4)-C(81)-C(82)-C(83) -179.7(15) 
C(81)-C(82)-C(83)-C(84) 0(3) 
C(82)-C(83)-C(84)-C(85) -1(4) 
C(83)-C(84)-C(85)-C(86) 2(5) 
C(84)-C(85)-C(86)-C(81) -2(4) 
C(82)-C(81)-C(86)-C(85) 0(3) 
P(4)-C(81)-C(86)-C(85) -179(2) 
C(2)-C(1)-N(1)-N(2) 155.7(16) 
C(2)-C(1)-N(1)-P(1) -85.9(18) 
C(4)-C(3)-N(2)-N(1) 56(2) 
C(4)-C(3)-N(2)-P(2) -108.5(18) 
C(1)-N(1)-N(2)-C(3) -102.7(15) 
P(1)-N(1)-N(2)-C(3) 134.1(11) 
C(1)-N(1)-N(2)-P(2) 62.7(15) 
P(1)-N(1)-N(2)-P(2) -60.4(12) 
C(6)-C(5)-N(3)-N(4) 64(2) 
C(6)-C(5)-N(3)-P(3) -97.2(18) 
C(5)-N(3)-N(4)-C(7) -93.3(18) 
P(3)-N(3)-N(4)-C(7) 69.0(18) 
C(5)-N(3)-N(4)-P(4) 137.7(12) 
P(3)-N(3)-N(4)-P(4) -60.0(14) 
C(8)#1-C(7)-N(4)-N(3) 130.2(14) 
C(8)#1-C(7)-N(4)-P(4) -103.1(13) 
N(2)-N(1)-P(1)-C(21) -169.7(10) 
C(1)-N(1)-P(1)-C(21) 71.1(13) 
N(2)-N(1)-P(1)-C(11) -62.6(11) 
C(1)-N(1)-P(1)-C(11) 178.2(12) 
N(2)-N(1)-P(1)-Ag(1) 55.2(9) 
C(1)-N(1)-P(1)-Ag(1) -64.1(12) 
C(26)-C(21)-P(1)-N(1) 46(2) 
C(22)-C(21)-P(1)-N(1) -133.6(15) 
C(26)-C(21)-P(1)-C(11) -60(2) 
C(22)-C(21)-P(1)-C(11) 121.1(15) 
C(26)-C(21)-P(1)-Ag(1) 161.8(15) 
C(22)-C(21)-P(1)-Ag(1) -17.5(19) 
C(12)-C(11)-P(1)-N(1) 144.8(15) 
C(16)-C(11)-P(1)-N(1) -35.4(17) 
C(12)-C(11)-P(1)-C(21) -108.9(16) 
C(16)-C(11)-P(1)-C(21) 70.9(17) 
C(12)-C(11)-P(1)-Ag(1) 37.1(17) 
C(16)-C(11)-P(1)-Ag(1) -143.2(14) 
C(3)-N(2)-P(2)-C(41) -51.5(14) 
N(1)-N(2)-P(2)-C(41) 145.0(11) 
C(3)-N(2)-P(2)-C(31) 57.9(14) 
N(1)-N(2)-P(2)-C(31) -105.5(12) 
C(3)-N(2)-P(2)-Ag(1) -167.7(12) 
N(1)-N(2)-P(2)-Ag(1) 28.9(12) 
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C(46)-C(41)-P(2)-N(2) 160.4(12) 
C(42)-C(41)-P(2)-N(2) -30.5(14) 
C(46)-C(41)-P(2)-C(31) 48.0(14) 
C(42)-C(41)-P(2)-C(31) -142.9(13) 
C(46)-C(41)-P(2)-Ag(1) -89.4(12) 
C(42)-C(41)-P(2)-Ag(1) 79.7(12) 
C(32)-C(31)-P(2)-N(2) 101.4(14) 
C(36)-C(31)-P(2)-N(2) -75.5(14) 
C(32)-C(31)-P(2)-C(41) -148.1(13) 
C(36)-C(31)-P(2)-C(41) 35.1(15) 
C(32)-C(31)-P(2)-Ag(1) -19.3(16) 
C(36)-C(31)-P(2)-Ag(1) 163.9(11) 
N(4)-N(3)-P(3)-C(61) 141.0(13) 
C(5)-N(3)-P(3)-C(61) -58.4(15) 
N(4)-N(3)-P(3)-C(51) -110.7(14) 
C(5)-N(3)-P(3)-C(51) 49.9(15) 
N(4)-N(3)-P(3)-Ag(1) 26.7(13) 
C(5)-N(3)-P(3)-Ag(1) -172.7(12) 
C(66)-C(61)-P(3)-N(3) -22.1(15) 
C(62)-C(61)-P(3)-N(3) 165.0(12) 
C(66)-C(61)-P(3)-C(51) -133.8(14) 
C(62)-C(61)-P(3)-C(51) 53.3(14) 
C(66)-C(61)-P(3)-Ag(1) 87.0(13) 
C(62)-C(61)-P(3)-Ag(1) -85.9(13) 
C(56)-C(51)-P(3)-N(3) 89.9(15) 
C(52)-C(51)-P(3)-N(3) -82.4(17) 
C(56)-C(51)-P(3)-C(61) -160.8(15) 
C(52)-C(51)-P(3)-C(61) 26.9(18) 
C(56)-C(51)-P(3)-Ag(1) -32.6(18) 
C(52)-C(51)-P(3)-Ag(1) 155.1(14) 
N(3)-N(4)-P(4)-C(81) -61.6(12) 
C(7)-N(4)-P(4)-C(81) 167.4(15) 
N(3)-N(4)-P(4)-C(71) -171.5(11) 
C(7)-N(4)-P(4)-C(71) 57.4(16) 
N(3)-N(4)-P(4)-Ag(1) 56.4(10) 
C(7)-N(4)-P(4)-Ag(1) -74.7(15) 
C(82)-C(81)-P(4)-N(4) -39.0(17) 
C(86)-C(81)-P(4)-N(4) 140.4(15) 
C(82)-C(81)-P(4)-C(71) 69.4(17) 
C(86)-C(81)-P(4)-C(71) -111.2(16) 
C(82)-C(81)-P(4)-Ag(1) -145.1(14) 
C(86)-C(81)-P(4)-Ag(1) 34.3(17) 
C(72)-C(71)-P(4)-N(4) 67(3) 
C(76)-C(71)-P(4)-N(4) -111.8(16) 
C(72)-C(71)-P(4)-C(81) -40(3) 
C(76)-C(71)-P(4)-C(81) 141.4(17) 
C(72)-C(71)-P(4)-Ag(1) -180(2) 
C(76)-C(71)-P(4)-Ag(1) 2(2) 
N(3)-P(3)-Ag(1)-P(2) -124.4(5) 
C(61)-P(3)-Ag(1)-P(2) 125.5(5) 
C(51)-P(3)-Ag(1)-P(2) 0.0(7) 
N(3)-P(3)-Ag(1)-P(4) 7.6(5) 
C(61)-P(3)-Ag(1)-P(4) -102.5(6) 
C(51)-P(3)-Ag(1)-P(4) 132.0(7) 
N(3)-P(3)-Ag(1)-P(1) 128.7(5) 
C(61)-P(3)-Ag(1)-P(1) 18.6(6) 
C(51)-P(3)-Ag(1)-P(1) -106.9(7) 
N(2)-P(2)-Ag(1)-P(3) -122.3(5) 
C(41)-P(2)-Ag(1)-P(3) 126.1(6) 
C(31)-P(2)-Ag(1)-P(3) 0.4(7) 
N(2)-P(2)-Ag(1)-P(4) 127.4(5) 
C(41)-P(2)-Ag(1)-P(4) 15.8(6) 
C(31)-P(2)-Ag(1)-P(4) -109.9(7) 
N(2)-P(2)-Ag(1)-P(1) 5.6(5) 
C(41)-P(2)-Ag(1)-P(1) -106.0(6) 
C(31)-P(2)-Ag(1)-P(1) 128.3(7) 
N(4)-P(4)-Ag(1)-P(3) -31.2(5) 
C(81)-P(4)-Ag(1)-P(3) 76.4(7) 
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C(71)-P(4)-Ag(1)-P(3) -146.7(9) 
N(4)-P(4)-Ag(1)-P(2) 101.0(5) 
C(81)-P(4)-Ag(1)-P(2) -151.5(7) 
C(71)-P(4)-Ag(1)-P(2) -14.5(9) 
N(4)-P(4)-Ag(1)-P(1) -157.0(5) 
C(81)-P(4)-Ag(1)-P(1) -49.4(7) 
C(71)-P(4)-Ag(1)-P(1) 87.5(9) 
N(1)-P(1)-Ag(1)-P(3) 100.1(5) 
C(21)-P(1)-Ag(1)-P(3) -16.7(8) 
C(11)-P(1)-Ag(1)-P(3) -151.8(6) 
N(1)-P(1)-Ag(1)-P(2) -30.8(5) 
C(21)-P(1)-Ag(1)-P(2) -147.5(8) 
C(11)-P(1)-Ag(1)-P(2) 77.3(6) 
N(1)-P(1)-Ag(1)-P(4) -159.9(5) 
C(21)-P(1)-Ag(1)-P(4) 83.3(8) 
C(11)-P(1)-Ag(1)-P(4) -51.8(7) 
C(94)-O(4)-C(91)-C(92) -41(6) 
C(91)-O(4)-C(94)-C(93) 36(6) 
O(4)-C(94)-C(93)-C(92) -20(6) 
C(94)-C(93)-C(92)-C(91) -2(7) 
O(4)-C(91)-C(92)-C(93) 28(7) 
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Appendix B 
 
IC50 Determination 
 
Initial Activity Screening 
 
0 1 2 3 4 5 6 7
0
20
40
60
80
100
120
Conc. (µM)
%
 
o
f C
o
n
tr
o
l
 
Graph 3.1: Effect of 37 on growth of 
HeLa. 
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Graph 3.2: Effect of 23 on growth of 
HeLa. 
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Graph 3.3: Effect of 24 on growth of 
HeLa. 
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Graph 3.4: Effect of 25 on growth of 
HeLa. 
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Graph 3.5: Effect of 27 on growth of 
HeLa. 
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Graph 3.6: Effect of 28 on growth of 
HeLa. 
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Graph 3.7: Effect of 29 on growth of 
HeLa. 
 
0 1 2 3 4
0
20
40
60
80
100
120
Conc. (µM)
%
 
o
f C
o
n
tr
o
l
 
Graph 3.8: Effect of 30 on growth of 
HeLa. 
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Graph 3.9: Effect of 31 on growth of 
HeLa. 
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Graph 3.10: Effect of 43 on growth of 
HeLa. 
 
 207 
0 1 2 3 4
0
20
40
60
80
100
120
Conc. (µM)
%
 
o
f C
o
n
tr
o
l
 
Graph 3.11: Effect of 45 on growth of 
HeLa. 
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Graph 3.12: Effect of 46 on growth of 
HeLa. 
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Graph 3.13: Effect of 47 on growth of 
HeLa. 
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Graph 3.14: Effect of 49 on growth of 
Hela. 
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Graph 3.15: Effect of 37 on growth of 
Jurkat. 
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Graph 3.16: Effect of 23 on growth of 
Jurkat. 
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Graph 3.17: Effect of 24 on growth of 
Jurkat. 
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Graph 3.18: Effect of 25 on growth of 
Jurkat. 
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Graph 3.19: Effect of 27 on growth of 
Jurkat. 
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Graph 3.20: Effect of 28 on growth of 
Jurkat. 
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Graph 3.21: Effect of 29 on growth of 
Jurkat. 
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Graph 3.22: Effect of 30 on growth of 
Jurkat. 
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Graph 3.23: Effect of 31 on growth of 
Jurkat. 
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Graph 3.24: Effect of 43 on growth of 
Jurkat. 
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Graph 3.25: Effect of 45 on growth of 
Jurkat. 
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Graph 3.26: Effect of 46 on growth of 
Jurkat. 
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Graph 3.27: Effect of 47 on growth of 
Jurkat. 
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Graph 3.28: Effect of 49 on growth of 
Jurkat. 
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Graph 3.29: Effect of 37on growth of 
resting Lymphocytes. 
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Graph 3.30: Effect of 23 on growth of 
resting Lymphocytes. 
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Graph 3.31: Effect of 24 on growth of 
resting Lymphocytes. 
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Graph 3.32: Effect of 25 on growth of 
resting Lymphocytes. 
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Graph 3.33: Effect of 27 on growth of 
resting Lymphocytes. 
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Graph 3.34: Effect of 28 on growth of 
resting Lymphocytes. 
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Graph 3.35: Effect of 29 on growth of 
resting Lymphocytes. 
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Graph 3.36: Effect of 30 on growth of 
resting Lymphocytes. 
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Graph 3.37: Effect of 31 on growth of 
resting Lymphocytes. 
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Graph 3.38: Effect of 43 on growth of 
resting Lymphocytes. 
 
0 10 20 30 40 50 60
0
20
40
60
80
100
120
Conc. (µM)
%
 
o
f C
o
n
tr
o
l
 
Graph 3.39: Effect of 45 on growth of 
resting Lymphocytes. 
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Graph 3.40: Effect of 46 on growth of 
resting Lymphocytes. 
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Graph 3.41: Effect of 47 on growth of 
resting Lymphocytes. 
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Graph 3.42: Effect of 49 on growth of 
resting Lymphocytes. 
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Graph 3.43: Effect of 37on growth of 
stimulated Lymphocytes. 
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Graph 3.44: Effect of 23 on growth of 
stimulated Lymphocytes. 
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Graph 3.45: Effect of 24 on growth of 
stimulated Lymphocytes. 
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Graph 3.46: Effect of 25 on growth of 
stimulated Lymphocytes. 
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Graph 3.47: Effect of 27 on growth of 
stimulated Lymphocytes. 
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Graph 3.48: Effect of 28 on growth of 
stimulated Lymphocytes. 
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Graph 3.49: Effect of 29 on growth of 
stimulated Lymphocytes. 
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Graph 3.50: Effect of 30 on growth of 
stimulated Lymphocytes. 
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Graph 3.51: Effect of 31 on growth of 
stimulated Lymphocytes. 
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Graph 3.52: Effect of 43 on growth of 
stimulated Lymphocytes. 
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Graph 3.53: Effect of 45 on growth of 
stimulated Lymphocytes. 
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Graph 3.54: Effect of 46 on growth of 
stimulated Lymphocytes. 
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Graph 3.55: Effect of 47 on growth of 
stimulated Lymphocytes. 
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Graph 3.56: Effect of 49 on growth of 
stimulated Lymphocytes. 
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Graph 3.57: Effect of 37on growth of 
Colo 320 DM. 
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Graph 3.58: Effect of 24 on growth of 
Colo 320 DM. 
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Graph 3.59: Effect of 25 on growth of 
Colo 320 DM. 
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Graph 3.60: Effect of 45 on growth of 
Colo 320 DM. 
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Graph 3.61: Effect of 46 on growth of 
Colo 320 DM. 
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Graph 3.62: Effect of 49 on growth of 
Colo 320 DM. 
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Graph 3.63: Effect of 37 on growth of 
A2780. 
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Graph 3.64: Effect of 24 on growth of 
A2780. 
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Graph 3.65: Effect of 25 on growth of 
A2780. 
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Graph 3.66: Effect of 45 on growth of 
A2780. 
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Graph 3.67: Effect of 46 on growth of 
A2780. 
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Graph 3.68: Effect of 49 on growth of 
A2780. 
_____________________________________________________________________ 
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Graph 3.69: Effect of 37on growth of 
A2780cis. 
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Graph 3.70: Effect of 24
 
on growth of 
A2780cis. 
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Graph 3.71: Effect of 25
 
on growth of 
A2780cis. 
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Graph 3.72: Effect of 45
 
on growth of 
A2780cis. 
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Graph 3.73: Effect of 46
 
on growth of 
A2780cis. 
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Graph 3.74: Effect of 49
 
on growth of 
A2780cis. 
_____________________________________________________________________ 
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Graph 3.75: Effect of 37on growth of 
MCF-7. 
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Graph 3.76: Effect of 24
 
on growth of 
MCF-7. 
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Graph 3.77: Effect of 25
 
on growth of 
MCF-7. 
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Graph 3.78 Effect of 45
 
on growth of 
MCF-7. 
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Graph 3.79: Effect of 46
 
on growth of 
MCF-7. 
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Graph 3.80: Effect of 49
 
on growth of 
MCF-7. 
_____________________________________________________________________ 
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Graph 3.81: Effect of 37 on growth of 
MCF-12A. 
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Graph 3.82: Effect of 24
 
on growth of 
MCF-12A. 
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Graph 3.83: Effect of 25
 
on growth of 
MCF-12A. 
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Graph 3.84: Effect of 45
 
on growth of 
MCF-12A. 
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Graph 3.85: Effect of 46
 
on growth of 
MCF-12A. 
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Graph 3.86: Effect of 49
 
on growth of 
MCF-12A. 
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Appendix C 
 
Apoptosis and Necrosis Assay Flowcytometry Results 
 
6 Hour Results 
 
Contol Samples (1 x IC50 Concentration) 
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Compound 37 (Ref) Samples (1 x IC50 Concentration) 
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Compound 25 Samples (1 x IC50 Concentration) 
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Compound 46 Samples (1 x IC50 Concentration) 
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Control Samples (2 x IC50 Concentration) 
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 227 
Compound 37 (Ref) Samples (2 x IC50 Concentration) 
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Compound 25 Samples (2 x IC50 Concentration) 
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Compound 46 Samples (2 x IC50 Concentration) 
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24 Hour Results 
 
Contol Samples (1 x IC50 Concentration) 
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Compound 37 (Ref) Samples (1 x IC50 Concentration) 
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Compound 25 Samples (1 x IC50 Concentration) 
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 235 
Compound 46 Samples (1 x IC50 Concentration) 
 
 
 
 236 
 
 
Control Samples (2 x IC50 Concentration) 
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Compound 37 (Ref) Samples (2 x IC50 Concentration) 
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Compound 25 Samples (2 x IC50 Concentration) 
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Compound 46 Samples (2 x IC50 Concentration) 
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48 Hour Results 
 
Contol Samples (1 x IC50 Concentration) 
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Compound 37 (Ref) Samples (1 x IC50 Concentration) 
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Compound 25 Samples (1 x IC50 Concentration) 
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Compound 46 Samples (1 x IC50 Concentration) 
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Control Samples (2 x IC50 Concentration) 
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Compound 37 (Ref) Samples (2 x IC50 Concentration) 
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Compound 25 Samples (2 x IC50 Concentration) 
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Compound 46 Samples (2 x IC50 Concentration) 
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